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Malignant haematopoiesis is usually associated with various genetic lesions such as 
chromosomal  translocations  or  mutations  in  individual  genes.  This  thesis 
investigates  the  genetic  basis  of  two  such  syndromes,  acute  megakaryoblastic 
leukaemia (AMKL) and myelodysplastic syndrome (MDS).
The  most  common  constitutional  aneuploidy  with  predisposition  to  leukaemia  is 
trisomy  21,  also  known  as  Down  Syndrome  (DS).  DS  children  have  a  500-fold 
increased risk for AMKL. Somatic mutations acquired during foetal haematopoiesis 
in the GATA1 transcription factor are detected in megakaryoblasts from all the DS 
patients with AMKL. Here we show that the Gatal  mutation co-operates with the 
chromosome  21  gene,  ERGS,  to  immortalize  foetal  megakaryocyte  progenitors 
with the  phenotype  of AMKL  megakaryoblasts.  We  show that  ERG-3  promotes 
megakaryopoiesis and acts as an oncogene and that progenitor cells harbouring a 
Gatal  mutation  plus  ERG-3  or  ERG-3  alone  lead  to  rapid  development  of 
leukaemia  in  vivo.  Our  data  support  a  model  where  trisomy  21  overexpressed 
genes, that promote foetal megakaryopoiesis, co-operate with mutations that arrest 
development and lead to DS-AMKL. This is also the first direct demonstration of 
the leukaemogenic activity of full length ERG protein, possibly explaining the poor 
prognosis of the acute myeloid leukaemias with high expression of ERG.
DS  patients  are  also  predisposed  to  TMD  (transient  myeloproliferative  disorder) 
and  MDS  (myelodysplastic  syndrome)  prior  to  AMKL  development. 
Myelodysplastic  syndromes  are  a  group  of  clonal  haematopoietic  disorders,
2characterised by aberrant proliferation and  differentiation of cells  of the  myeloid 
lineage  resulting  in  severe  cytopenia  and  dysplasia  of  myeloid,  erythroid  and 
megakaryocytes.  The  most  common  chromosomal  translocation  associated  with 
MDS  is  the  t(3;5)(q25q35)  translocation.  This  rearrangement  results  in  a  fusion 
transcript comprised of nucleophosmin (NPM) gene and myeloid leukaemia factor 
1   (MLF1) gene. To determine the importance of the NPM-MLF1  fusion protein in 
the  development  and progression  of MDS  to  AML,  its  role  in  myelopoiesis  and 
megakaryopoiesis was investigated. Our results show that NPM-MLF1  affects the 
differentiation of myeloid cells. Our preliminary data predicts that NPM may have 
a  role  in  megakaryopoiesis  and  its  interaction  with  NPM-MLF1  may  affect  the 
function of the fusion protein.
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24Chapter 1: Introduction
Human  leukaemias  and  haematopoietic  disorders  arise  primarily  as  a  result  of 
abnormal regulation and development of stem and progenitor cells that give rise to 
red  and  white  blood  cells.  Overexpression  of  a  gene,  genetic  mutations, 
chromosomal  aneuploidy or translocations can result in the aberrant regulation of 
cellular proliferation and differentiation that can lead to proliferative disorders and 
leukaemic development.
Down  Syndrome  (DS)  is  an  example  of a  disorder  that  involves  chromosomal 
aneuploidy  (trisomy  21).  Down  syndrome  neonates  are  highly  predisposed  to 
development of acute megakaryoblastic leukaemia (AMKL).  DS-AMKL is almost 
always  coupled  with  a  mutation  in  the  GATA1  gene,  which  is  crucial  for  the 
development and differentiation of platelet producing cells, megakaryocytes. In this 
study we examined the potential collaboration between ERGS, a gene localised to 
chromosome 21, and GATA1 mutation in leukaemogenesis. Below, current models 
of  mouse  haematopoiesis,  different  DS  murine  models  and  the  transcriptional 
regulation  of  megakaryopoiesis,  will  be  discussed.  The  function  of  GATA1 
mutation in haematopoiesis and disease will also be addressed.
Individuals  with  DS  are  also  predisposed  to  a  myeloproliferative  disease,
myelodysplastic  syndrome  (MDS),  prior  to  AMKL  development.  In  addition,
trisomy 21  has been detected as a sole genetic abnormality in some non-DS AML
as well as patients suffering from MDS alone (Wan et al., 1999). MDS is associated
with poor prognosis and there are number of genetic mutations and chromosomal
25translocations correlated with MDS. The second part of this study was to elucidate 
the  functional  importance  of the  NPM-MLF1  fusion  gene  created  as  a  result  of 
t(3;5)  associated  with  MDS.  The  clinical  characteristics  of MDS  and  the  role  of 
wild type NPM. MLF1 and NPM-MLF1 will be discussed below.
1.1 Haematopoietic development in mice
Haematopoiesis refers to the formation and the development of red and white blood 
cells which occurs during embryogenesis and throughout normal life. Mature blood 
cells of all  lineages are derived from pluripotential long-term (LT) haematopoietic 
stem cells (HSCs) which are a rare, quiescent population of cells representing less 
than 0.1% of total nucleated cells in the bone marrow. These cells can reconstitute 
the  haematopoietic  system  of lethally  irradiated  recipient  mice  and  the  long-term 
self-renewal  potential  of  these  cells  has  been  demonstrated  by  the  serial 
transplantation  of HSCs  into  secondary  and  tertiary  recipient  mice  (Smith  et al., 
1991;  Spangrude  et  al.,  1995).  LT-HSCs  give  rise  to  short-term  (ST)  HSCs  that 
have  limited  self-renewal  capacity  of  around  three  months  and  these  cells  can 
generate multipotent progenitors (MPP) that do not self renew but can diverge and 
commit into two main pathways of the haematopoietic system, the myeloid and the 
lymphoid lineage (Christensen and Weissman, 2001). The LT-HSCs, ST-HSCs and 
MPPs  exist  in  a  small  population  of  cells  in  the  bone  marrow  that  lack  the 
expression of lineage marker (Lin) and express  stem cell associated markers  Seal 
and  c-Kit  (Lin'Scal+c-kithlgh or  LSK).  These  can  further  be  distinguished  by  the 
expression of CD34 and the cytokine receptor FMS-like tyrosine kinase 3  (FLT3). 
LT-HSCs  lack  the  expression  of  both  CD34  and  FLT3  (Osawa  et  al.,  1996;
26Adolfsson et al., 2001) whereas ST-HSCs are CD34  FLT3'(Yang et a l, 2005).
1.1.1  Models of haematopoiesis
The  conventional  model  of  haematopoiesis  involves  the  commitment  and 
differentiation  of ST-HSCs  or  MPPs  along  one  of two  pathways,  giving  rise  to 
either  the  common  myeloid  progenitor  (CMP)  or  to  the  common  lymphoid 
progenitor (CLP) (Ogawa et al.,  1993; Morrison et al.,  1995; Akashi et al., 2000). 
CMPs  are  multi-potent  cells  that  can  differentiate  into  either  granulocyte- 
macrophage  progenitor  (GMP)  or  megakaryocyte-erythrocyte  (MegE)  progenitor 
cells.  The  GMP  can  give  rise  to  granulocytes  (neutrophils,  basophils  and 
eosinophils) and monocytes whereas the MEP can generate erythrocytes or platelet 
producing megakaryocytes (Figure  1.1  A).  The CLP have the capacity to develop 
into  pro-B  and  pro-T  cell  progenitors  that  generate  B  lymphocytes  and  T 
lymphocytes respectively. Natural Killer cells are also derived from CLPs.
Improvements  in  the  isolation  of  lineage  specific  progenitors  have  lead  to  the 
proposal  of more  flexible  hierarchical  models  of haematopoiesis.  An  alternative 
model  was  suggested  by  Adolfsson  et  al  following  the  identification  of another 
LSK progenitor cell, the lymphoid primed multipotent progenitor (LMPP), which is 
LSKCD34+Flt3+   (Adolfsson  et  al.,  2001;  Adolfsson  et  al.,  2005).  LMPP  can 
generate  GMP  but  in contrast to  ST-HSCs have  lost the ability to  commit to the 
MK  and  E  lineage  as  shown  by  the  down  regulation  of  erythroid  and
27Figure  1.1.  Models  of haematopoiesis.  A.  Conventional  model.  Haematopoietic 
stem cells (HSCs) can be divided into long term (LT) HSCS capable of indefinite self 
renewal which can provide life long maintenance of the entire haematopoietic system 
or short term (ST) HSCs that can self renew for a limited period.  ST-HSCs can give 
rise  to  multipotent  progenitor  (MPP)  cells  and  can  self  renew  and  commit  to 
differentiate into either the common lymphoid progenitor (CLP) or common myeloid 
progenitor (CMP).  CLP gives rise to  T  and  B  lymphocytes  as  well  as  natural  killer 
(NK)  cells,  whereas  CMP  gives  rise  to  granulocyte-monocyte  progenitor  (GMP)  or 
megakaryocyte-erythrocyte  progenitor  (MEP).  GMPs  produce  granulocytes 
(basophils,  neutrophils  and  eosinophils)  and  monocytes.  MEPs  develop  into  either 
megakaryocytes or erythrocytes. B.  Alternative model.  In this model MPPs develop 
into  a  lymphoid  primed  multipotent  progenitor  (LMPP)  following  the  loss  of 
megakaryocyte  and  erythroid  potential.  LMPP  can  generate  GMP  and  CLP.  C. 
Composite  model.  Coexistence  of LMMP  and  CMP  where  LMPP  can  give  rise  to 
CLP as well as GMP.  (Adapted from Adolfsson et al., 2005).
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29megakaryocytic  specific  transcription  factors  in  the  LSKCD34+Flt3+   population. 
LMPP  cells  generate  CLP  upon  loss  of GMP  potential.  In  this  model,  Flt3~ ST- 
HSCs contribute to the MEP (Figure  1.1  B).  This model predicts that LMPP cells 
have  lost  their  multipotency  due  to  the  reduced  MEP  lineage  potential.  The 
composite model takes into account the coexistence of LMPP and CMP in normal 
haematopoiesis, whereby the  LMPP have the capacity to generate CLP and GMP 
and the  MEP  is derived from CMP (Figure  1.1  C).  In contrast to the findings of 
Adolfsson,  Forsberg  et  al  showed  that  LMPPs  sustained  their  MegE  potential  in 
vivo  (Forsberg  et al.,  2006).  This  was proposed to  be due to  the  variation  in the 
number  of  cells  and  the  timing  of  assays  used  in  the  studies.  This  study 
demonstrated that the  LMPPs  represent a more  differentiated  population of MPP 
that have retained their multipotency and appear to be upstream of CLP and CMP. 
The  emergence  of recent  data  from  Bell  and  Bhandoola  and  Wada  et  al,  has 
provided new insight into the organization and development of haematopoietic cells 
(Bell and Bhandoola, 2008; Wada et al., 2008). They propose that T cells may not 
be derived from a lymphoid-restricted progenitor cell (CLP) but are generated from 
a multipotent progenitor cell that has lost B cell potential but has retained both T 
and myeloid potential. They demonstrate the existence of progenitors in the thymus 
that retained the ability to generate both macrophages and granulocytes in vivo.
Evidence from several groups implies that there is a certain degree of plasticity in 
the current models of haematopoiesis and they are not mutually exclusive.  CMPs 
have been shown to have low B cell  commitment potential  in vivo (Akashi et al., 
2000).  The  progenitor  cell  microenvironment,  such  as  cytokine  availability,  and 
intrinsic  factors,  such  as  expression  of specific  transcription  factors,  also  play  a
30crucial role in determining cell fate decisions.
1.1.2  Foetal and adult haematopoiesis
The generation of HSCs can be divided into two stages based on the physiological 
location of blood cell development, cellular morphology and the expression of cell 
specific genes. Primitive haematopoiesis occurs in the blood islands of the yolk sac 
(YS) on embryonic  day  7  (E7)  and  later in the aorta-gonad-mesonephros  (AGM) 
from E8-10. The development of nucleated erythroid cells begins between E7 and 
E8 (Silver and Palis, 1997; Kingsley et al., 2004). These cells express high levels of 
foetal (e and Q and low levels of adult haemoglobin genes (a and p) and after E8 
they become the dominant cells in circulation. Recently, primitive megakaryocytes 
have  also  been  identified.  In  comparison  with  adult  megakaryocytes,  these  cells 
have reduced ploidy and a higher platelet production (Xu et al., 2001). From E10, 
primitive haematopoiesis is replaced with definitive haematopoiesis in foetal  liver 
(FL),  where  it  is  now the  predominant  site  for embryonic  blood production  until 
birth. At El2.5, definitive enucleated erythrocytes begin to develop.  In contrast to 
primitive erythrocytes, these cells only express adult haemoglobin genes.
There are many differences between adult and embryonic haematopoiesis, some of 
which  include  expression  of  cell  surface  markers  (Mikkola  and  Orkin,  2006), 
proliferative  and  differentiation  capacity  in  culture  and  responsiveness  to  growth 
factors (Sanchez et al., 1996; Traver et al., 2001).
311.2 Myelopoiesis
Development  of granulocytes  and  monocytes  from  multipotential  haematopoietic 
stem  cells  is  referred  to  as  myelopoiesis.  Myeloid  cells  play  a  pivotal  role  in 
initiating  an  immune  and  inflammatory  response.  Monocytes  differentiate  into 
macrophages,  mainly  function  to  destroy  target  cells  and  pathogens  by 
phagocytosis.  Dendritic  cells  can  induce  T  cell  mediated  immune  responses  by 
presenting  antigens  in  the  context  of major  histocompatibility  complex  (MHC) 
molecules.  Cells  of  granulocyte  origin  include  neutrophils,  basophils  and 
eosinophils  all  of which  have  distinctive  functions  in  an  inflammatory  response. 
Granulocytes can be identified through the expression of high levels of Grl  (Ly6G) 
and Macl  (CDllb) whereas monocytes express low levels of Grl  and high levels 
of Mac 1   (Taylor et al., 2003).
1.2.1  Transcriptional control of myelopoiesis
The main transcriptional regulators of myeloid cell development include PU.l  and 
CCAAT/enhancer  binding  protein  C/EBPa.  PU.l  is  a member of ETS  family  of 
transcription factors that is expressed in B cells, macrophages, mast cells and early 
erythroblasts.  The  importance  of  PU.l  in  myelopoiesis  was  revealed  by  the 
generation of Pu. 1 knock out mice, in which most of the ETS DNA binding domain 
was replaced with the neomycin-resistance gene. These mice were embryonic lethal 
between days  16.5 and  18.5  of gestation.  However, analysis of cells in the foetal 
livers  of  embryonic  day  (E)-14.5  embryos,  showed  a  normal  development  of 
erythrocytes  and  megakaryocytes,  but  revealed  an  absence  of  progenitors  for 
monocytes and granulocytes (CMP and GMP) (Scott et al.,  1994). McKrecher et al
32also generated Pu. 1 knock out mice by inserting the neomycin-resistance gene into 
the ETS domain (McKercher et al.,  1996). These mice lacked mature granulocytes 
and  macrophages  in  the  bone  marrow  and  foetal  liver,  whereas  deletion  of Pu.l 
after GMP formation resulted in excess granulocyte production (Dakic et al., 2005). 
These studies suggest that PU.l  is required for early myelopoiesis and is essential 
for  the  regulation  of  granulocytic  terminal  differentiation  (Olson  et  al.,  1995; 
Anderson et al.,  1998). One mechanism by which PU.l  mediates its function is by 
inhibiting  progenitor  cell  commitment  to  other  lineages.  This  process  is  mainly 
mediated  by  downregulating  the  expression  or  repressing  the  activity  of lineage 
specific  genes.  In this  context,  PU.l  has  been  shown  to  restrict  myeloid  lineage 
development by repressing the activity of the megakaryocyte-erythrocyte (Meg-E) 
specific  gene, GATA1.  GATA1  mediated activation of its target gene is  inhibited 
by  interaction  of PU.l  with the  GATA1  DNA  binding  domain,  thus  preventing 
binding  of  GATA1  to  DNA  and  blocking  transcription  of  genes  required  for 
commitment to MEP lineage (Zhang et al., 2000).
Another  important  regulator  of myeloid  differentiation  is  C/EBPa,  a  member  of 
leucine  zipper  transcription  factor  family  that  is  expressed  in  multiple 
haematopoietic lineages.  There are six members of the C/EBP family, all of which 
affect  different  stages  of haematopoiesis  (Antonson  et  al.,  1996;  Nerlov  et  al., 
1998).  C/EBPe,  for  example  is  required  for  terminal  maturation  of granulocytes 
(Yamanaka  et  al.,  1997).  Generation  of C/ebpa deficient  mice  has  revealed  the 
importance  and  nonredundant  role  of  the  protein  in  myeloid  and  granulocyte 
differentiation. Myeloid differentiation was blocked at the myeloblast stage in these 
mice and the expression of receptors for granulocyte-colony stimulating factor (G-
33CSF)  and  interleukin-6  (IL6)  could  not  be  detected  on  these  cells  (Zhang  et al., 
1997). In addition, progenitor cells isolated from these mice failed to form colony- 
forming  unit (CFU)-G colonies  in  vitro.  Granulopoiesis was partially restored  by 
retroviral  rescue  of G-CSF  or  IL-6  receptor  in  foetal  liver  progenitors  lacking 
C/EBPa (Zhang et al.,  1998). Monocytes, erythroid cells and lymphocytes were not 
affected in these mice. Furthermore, forced expression of C/EBPa in the bipotential 
myeloid  cell  line,  U937,  promotes  granulocyte  differentiation  at  the  expense  of 
monocytic  differentiation.  C/EBPa  has  also  been  shown  to  induce  granulocyte 
differentiation by affecting granulocyte specific genes such as G-CSF-R, GM-CSF- 
R, lactoferrin and neutrophil collagenase (Radomska et al., 1998).
1.3 Megakaryopoiesis
The  development  of  megakaryocytes  is  referred  to  as  megakaryopoiesis. 
Megakaryocyte-erythroid  progenitors  (MEPs)  are  early  precursors  that  have 
bilineage  potential.  Depending  on the  environmental  factors  and  the  presence  of 
specific  transcription  factors,  MEPs  can  differentiate  and  commit  to  the 
megakaryocytic  pathway  giving  rise  to  early  megakaryocyte  progenitor  cells, 
megakaryoblasts.  During  megakaryocyte  development,  megakaryoblasts  undergo 
endomitosis,  a  process  whereby  cells  undergo  DNA  replication  without  cell 
division.  This  is  observed  in  many  eukaryotic  cells  such  as  plant  endosperms, 
Drosophila and mouse trophoblast giant cells (Varmuza et al,  1988; Grafi  et al., 
1996). However, the biological importance of endomitosis in different cell types is 
as  yet  unclear.  As  the  megakaryocyte  development  progresses  the  DNA  ploidy 
increases from 8N to  128N, the nuclei become segmented and the cells increase in
34size, ultimately resulting in mature megakaryocytes with multi-lobed nuclei.  Since 
the  function  of  megakaryocytes  is  platelet  biogenesis  and  release  into  the 
bloodstream,  it  is conceivable that endomitosis  provides  a mechanism  for storing 
high  levels  of  platelets  by  limiting  the  use  of  cellular  machinery  to  platelet 
production rather than cell division. In this regard, the nuclear polyploidisation can 
also provide the increase transcriptional capacity required for high levels of platelet 
production necessary during disease or trauma.
Megakaryocytes  represent  0.03-0.06%  of all  nucleated  cells  in  the  bone  marrow 
(Berkow et al.,  1984). They are large cells (around 50-70 pm in diameter) and their 
cytoplasm  is  composed  of a  perinuclear  zone,  containing  organelles  for  protein 
synthesis,  an  intermediate  zone,  which  serves  as  cytoplasmic  demarcation 
membrane  thought  to  be  required  for  platelet  production  and  release,  and  a 
peripheral ring of cytoplasm that is free of organelles. Platelet granules are of two 
types, a-granules and dense bodies. Dense bodies contain nucleotides, calcium and 
lysosomes whereas a-granules consist of von-Willebrand factor (VWF), factors V, 
VIII and fibrinogen.
1.3.1  Thrombopoietin (TPO) and its effect on megakaryopoiesis
One  of the  major  regulators  of MK  development  and  platelet  production  is  the 
hormone  thrombopoietin  (TPO/  c-mpl-ligand/  megakaryocyte  growth  and 
development factor (MGDF). The major site of TPO production is in the liver and 
the  kidney.  TPO  is  comprised  of two  domains  based  on  its  homology  with  the 
erythroid differentiation factor erythropoietin (EPO).  The N-terminus  domain has
3546% homology with EPO and it is responsible for binding to its receptor c-mpl.  In 
contrast,  other  than  containing  N-  and  O-linked  carbohydrate  residues,  the  C- 
terminus does not show homology with any known protein domains (Bartley et al., 
1994; Sohma et al., 1994).
TPO has an important role in the proliferation and survival of megakaryocytes and 
hence  the  production  of platelets.  Tpo  and  c-mpl  deficient  mice  have  a  severe 
reduction  in the  level  of megakaryocytes  and  circulating platelets  (Gurney  et al,
1994). However, the megakaryocytes and platelets that are present are functionally 
and  morphologically  normal  (Bunting  et  al.,  1997).  This  suggests  that  TPO  is 
required for survival and not maturation of megakaryocytes in vivo. Multipotential 
progenitor cells were also reduced in these mice, implying a possible role for TPO 
in early haematopoiesis (Alexander et al.,  1996). Indeed, it was later confirmed that 
TPO can promote the proliferation and survival of primitive progenitor cells (Ku et 
al.,  1996; Ramsfjell et al.,  1997).  The effect of TPO on the clonal growth of Lin’ 
Scal+   progenitors  isolated  from  BM  was  investigated  by  performing  semi-solid 
colongenic assays.  These progenitors were shown to have a multilineage potential 
in the presence of TPO. In addition, TPO, in synergy with the cytokines FLT3 and 
SCF,  increased  the  growth  of multipotent  progenitor  colonies  (Ramsfjell  et  al,
1996).
Several  studies  have  also  highlighted  the  requirement  for TPO  in  erythropoiesis. 
TPO in combination with EPO was shown to increase erythroid colony formation 
of foetal  liver and BM derived progenitors (Kobayashi et al.,  1995) in addition to 
progenitors  isolated  from  yolk  sac  (Era  et  al.,  1997).  These  studies  reflect  the
36pleiotropic function of TPO in haematopoiesis.
1.3.2  Megakaryocytic cell surface markers
Megakaryocytes  can  be  distinguished  from  other  haematopoietic  cells  by  the 
expression of the CD41  antigen on the cell surface. CD41  is expressed throughout 
megakaryocytic  development  and  maturation.  The  protein  is  a  heterodimer 
containing  a  heavy  chain  glycoprotein  Ilb-alpha  (GPIIb-a)  and  a  light  chain 
glycoprotein  Ilb-beta  (GPIIb-p),  linked  by  a single  disulfide  bond.  CD41  is  also 
expressed on platelets, where the GPIIb-a chain of CD41  interacts with the GPIIIa- 
P  of CD61  to  form  the  platelet  glycoprotein  complex  gpIIb/IIIa  (CD41/CD61) 
(Mitjavila-Garcia et al.,  2002).  This complex is required for platelet function and 
aggregation  and  acts  as  a  receptor  for  adhesion  molecules  such  as  fibrinogen. 
CD41  is also recognized as a haematopoietic progenitor cell marker.  It is expressed 
on  early  HPCs  derived  from  both  the  aorta-gonad-mesonephros  (AGM)  and  the 
yolk  sac  and  its  expression  is  lost  upon  differentiation  (Mitjavila-Garcia  et  al., 
2002).  Since CD41  is expressed on HPCs derived from embryonic stem (ES) cells, 
it is suggested that its expression indicates an initiation of definitive haematopoiesis 
during embryoid body (EB) development in vitro (Mikkola et al, 2003). This was 
further  supported  in  the  yolk  sac  in  vivo,  where  CD41  expression  preceded  the 
expression of the panhaematopoietic marker, CD45. At the foetal liver stage, CD41 
expression is downregulated and all definitive haematopoietic cells express CD45 
(Mitjavila-Garcia et al., 2002; Mikkola et al., 2003). In adult haematopoiesis, CD41 
expression is detected on BFU-E and CFU-MK, and later on megakaryocytes and 
platelets in the bone marrow.
37Another protein expressed on the cells of the megakaryocytic lineage is CD9 which 
is a member of the tetraspanin family of transmembrane receptors. The expression 
pattern  of  CD9  is  more  complex  than  CD41.  CD9  is  expressed  on  pre-B 
lymphocytes,  basophiles,  eosinophils,  activated  T  cells,  megakaryocytes  and 
platelets  (Cramer  et  al.,  1994;  Berger  et  al.,  1996).  CD9  upregulation  in 
megakaryocytes occurs prior to the expression of CD41 and CD61  (Le Naour et al.,
1997)  and  its  expression  is  not  detected  on  the  cells  of the  erythroid  lineage, 
making  it an  important  marker to distinguish megakaryocytes  from these  closely 
related  lineages.  In  contrast  to  CD41,  CD9  is  not  expressed  on  early  HSCs. 
However, an anti-CD9 antibody has been used to isolate and purify megakaryocytic 
progenitors  from  the  bone  marrow  stem  cell  progenitor  (c-kit+,  Seal’,  IL7R-a', 
Thyl.l’,  Lin’)  population.  This  population  of cells  was  shown to  be  positive  for 
CD41 and gave rise to megakaryocytes and platelets in vitro and in vivo. (Nakom et 
al., 2003)
1.3.3  Transcriptional regulation of megakaryopoiesis
Gene  targeting  studies  in  mice  have  highlighted  the  importance  of  various 
transcription  factors  required  for  progenitor  cell  commitment,  proliferation  and 
terminal differentiation of megakaryocytic cells. These transcription factors include 
members of the GATA1  family (GATA1  and GATA2), BACH1, RUNX1, NF-E2 
and ETS family members FLU  and ETV6. The role of some these vital proteins at 
the different stages of megakaryocyte development will be discussed below (Figure 
1.2).
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Figure  1.2.  Megakaryocyte development.  A. Megakaryocyte-erythroid  progenitors (MEPs) 
are bipotential cells capable of commitment to either the megakaryocyte or the erythroid lineage. 
This lineage commitment is dependent on cytokine conditions and on the level and availability 
of specific transcription factors.  GATA1  and FOG-1  are involved in the commitment of CMPs 
to the megakaryocyte or erythroid lineage. NF-E2 and FLI1 transcription factors are essential for 
terminal  differentiation,  which  involves  platelet  production  and  release.  The  cell  surface 
markers  that  differentiate  different  population  of  HSCs,  progenitors  and  mature  cells  are 
indicated in red. Thyl, thymus  1;  FLT3,  FMS-Like Tyrosine Kinase 3;  EPOR, Erythropoietin 
Receptor;  CD41,  Glycoprotein  Ilb/IIIa  integrin receptor;  GCSF-R,  G-CSF  Receptor.  Diagram 
adapted from Pang et al 2005 and Iwasaki et al 2003. B.  The morphology of cells undergoing 
maturation (Wright-Giemsa stained cells). Megakaryoblasts have a higher nucleus to cytoplasm 
ratio  and as  megakaryoblasts  differentiate they  become  larger  in size  and  the  nuclei  become 
multi-lobulated (Hoffbrand and Pettit, 1988).
391.3.3.1 GATA1
Gatal  is  located  on  the  X-chromosome  and  is  a member of GAT  A  transcription 
factor  family  (GATA2-GATA6).  These  proteins  regulate  gene  expression  in 
different haematopoietic cells by specific recognition and binding to the consensus 
DNA sequence (A/T)GATA(A/G).  The GATA-1  protein comprises two zinc finger 
(ZnF) domains,  located at the N-terminus (NF) and C-terminus (CF), and encoded 
by  exons  IV  and  V,  respectively  (Figure  1.4).  The NF and  CF  domains  are  both 
required  for  DNA  binding,  whereas  NF  is  also  involved  in  protein-protein 
interactions especially with its transcriptional cofactor FOG1 (Friend Of GATA1).
Targeted disruption of the Gatal gene in mice, has revealed the role of GATA1  as 
the  main transcriptional  regulator of erythropoiesis and megakaryopoiesis  (Table 
1). The generation of Gatal  null mice demonstrated the importance of GATA1  in 
erythropoiesis. These mice were embryonic lethal and died at mid gestation due to 
severe anaemia. The erythroid precursors deficient in GATA1  had a differentiation 
block  at  the  proerythroblast  stage  of the  erythroid  development  (Fujiwara et al.,
1996). As these embryos die between El0.5  and El 1.5, the functional importance 
of GATA1  in the  megakaryocyte  development could not be  investigated  in these 
mice.
The  Gatal  null  embryonic  stem  cells  generated  by  Pevny  et al also  showed  the 
importance of GATA1  in erythroid maturation (Pevny et al.,  1991).  The resultant 
chimeric  mice  were  anaemic  and  the  cells  failed  to  contribute  to  differentiated 
erythroid cells. Further studies on these mice revealed that lack of GATA1  resulted
40in  abnormal  proliferation  of  megakaryocytes  but  that  megakaryocyte  terminal 
differentiation, as measured by platelet production, was not affected (Pevny et al.,
1995). The authors concluded that the function of GATA1  was compensated for by 
another family member, GATA2. GATA2 is also expressed in megakaryocyte cells, 
but  expressed  at  very  low  levels  in  early  erythropoiesis,  explaining  the  non­
redundancy in the erythroid cells.
Lineage  specific  deletion  of  GATA1  has  demonstrated  its  importance  in 
megakaryocyte  development.  In  the  GatalneoAH S  mice,  sequences  including  the 
DNasel hypersensitivity (HS) sites present upstream of the GATA1  promoter were 
replaced with a neomycin-resistance cassette by homologous recombination in ES 
cells (McDevitt et al., 1997). The level of GATA1 expression in erythroid cells was 
reduced by  5  fold,  but its  expression was not detected  in megakaryocytes.  These 
mice exhibit primitive erythrodysplasia and definitive erythroid cells are arrested at 
the  proerythroblast  stage.  Most  mice  died  during  embryogenesis  due  to  anaemia 
and thrombocytopenia.
In a second GatalMeoAm gene targeted mutant mouse, the neomycin cassette was 
removed  by  CRE-mediated  site  specific  recombination,  which  restored  GATA1 
expression in erythrocytes (Shivdasani et al.,  1997). The reduced levels of GATA1 
in  erythrocytes  of  GatalneoAHS  mice  were  attributed  to  the  transcriptional 
interference  caused  by  the  insertion  of neomycin  cassette  in  a  transcriptionally 
active  region.  Since  GATA1  expression  was  normal  in  erythroid  cells,  the 
GatalAneoAH S mice were not anaemic  and did not exhibit any abnormalities  in the 
erythroid lineage.  In common with the GatalneoAH S mice,  GATA1  expression was
41undetectable in megakaryocytes of these mice. There was a profound reduction in 
the number of circulating platelets and thrombocytopenia was manifested in these 
mice as a consequence.  In contrast to erythroid cells, there was an increase in the 
levels  of immature  megakaryocytes  in  the  spleen  and  bone  marrow  and  colony 
forming  assays  using  progenitor cells  isolated  from  the  yolk  sac  and  foetal  liver 
resulted  in  hyperproliferative  colonies  which  represent  the  accumulation  of 
megakaryoblasts  (Shivdasani  et  al.,  1997).  There  were  however,  some  mature 
megakaryocytes present in these mice, although these were shown to be abnormal 
in  size  and  in  their  ability  to  undergo  endomitosis.  Furthermore,  the  platelets 
produced  by  these  megakaryocytes  were  functionally  defective  as  shown  by  the 
prolonged  bleeding  in  these  mice  upon  exposure  to  trauma  (Vyas  et  al.,  1999). 
These  studies  suggest  that  GATA1  is  not  essential  for  the  initial  stages  of 
megakaryopoiesis.
The  role  of  GATA1  in  terminal  megakaryocyte  maturation  and  primitive 
erythropoiesis was further confirmed by the analysis of the Gatal.05 mouse line. 
The erythroid specific regulatory elements of the Gatal gene, were disrupted by the 
insertion of the neomycin cassette.  Since  Gatal  is  an X-linked gene,  males  only 
have one copy of the gene and are therefore hemizygous for the Gatal  gene.  The 
male embryos express GATA1  at 5% of the total mRNA level expressed in wild- 
type embryos  and  hence the  mouse  line  is  referred to as Gatal.05.  The  resultant 
mutant mice had a 20 fold reduction of GATA1  expression in erythroid cells.  In 
common with the GatalneoAH S mutant line and the Gatal null embryonic stem cell 
model, erythroid development was arrested at the proerythroblast stage in Gatal. 05 
mice.  As a result, hemizygous males are embryonic lethal at El2.5  due to  severe
42anaemia. Some of the heterozygous females survived but died of a myelodysplastic 
syndrome  (MDS)  by  5  months  of age  (Takahashi  et  a l,  1997;  Takahashi  et al.,
1998). Although megakaryopoiesis appeared normal and the cells stained normally 
with  acetylcholinesterase,  terminal  differentiation  appeared  defective  due  to  the 
reduction in platelet levels, which was reflected in thrombocytopenia in these mice.
T able  1: Summary of GATA1 gene-targeted mice 
GATA1 mice  Targeting strategy  MK  Ery  Phenotype
GAT  A 1nul1  Total G  ATA1  KO  x
GATAl***^  Replacement  of sequences  x
upstream  of  GATA1 
promoter with a neomycin 
cassette
x  - Embryonic lethal (El0.5)
4 5F  - Most die during embryogenesis
-  5%  of  die  hemizygous  males  are 
bom anaemic and thrombocytopenic 
Few animals that survive recover from 
anaemia but remain thrombocytopenic
G  A T A  1AneoAHS  Deletion  o f  the  neomycin
cassette  from  the
GATA1.05
GATA1
neoAHS
Disruption  of  erythroid 
specific  sequences  in  die 
promoter of GATA1
Mutation  in  FOG1  interaction 
domain
GATA 
Val205Gly
MK:  m egakaryocyte,  Ery:  Erythrocyte,  KO:  Knock out,  F:  Fold 
Adapted from (Gurbuxani et al., 2004)
- Thrombocytopenia
j   - Increased levels of immature MK
- Abnormal differentiated MK
I  -Hemizygous males die by E12.5
20F  - Heterozygous females exhibit anemia
and thrombocytopenia and begin to die
by 5 months
- Hemizygous males die by El2.5
431.3.3.2 FOG1
The  function  of GATA1  in  erythroid  and  megakaryocyte  development  is  partly 
dependent on the interaction with its cofactor FOG1  (Friend Of GATA1). FOG1  is 
a  9  zinc  finger  protein  that  can  interact  with  the  N-terminus  zinc  finger  of all 
GAT  A family members via its 6th zinc finger (Fox et al.,  1998). Fog" mice had a 
marked  defect  in  erythroid  development  with  maturation  arrest  at  the 
proerythroblast  stage  and  died  at  El 0.5-El 2.5.  This  resembles  the  phenotype 
detected in the Gatal"  mice, suggesting that both GATA1  and FOG1  proteins are 
required for effective erythropoiesis. Several groups have generated in vivo models 
to demonstrate the importance of the GATA-FOG interaction in megakaryopoiesis.
In contrast to the GataAneoAHS miCe where only megakaryocyte terminal maturation 
was affected, the  Fog'' mice failed to produce any megakaryocytes,  suggesting a 
GATA1  independent  function  of FOG1  in  early  megakaryopoiesis  (Tsang  et al.,
1997).  Alternatively,  as  GATA2  is  expressed  in  primitive  HSCs  and  in 
megakaryocytes,  it  is  possible  that  in  GatalAneoAH S miC e  GATA2  interacts  with 
FOG1  and  compensates  for  the  function  of GATA1  in  early  megakaryopoiesis. 
This  hypothesis  was  confirmed  by  the  generation  of  a  double  knock-in  mice 
containing a mutation (Valine-to-Glycine substitution) in the GATA1  and GATA2 
motif required  for  interaction  with  FOG1  (Chang et al.,  2002).  This  mutation  is 
identical to the natural occurring missense mutation in the GATA1 N-terminus zinc 
linger domain identified in patients with X-linked thrombocytopenia and anaemia 
(Nichols  et al.,  2000).  Yolk  sac  derived progenitors  from  these  double  knock-in 
mice (GataV 205G ) failed to form any megakaryocytic colonies thus  suggesting that
44the function of FOG1  in early megakaryopoiesis is GATA dependent (GATA1  or 
GATA2).
It has also been demonstrated that the GATA 1-FOG 1   interaction is crucial for the 
late stages of megakaryopoiesis (Chang et al., 2002; Shimizu et al., 2004; Muntean 
and  Crispino,  2005).  Shimizu  et  al  showed  that  although  the  Gatal12050  cDNA 
transgene  rescued  the  Gatal.05  mutant  mice  from  embryonic  lethality,  the 
dysregulated  megakaryocyte  terminal  maturation  in  adult  mice  could  not  be 
rescued.  In  this  regard,  expression  levels  of  genes  required  for  late  stages  of 
megakaryocyte differentiation, such as NF-E2 and MAFK, were severely reduced 
(Shimizu  et  al.,  2004).  This  study  suggests  that  the  GATA-FOG  interaction  is 
dispensable for early erythropoiesis but it is vital for regulating genes required for 
megakaryocyte differentiation and platelet formation.  This  study  also  highlighted 
the fact that some GATA1 mediated gene regulation may be FOG1  independent, as 
shown by the altered expression of some genes in the rescued mice.
1.3.3.3  GATA2
In common with GATA1,  GATA2  is expressed  in mast cells,  erythroid cells and 
megakaryocytes.  In contrast to  GATA1,  GATA2  is expressed  in early HSCs and 
current  data  suggests  that  this  protein  is  critical  for  survival  and  proliferation  of 
primitive HSCs (Ling et al., 2004).  In addition, expression of GATA2 protein at 
different  developmental  stages,  is  essential  for  lineage  commitment  and 
differentiation. The generation of Gata2 deficient mice revealed the importance of 
GATA2 in erythropoiesis, as these have low numbers of erythroid cells and died at 
El 0-El 1   gestation (Tsai et al.,  1994). Indeed, GATA2 expression decreases duringerythroid terminal differentiation and enforced expression of the protein in primary 
erythroblasts results in growth and differentiation arrest at the proerythroblast stage. 
Furthermore, over-expression of GATA2 in the K.562 erythroleukemic cell line was 
shown  to  inhibit  erythroid  differentiation  and  promote  megakaryocyte 
differentiation  (Ikonomi  et  al.,  2000).  GATA2  alone  is  not  required  for 
megakaryocytic  development  since  in  vitro  differentiated  Gata-2~~  murine  ES 
cells produce normal  megakaryocytes (Tsai  and  Orkin,  1997).  However,  GATA2 
can compensate for the function of GATA1  in early but not late megakaryopoiesis 
(Chang et al., 2002).
1.3.3.4  NF-E2  and  FLI1  are  required  for  terminal  maturation  of 
megakaryocytes
Megakaryocyte terminal  differentiation  is  characterised  by the  change  in  cellular 
morphology and proplatelet formation and release, all of which are accompanied by 
an  increase  in  expression  levels  of genes  required  for  these  processes.  Nuclear 
factor-erythroid  2  (NF-E2)  is  a  heterodimeric  protein  that  regulates  the  terminal 
maturation  of  megakaryocytes  and  platelet  biogenesis.  Expression  of  erythroid 
specific globin genes are mediated by core enhancers, such as NF-E2 motifs within 
the  locus  control  region  (LCR).  The  NF-E2  heterodimeric  complex  is  the  major 
protein that binds these sites.  The NF-E2 complex is an heterodimer of two basic 
leucine  zipper (bZIP)  proteins,  a  large  p45  NF-E2  subunit belonging to  a family 
closely  related  to  the  Drosophila  Cap-N-Collar  (CNC)  family,  and  the  smaller 
subunit,  pi8  NF-E2  or  MAFK,  belonging  to  the  small  MAF  subfamily.  The 
expression of p45  NF-E2  is restricted  to the  haematopoietic tissues  whereas  p i8 
NF-E2  is  widely  expressed.  The  p45  subunit  can  bind  to  NF-E2  sequences  by
46forming  heterodimers  with  MAFK  protein  and  the  other  small  MAF  proteins, 
MAFF  and  MAFG,  however,  the  NF-E2  complex  containing  MAFK  and  p45 
display the highest affinity to NF-E2 binding sites (Igarashi et al.,  1994; Meguro et 
al.,  1995).  The role of NF-E2 in late stages of megakaryooiesis was confirmed by 
the  phenotype  of mice  deficient  in  the  p45  subunit  of NF-E2.  These  mice  lack 
terminally  differentiated  megakaryocytes  and  circulating  platelets  and  as  a result 
die  of haemorrhage  (Shivdasani  et  al.,  1995;  Lecine  et  al.,  1998).  The  MAFK 
subunit  of  NF-E2  also  plays  a  role  in  the  regulation  of  megakaryocytic 
differentiation, although only in synergy with another family member, MAFG. This 
is based on reports that mice lacking MafK did not exhibit any abnormalities in the 
megakaryocyte  lineage  and  were  otherwise  viable  and  healthy.  In  contrast,  mice 
deficient in MafG, where the entire coding sequence was replaced with Escherichia 
coli  lacZ  gene,  had  abnormal  megakaryopoiesis  as  shown  by  impaired  platelet 
formation  and  increased  megakaryocyte  proliferation  (Shavit  et  al.,  1998). 
However, the phenotype of the MafG mutant mice was exacerbated when combined 
with  the  MafK  heterozygotes  (MafG'VMaffC').  These  mice  exhibited  profound 
thrombocytopenia  and  megakaryocytes  were  defective  in  proplatelet  formation 
(Onodera  et  al.,  2000).  These  results  suggest  a  dosage  dependent  function  for 
MAFK, in platelet biogenesis.
Flil  (Friend  leukemia  virus  integration  1),  a  member  of  the  ETS  family  of 
transcription  factors,  is  also  required  for effective megakaryocytic  differentiation. 
Mice  lacking Flil  display  dysmegakaryopoiesis.  These mice die  at mid  gestation 
and in vitro analysis of megakaryocyte development has revealed abnormalities in 
cellular morphology and a block in megakaryocytic maturation (Hart et al., 2000).
47The expression of the  late megakaryocyte  specific  gene,  glycoprotein  IX  (GPIX), 
was  markedly  reduced  in  F lf  megakaryocytes,  whereas  the  expression  of early 
genes,  cMpl  and  CD41,  remained  unchanged.  One  mechanism  of  Flil  gene 
regulation  may  be  through  its  interaction  with  GATA1  zinc  fingers,  as  this 
interaction  was  found  to  mediate  the  activation  of  genes  associated  with 
megakaryocyte  maturation,  such  as  GPIX (Eisbacher  et  al.,  2003).  Observations 
from  Paris-Trousseau  syndrome  (PTS)  patients,  further  imply  a  role  for  FLU  in 
megakaryopoiesis. Terminal deletion of the long arm of chromosome  11, results in 
the deletion of the Flil  gene. As a consequence, these patients suffer from severe 
thrombocytopenia  and  there  is  an  abnormal  accumulation  of  immature 
megakaryocytes (Raslova et al., 2004).
1.4 Acute childhood leukaemia
Human  acute  leukaemias  can  be  characterised  by  the  abnormal  proliferation  or 
differentiation  of cells  of the  haematopoietic  system  with  the  subsequent  clonal 
accumulation of immature cells or blasts in the bone marrow (BM) and peripheral 
blood  (PB).  Acute  leukaemias  can  be  subdivided  into  either  acute  lymphocytic 
leukaemia (ALL) or acute myelogenous leukaemia (AML), which affect cells of the 
lymphoid or the myeloid  lineage, respectively.  ALL is the most common form of 
childhood malignancy accounting for approximately 70% of childhood leukaemias, 
whereas around 30% of children with leukaemia have AML. Chronic myelogenous 
leukaemia (CML)  is  also  observed  in  children but with a much  lower incidence. 
Myeloid  leukaemias can be divided into  subgroups based on the type of myeloid 
cells affected and the chromosomal aberrations associated with the disease (Table
482).
Table 2: French-American-British (FAB) classification of AML
FAB Type  Description
MO
Ml
M2
M3
M4
M 4 eo
M5
M6
M7
Undifferentiated
Myeloblastic without maturation
Myeloblastic with maturation 
Promyelocytic
Myelomonocytic
Myelomonocytic with 
bone marrow eosinophilia
Monocytic
Erythroleukemia
Megakaryoblastic
Mutations
AMLl,  Myeloperoxidase  negative; 
myeloid markers positive
Some  evidence  of  granulocytic 
differentiation
t(8;21) AML 1  -ETO and AML 1-EV11
t( 15; 17) PML-RARa or other - RARa 
translocations
llq23  translocations  t(9; 11)  MLL-AF9 
and t(2;l 1) HOXD13-NUP98 
Inversion  of chromosome  16  involving 
CBFP
llq23  translocations  t(9; 11)  MLL-AF9 
and t(8; 16) MOZ-CBP
GATA1  mutations  in  those  associated 
with  DS,  t(l;22)  RBM15-MLK 
associated with non DS-AMKL
Table from (Tenen, 2003).
1.4.1  Models of leukaemic initiation and progression
There are currently two proposed models of leukaemic initiation and progression. 
The  stochastic  model  predicts  that  all  the  cells  in  the  leukaemic  clone  have  the 
potential to give rise to leukaemia and are therefore homogenous. According to this 
model,  genetic  changes  that  cause  leukaemia  can  be  detectable  in  every  cell 
population. The stochastic model of leukaemic initiation is the basis of most of the 
current  therapeutic  approaches,  which  are  designed  to  target  all  the  cells  in  the
49leukaemia,  especially  proliferating  blasts.  In  contrast,  the  stem  cell  model 
postulates that there  is a heterogeneous population of cells,  each having different 
self renewal and differentiation capacities. According to this model, leukaemic cells 
have their own stem cells, capable of initiating and maintaining the growth of the 
leukaemia. These leukaemic stem cells (LSC) retain many properties of stem cells 
including  self  renewal,  proliferative  and  differentiation  potential.  This  model 
proposes that LSCs can be purified from the total leukaemic cell population based 
on distinctive expression of cell surface marker.
The first experimental evidence in support of the stem cell model was provided by 
AML xeno-transplantation into  immune deficient recipient  SCID  and NOD/SCID 
mice. It became clear that a subset of cells termed SCID leukaemia initiating cells 
(SL-ICs),  were  capable  of  maintaining  the  leukaemic  clone  in  recipient  mice 
(Lapidot et al.,  1992).  These cells demonstrated high self renewal capacity in the 
immune  deficient  NOD/SCID  mice.  In  these  xeno-transplantations  studies,  only 
CD34+CD38* HSCs from all AML subtypes, except for AML-M3, were capable of 
transplanting  leukaemia  in  NOD/SCID  mice  (Bonnet  and  Dick,  1997).  This 
suggests the existence of a hierarchy in AML, as in normal haematopoiesis. Further 
characterisation of these cells revealed differences in the expression of cell surface 
markers between normal HSCs and LSCs. Expression of the IL-3 receptor a chain 
(IL-3Ra), for example, is confined to LSCs, whereas c-Kit and Thy-1 are expressed 
on HSCs and are lacking on LSCs (Blair and Thomas,  1997; Blair and Athanasiou, 
2000; Jordan, 2002).  Further understanding of the distinctive biological features of 
LSCs and normal HSCs would allow for the development of therapeutic approaches 
to specifically target the leukaemic initiating cells in paediatric leukaemia.
50Many studies have addressed the nature of the target cell in the AML transforming 
events.  The  most  obvious  candidate  cells  are  the  uncommitted  HSCs  since  these 
cells have a high  self renewal  capacity which removes the necessity to  activate a 
self renewal program by the transforming mutations. Furthermore, the longevity of 
HSCs  could  allow  for  the  acquisition  of additional  genetic  events  required  for 
leukaemic transformation.  The possibility that HSCs are target cells  in AML was 
supported  in  mouse  transplantation  assays.  Transduction  of HSCs  by  the  MLL- 
GAS7 fusion gene  induced mixed lineage leukaemia in transplanted mice, but not 
with CMP or GMP transduced cells (So et al., 2003). A study by Miyamoto et al 
demonstrated that although HSCs may be a target cell for a specific transforming 
event, it is the subsequent changes in a more committed progenitor that gives rise to 
LSC (Miyamoto et al., 2000).
The hypothesis that the primary leukaemic event occurs in the HSCs, with high self 
renewal  capacity,  was  challenged by the discovery that leukaemic transformation 
can also occur in a more committed progenitor cell, where the self renewal potential 
is reactivated by the transforming mutation. Thus, the MLL-ENL fusion gene was 
shown  to  give  rise  to  the  same  leukaemia  independent  of whether  the  target  of 
transformation  was  HSC,  CMP  or  GMP  (Cozzio  et  al.,  2003).  In  addition,  the 
MOZ-TIF2 fusion gene associated with AML was shown to transform both HSCs 
and CMPs and GMPs (Huntly et al.,  2004).  These studies suggest that depending 
on the type of transforming mutation, LSC can be generated from either progenitor 
cells or a more primitive HSC.
511.5 Down syndrome
The hallmark of Down syndrome (DS) is the acquisition of an extra copy of human 
chromosome 21  (Hsa21/ Homo sapien 21)/ trisomy 21. Trisomy 21  occurs in  1   out 
of 700 live births and is the only autosomal aneuploidy that is not embryonic lethal 
and  is  associated  with  postnatal  survival.  The  pathology  of DS  affects  multiple 
systems  in  an  individual  ranging  from  the  nervous  system  to  immune  system 
abnormalities and an aberrant haematopoietic system. The occurrence and severity 
of the clinical  features of DS are highly variable amongst individuals.  Phenotypic 
characteristic of DS include, broad hands, hypotonia, short stature, and craniofacial 
dysmorphology such as flat nasal bridge and open mouth. There are two congenital 
diseases that affect DS individuals. Congenital heart defects (CHD) occur in ~50% 
of all DS newborns, whereas, the congenital gastrointestinal tract (CGI) dysfunction 
is detected in 4-5% of newborns.  Both disorders can be fatal if left untreated.  DS 
individuals suffer variable pathological penetrance in the nervous system.  Patients 
with  DS  have  delayed  cognitive  development  and  mild  to  moderate  mental 
retardation.  Furthermore,  individuals  over  the  age  of  30  commonly  exhibit 
pathological abnormalities correlated with Alzheimer’s disease (AD). Other clinical 
manifestations  of DS  disorder  include  infertility,  which  mostly  affects  men,  and 
thyroid dysfunction.
Detection of solid tumours is extremely rare in DS. There are a few reported cases 
of DS  patients with retinoblastoma (RB),  however,  evidence based on population 
studies indicate that there is no significant correlation between DS and RB (Hasle et 
al.,  2000;  Patja  et  a l,  2006).  Incidence  of other  solid  tumours  such  as  Wilms
52tumour  and  neuroblastoma,  is  lower  in  DS  patients  compared  with  the  general 
population  (Satge  et  al.,  1998).  Less  frequently,  Ewing’s  sarcoma  has  been 
associated  with  DS.  On  the  other  hand,  the  haematopoietic  system  is  severely 
affected in DS individuals. There is a high incidence of childhood leukaemias, such 
as  acute  myeloid  leukaemia  (AML),  and  in  particular,  acute  megakaryoblastic 
leukaemia (AMKL).
1.5.1  The  origin  of trisomy  21:  Chromosome  recombination  and 
non-disjunction
Aneuploidy (trisomy or monosomy) is the most common chromosomal abnormality 
identified  in  humans.  Events  occurring  during  the  meiotic  division  are  a 
contributing  factor  to  the  development  of  aneuploidies.  Meiosis  involves  two 
nuclear divisions after a single phase of DNA replication. During the first meiotic 
division  (MI),  which  is  dominated  by  prophase  I,  the  two  sets  of homologous 
chromosomes each consist of two sister chromatids.  Chromosomal recombination 
occurs between non sister chromatids at chiasmata (point at which the exchange of 
genetic material occurs on the chromatids).  Following the chromosomal crossover 
events,  homologous  chromosomes  are  segregated  into  two  separate  cells  thereby 
reducing the number of chromosomes from 4n to 2n. The second meiotic division 
(Mil) involves the alignment of chromosomes on a second spindle without further 
DNA replication and separation of sister chromatids into four haploid cells. Failure 
of  homologous  chromosomes  to  separate  during  meiosis  is  referred  to  as 
chromosome non-disjunction. This results in haploid cells with either an additional 
or reduced copy of a particular chromosome.
53Chromosomal  non-disjunction  in  lower  organisms,  such  as  Saccharomyces 
cerevisiae  and  Drosophila,  is  well  documented.  Isolation  of  mutations  in 
Drosophila  has  revealed  a reduction  in  recombination,  in  particular,  in  the  distal 
regions and premature segregation of homologous chromosomes at MI (Carpenter 
and  Sandler,  1974).  Mutations  in  genes  such  as  the  Ord  and  Me/-S332  in 
Drosophila  result  in  the  premature  disjoining  of  sister  chromatids  in  MI  at 
prometaphase I and anaphase I, respectively (Miyazaki and Orr-Weaver, 1992).
The  mechanism(s)  underlying  chromosome  non-disjunction  in  humans  has  been 
under intense investigation. The hypothesis that alterations in recombination are a 
critical factor in human trisomy was initially proposed by Henderseon and Edwards 
in  1968  (Henderseon  and  Edwards  1968).  A  study  carried  out  by  Warren  et  al 
measuring  the  recombination  frequency  on  chromosome  21,  provided  the  first 
evidence correlating reduced recombination with human trisomy 21. This reduction 
was not due to failure or absence of any homologous chromosome 21  exchange at 
meiosis  I  (MI),  as initially predicted (Warren et al.,  1987;  Sherman et al.,  1991). 
The genetic linkage map of chromosome 21  revealed that the number of chiasmata 
between  non-sister  chromatids  may  play  a  crucial  role  in  efficiency  of 
recombination  (Sherman  et  al.,  1994).  It  later  became  apparent  that  efficient 
separation of chromosomes appears to be influenced by the position at which the 
exchange occurs.  There  is a reduced efficiency of chromosome segregation when 
exchange  occurs  at distal  21 q,  or telomeric  region,  of the  chromosome  at  MI,  in 
comparison  with  centromeric  exchanges.  Errors  at  Mil  are  also  linked  with 
chromosomal  non-disjunction.  In  contrast  to  MI,  there  is  an  increased 
recombination in proximal 21q, pericentromeric region, of the chromosome at Mil
54(Lamb et al.,  1996). It is as yet unclear if Mil non-disjunction originates in MI or if 
it is an event specific to MIL
Sherman and colleagues provided the first evidence for a link between maternal age 
and reduced recombination events at MI.  Studies of 300 DS  individuals of varied 
ages revealed a reduction in recombination along 21 q with increased maternal age 
(Sherman et al.,  1994).  Chromosome  15 non-disjunction and recombination events 
have also been shown to be associated with maternal age (Robinson et al.,  1998). 
A two hit hypothesis has been proposed to explain the link between chromosomal 
non-disjunction and  maternal  age.  The  first  hit  involves  age-independent  events 
that  occur  in  MI  with  the  establishment  of a  chromosome  configuration  that  is 
susceptible to non-disjunction. The second hit requires degradation of meiotic cell 
cycle  machinery  which  prevents  effective  processing  or  segregation of non-sister 
chromatids.  The defective meiotic process is associated with maternal age and as 
yet unknown environmental factors.
It is now believed that reduced recombination at MI is a common source of human 
aneuploidy. The origin and possible cause of chromosome nondisjunction varies in 
trisomy 16, 18,  15, 22 and paternally and maternally derived sex chromosomes. For 
example  in maternally  derived  trisomy  22,  most cases  involve  MI  nondisjuntion, 
whereas for trisomy 18 most cases are linked with errors at MIL
551.5.2 Murine models of Down syndrome
Genetic  mapping  of  DS  individuals  who  shared  clinical  features  led  to  the 
identification  of a  common  region  on  chromosome  21,  referred  to  as  the  Down 
syndrome  critical  region  (DSCR).  It  is  proposed  that  genes  within  this  region 
contribute to the pathogenesis of various DS phenotypes.  The initial  reports were 
based  on the  analysis  of patients with partial  trisomy  21,  where  patient’s  clinical 
phenotypes were assigned to  specific  segment in chromosome 21  (Korgaonkar et 
al.,  2005).  This  region  extends  about  5  Mb  from  DSJS17  to  Mxl  and  clinical 
features linked to this region include mental retardation, craniofacial anomalies and 
short stature. However, there is currently a discrepancy in the location of the DSCR 
within  chromosome  21,  since  several  reports  have  associated  DS  clinical 
manifestations to different regions on HSA21. This has made it difficult to correlate 
a certain phenotype associated with DS to a single “critical chromosomal region”. 
Several murine models of DS have been generated in order to attempt to link these 
genes on chromosome 21 to different clinical traits of DS. The orthologues of genes 
located on  HSA21  are  located on three  separate  mouse chromosomes  (Mmu)  16, 
Mmul7  and  Mmu 10.  The conserved genes are distributed on different regions of 
the chromosomes (Figure 1.3).
Two transgenic murine models, Ts65Dn and TslCje, partially trisomic for MMul6, 
have  been  generated.  The  Ts65Dn  segment  is  comprised  of genes  from  the App 
(amyloid  beta (A4)  precursor protein)  gene up to the Znf295  (zinc  finger protein 
295) gene (Davisson et al.,  1990). Phenotypes in the Ts65Dn mice that recapitulate 
those found in human DS, include abnormal development of the cerebellum (Baxter
56et  al.,  2000)  and  reduced  development  of craniofacial  skeleton.  These  mice  also 
develop  myeloproliferative  disorders  characterised  by  thrombocytosis,  bone 
marrow fibrosis and anaemia (Kirsammer et al., 2008). In the TsCje mice, the extra 
copy  of chromosome  16  spans  from  the  Sodl  (21q22.1)  to  the  Mxl  (21q22.3) 
region.  However,  the Sodl  gene  is  functionally  inactive due to the  insertion of a 
neomycin resistance gene (Figure  1.3).  In comparison with Ts65D, the deficiency 
in learning is much less pronounced in the TslCje model, and degeneration of the 
basal forebrain cholinergic neurons is absent (Sago et al., 1998).
O'Doherty  et  al  have  generated  the  trans-chromosomic  mouse  line  TCI  that 
closely reflects the genetic situation in human DS (O'Doherty et al, 2005). These 
mice carry a copy of HS A21  and are therefore trisomic only for the genes expressed 
on  this  chromosome.  The  other  murine  models  generated  to  date  comprise  of a 
limited percentage of the orthologs of genes present on HSA21.  In contrast,  TCI 
mice  contain  92%  of the  genes  on  HSA21,  making  it the most applicable  model 
system  to  study  the  pathology  of  DS.  The  human-mouse  tranchromosomic 
embryonic  stem (ES) cell  line,  lacked two  segments of HSA21  (O'Doherty et al., 
2005).  One  region  spans  3.4  Mb  from  CXADR  and  DS1S1922  and  the  second 
region  spans  1.5  Mb  from  IFNAR1  and  RUNX1.  Abnormalities  detected  in  mice 
generated  from  these  ES  cells,  include  learning  difficulties  and  a  reduction  in 
cerebella neuron density. The most striking feature of these mice is the occurrence 
of congenital heart defects which are a prominent clinical manifestation in human 
DS. This phenotype is rarely observed in other mouse models. However, in contrast 
to Ts65Dn and TslCje, the TCI  mice did not display any defects in the craniofacial 
morphology (O'Doherty et al., 2005).
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Figure  1.3.  Murine  models  of  Down  syndrome  (DS).  The  genes  located  on  the  human 
chromosome 21 are located on three separate mouse chromosomes, Mmu 10, Mmu 16 and Mmu 17. 
The  red  bars  represent  the  region  of the  mouse  chromosome  and  the  genes  located  on  the 
chromosomes that are orthologous to the human chromosome 21  genes. The genes located within 
the Down syndrome critical region (DSCR) are highlighted in grey.  Several  DS  murine models 
have been generated.  The green bars represent the genes that are trisomic in these mouse models. 
Ts65Dn, Tsi  Cje and Tsi  Rhr mouse models are trisomic for mouse chromosome  16.  The TCI 
model uses the human chromosome 21.  There are two gaps within HSA21  in the TCI  mice which 
results  in  absence  of 8%  of the  genes  expressed  on  this  chromosome.  Diagram  adapted  from 
Reeves et al., 2001 and Arron et al., 2006).
58Recent analysis of the haematopoietic  system  in Ts65Dn mice  showed that these 
mice developed a myeloproliferative disease (MPD) (Kirsammer et al., 2008). The 
characteristic  features  of  MPD  include  megakaryocytic  dysplasia, 
thrombocytopenia  and  myelofibrosis.  However,  these  mice  did  not  develop 
leukaemia, suggesting that other genes on HSA21  not represented in Ts65Dn mice 
are  required  or  additional  genetic  mutations  are  necessary  for  leukaemic 
transformation.  The  murine  models  generated  thus  far  do  not  display  all  defects 
detected  in  DS.  Importantly,  none  of  the  mouse  models  develop  the  AMKL 
detected  in  DS  neonates.  As  DS  individuals  have  a  high  propensity  to  develop 
leukaemia, it is vital to develop an in vivo model to investigate the mechanisms by 
which trisomy 21 contributes to development and progression of leukaemia in DS.
1.5.3  Down syndrome and leukaemia
As  mentioned  previously,  haematopoietic  development  in  DS  patients  is  highly 
defective,  manifested  in  part  by  an  increased  risk  of leukaemia.  Development of 
leukaemia is more prevalent in children and the risk decreases with age (Hasle et 
al., 2000). There is a 20 fold increased chance of leukaemia in DS compared with 
non-DS  patients,  and  in  particular  there  is  a  600-fold  increase  risk  for  acute 
megakaryoblastic  leukaemia  (AMKL)  development  in  these  children.  Leukaemia 
usually occurs within the first 3-4 years of life and around 10% of children with DS 
are bom with a disorder referred to as transient myeloproliferative disorder (TMD) / 
transient abnormal myelopoiesis (TAM) / transient leukaemia (TL).
TMD  is  characterised  by  the  abnormal  accumulation  of  myeloblasts  in  the
59peripheral  blood  (PB)  and  bone  marrow  (BM).  TMD  can  be  distinguished  from 
AML  by  clinical  presentation,  characteristic  cytogenetic  and  haematological 
abnormalities and by  its spontaneous resolution, typically in the first 3  months of 
life. TMD is usually diagnosed during the first few days of life and AML generally 
occurs after  1   year of age (Hayashi et al.,  1988). The blasts associated with TMD 
often  exhibit  AMKL  morphology,  expressing  megakaryocytic  and  sometimes 
erythroid markers.  In most cases, trisomy 21  is the sole chromosomal abnormality 
(Massey  et  al.,  2006),  whereas  blasts  in  AML  may  show  complex  cytogenetic 
abnormalities.  AML blasts express high levels of myeloid markers in comparison 
with  the  TMD  blasts  (Karandikar  et  al.,  2001).  In  the  majority  of cases,  TMD 
resolves  spontaneously  in  the  first  three  months  of life.  However  approximately 
20% of patients with TMD will subsequently progress to develop FAB M7 AMKL. 
It is generally believed that the occurrence of TMD may be under diagnosed. This 
has been mainly attributed to the fact that blood counts are not performed on every 
DS neonates and therefore many cases are left unreported.
AMKL is characterised by the proliferation and accumulation of megakaryoblasts 
in  the  BM.  The  differentiation  block  at  the  early  stages  of the  megakaryocytic 
development  causes  reduced  production  of  platelets  which  is  manifested  as 
thrombocytopenia in the affected patients. AMKL usually presents with one of two 
genotypic  abnormalities,  either  Down  Syndrome  accompanied  by  the  somatic 
GATA1  mutation  or  non-DS  AMKL  associated  with  the  translocation  t(l;22) 
involving  RBM15  (RNA  Binding  Motif  protein  15)  and  MKL  genes.  AMKL 
patients with DS have a much better prognosis than de novo AMKL or patients with 
secondary AMKL.
60Children with DS also have an increased risk of developing ALL and AML.  There 
are some differences between the pathogenesis and clinical features of ALL-DS and 
ALL-non-DS patients. There is a marked difference in the age of onset.  Whereas, 
ALL commonly occurs in neonates,  ALL in DS  is not manifested in patients  less 
than  1   year  of  age.  There  is  also  a  reduced  occurrence  of  chromosomal 
translocations,  such  as  the  t(9;22)  and  t(4; 11),  in  the  presence  of  trisomy  21 
(Dordelmann et al., 1998; Whitlock et al., 2005).
Understanding  the  mechanism  by  which  DS  neonates  develop  AMKL  is  under 
intense  investigation.  Mutations  in  the  GATA1  gene  and  genes  located  in  the 
DSCR have been associated with leukaemogenesis in DS.
1.6  GATA1 mutations
1.6.1  GATA1 mutations in haematopoietic disorders
Studies  of  families  suffering  from  dyserythropoietic  anaemia  with
thrombocytopenia,  X-linked  thrombocytopenia  and  X-linked  thalassemia  with
thrombocytopenia, have  led to the identification of mutations in the exon 4 of the
GATA1  gene which encodes the N-finger domain of the GATA1  protein.  As this
region  is  involved  in  protein-protein  interactions  and  GATA1  DNA  binding
stabilisation,  acquisition of mutations  could  interfere  with the normal  function of
GATA1.  Indeed,  these  inherited  mutations  have  been  shown  to  affect  different
amino acid residues, which ultimately interfere with the interaction of the GATA1
protein with FOG1, albeit at varying levels. These studies highlight the importance
of the GATA1-FOG interaction in the regulation of megakaryocytic and erythroid
61cell development.
The  V205M  mutation,  which  causes  the  substitution  of methionine  for  valine  at 
amino  acid  205  ol  GAIA-1.  was  isolated  in  a  patient  with  dyserythropoietic 
anaemia  (Nichols  et  al..  2000).  The  off-spring  of this  patient  also  suffered  from 
abnormalities  of erythroid  as  well  as  megakaryocytic  cells.  The  V205M  GATA1 
was  ectopically  introduced  in  GATA1  null  erythroid  line  G1E. 
Immunoprecipitation  experiment  showed  that  the  V205M  mutation  severely 
reduced the interaction of GATA1  with its cofactor FOG1  (Nichols et al., 2000).  In 
addition,  the expression of mutant  GATA1  in cell  lines that are GATA1  deficient 
failed to rescue the erythroid maturation defect,  whereas introduction of wild-type 
GATA1  lead  to  erythroid  differentiation.  The  D218G  mutation  was  found  in  the 
context  of  X-linked  thrombocytopenia.  Patients  had  defective  megakaryocytic 
development, as exhibited by abnormal platelet size, reduction in expression of the 
of GATA1  target  genes.  GPlba and  GPlbft in the platelets of patients (Freson et 
al..  2002).  This  suggests  an  important  role  for  the  GATA1-FOG1  interaction  in 
megakaryocytic maturation. Other mutations, identified in the N-finger of GATA1, 
include  D218Y  and  G208S,  which  strongly  and  weakly  reduce  the  affinity  of 
GATA1  for  FOG-1,  respectively (Mehaffey et al..  2001;  Freson et al., 2002).  The 
R216Q  mutation,  associated  with  macro  thrombocytopenia and  p-Thalassemia,  is 
the  only  mutation  identified  thus  far  that  reduces  the  sequence  specific  DNA 
binding  of  GATA1  (Yu  et  al..  2002).  This  mutation  also  results  in  a  weaker 
interaction with FOG-1  in comparison with the wild-type GATA1.
621.6.2 GATAls, the DS-associated GATA mutation
Mutations  located  at  the  N-terminus  of the  GATA1  protein  that  do  not  impair 
FOG1  binding  or  DNA  binding activity but  lead  to the truncation of the GATA1 
transactivation domain, occurs in all  DS-AMKL patients. These somatic mutations 
(missense, deletions, duplications or insertions) introduce a premature stop codon at 
methionine  1   in  exon  2  or  interfere  with  the  alternative  splicing  of exon 2. This 
leads to  initiation of translation  from exon 3, replacing full  length GATA1  with a 
shorter  isoform,  GATAls  (Figure  1.4A).  The  net effect of these  mutations is the 
truncation  of the  amino-terminal  transactivation  domain  in  the  GATAls  protein 
making it transcriptionally less active than GATA1  (Figure  1.4B). The full length 
GATA1, and its shorter variant, GATA 1  s. are normally expressed at different levels 
in  the  mouse  embryonic  tissues  (Calligaris  et  al.,  1995).  This  suggests  that the 
balance  between  these  proteins  may  be  essential  in  normal  development  and  in 
oncogenic transformation in the context of trisomy 21.
GATA1 mutations are unique to DS-AMKL and are not found in non-DS AMKL, in 
DS  ALL  or  AMKL  associated  with  myelodysplastic  syndromes.  Current  data 
suggests that acquisition of GATA 1  mutations occurs in utero. This is supported by 
the findings of several groups who detected these mutations in DNA from neonatal 
blood  spots.  Importantly,  almost  all  patients  diagnosed  with  TMD  contain
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Figure 1.4.  Diagram depicting the translation sites on GATA1 and GATAls mRNA 
and  the  functional  domains  of GATA1  and  GATAls  proteins.  A.  The  full  length 
GATA1  is translated from the methionine  1   within exon 2.  The first exon of GATA1  is a 
non-coding  exon.  The  shorter  variant  of  GATA1,  GATAls  is  translated  from  the 
methionine  84 within  exon  3.  The  GATAls protein  can  be  translated  either  from  full 
length GATA1  mRNA or from the GATAls mRNA.  GATA1  mutations are found  in DS 
individuals  and  almost  all  are  located  in  the  exon  2  as  indicated  by  red  asterisk.  B. 
GATA1  is  a 47-kDa protein  containing  a transactivation  domain  (TAD)  at  the  amino- 
terminal region, two nuclear localisation sequences (NLS) and two zinc finger domains, 
one located at C-terminus (CF) which is essential for DNA binding.  The N-terminal zinc 
finger (NF) is also required for DNA binding domain as well as interaction with FOG-1 
protein.  The GATAls  which  is  generated  due  to  the use  of an  alternative  translational 
start  codon  is  a  smaller  40-kDa  protein  that  lacks  the  amino-terminal  transactivation 
domain.
64mutations  in  the  GATA1  gene.  The  study  of  DS  patients  showed  that  upon 
spontaneous resolution of TMD or AMKL remission, DS patients become negative 
for GATA1  mutations (Rainis et al., 2003; Pine et al., 2005).  Such mutations were 
also  detected  in  DS  cases  where  there  was  no  clinical  presentation  of TMD  or 
AMKL at birth (Ahmed et al., 2004). Some studies, have failed to detect mutations 
in the  GATA1  gene at  birth.  This  may  be due to  the  limitation of techniques  and 
material  in  Guthrie  cards,  which  are  currently  used  to  identify  these  mutations 
which are thought to be present in rare clones.
1.6.3  The role of GATAls in haematopoiesis
The  functional  importance  of GATAls  has  been  demonstrated  in  several  in  vitro 
and  in  vivo  studies.  GATA1  deletion  mutants  were  generated  to  delineate  the 
importance  of different  functional  domains  in  inducing  differentiation.  Enforced 
expression  of full  length  GATA1  induces  megakaryocytic  differentiation  of the 
myeloid cell  line 416B.  The deletion of N-terminal transactivation domain, lost in 
GATAls, did not affect megakaryocytic maturation of these cells (Visvader et al., 
1995).  This  suggests  that  GATAls  contains  all  domains  essential  for 
megakaryocytic differentiation.
The  generation  of a  knock-in  mouse  containing  GATAls alone demonstrated  the
ability  of  this  protein  to  maintain  effective  adult  haematopoiesis.  These  mice
exhibited normal megakaryopoiesis and erythropoiesis as measured by the number
and  morphology  of platelets  and  red  blood  cells  (Li  et  al.,  2005).  In  contrast,
GATAls  caused  aberrant  foetal  haematopoiesis.  Foetal  liver progenitors  isolated
from  GATAls  mutant  mice  generated  abnormal  CFU-MK  colonies  in  vitro  and
65there  was  a profound  hyperproliferation  of these  progenitor cells  when  grown  in 
liquid culture. This study suggests that GATAls affects proliferation of foetal liver 
progenitor cells. In contrast to this animal study, in which adult haematopoiesis was 
unaffected, Hollanda et al demonstrated that the GATAls mutation alone abrogates 
normal  megakaryopoiesis and erythropoiesis in humans.  Male individuals with the 
GATAls  mutation  suffered  from  severe  anaemia  and  had  hyperproliferative  and 
morphologically abnormal megakaryocytes (Hollanda et a l 2006). Since GATA1 is 
an X-linked gene, carrier females of the family harboured both normal GATA I and 
GATAls  mRNA.  The  mutation  in  the  affected  male  individuals  resulted  in  the 
production of GATAls alone and the levels of GATAls were the same as the levels 
in  normal  bone  marrow.  This  study  suggests  that  the  N-terminal  transactivation 
domain  is  required  for  normal  erythropoiesis  in  humans  and  normal  levels  of 
GATAls  in the absence of GATA1  is not sufficient for effective haematopoiesis. 
The  discrepancy  in  the  role  of GATAls  in  animals  and  humans  may  be  due  to 
differences  in  the  level  of  GATAls  protein  expression,  since  this  has  been 
demonstrated to have an affect on haematopoiesis (Shimizu et al., 2001).  Shimizu 
et  al  generated  transgenic  mice  expressing  GATA1  with  a  deleted  N-terminal 
domain. The potential of this transgene to rescue the GATA1 mutant phenotype was 
investigated  in  the  GATA 1.05  background.  The  levels  of  GATAls  transgene 
expression in comparison with the endogenous levels of GATA1  was a key  factor 
in  the  efficiency  of the  rescue of the  GATA1  phenotype.  The  increased  levels of 
GATAls  were  sufficient  to  rescue  both  primitive  and  definitive  erythropoiesis, 
whereas  similar  expression  levels  to  GATA1  led  to  inefficient  definitive 
erythropoiesis.
661.7 ETS-Related-Gene (ERG)
ETS-relate  gene  (ERG)  is  a  proto-oncogene  located  on  chromosome  21 
(21q22.3)(Rao  et  al.,  1987;  Rao  e/  al.,  1988).  There  are  five  isoforms  of ERG 
produced  as  a  result  of differential  mRNA  splicing,  alternative  polyadenylation 
sites  and  translational  codons  (Figure  1.5).  Both  ERG-2  and  ERG-3  mRNA 
expression is detectable in DS-AMKL patient samples and, in the megakaryoblastic 
cell  lines,  Meg-01  and  CMK  (Rainis  et al.,  2005).  All  isoforms  differ in their 5' 
regions and the expression of two exons. The A81  (81 bp) exon (ERS domain-ERG 
specific  domain)  is  present  in  ERG-1,  2,  3  and p38erg,  whereas  the  A72  (72  bp) 
exon is present only in ERGS (Prasad et al., 1994).
ERG proteins can bind DNA via their Ets binding domain, which forms a Helix- 
loop-Helix  structure  (Schneikert  et al.,  1992;  Siddique  et a l,  1993).  In  common 
with the RUNT domain, the ETS domain is involved in protein-protein interaction 
as  well  as  DNA  binding.  Recombinant  ERG  proteins  have  been  shown  to  be 
sequence  specific  transcritptional  activators  (Reddy  and  Rao,  1991).  ERG  can 
homodimerise  and  heterodimerise  with  Jun  and the  Fos/Jun  API  complex  via  it 
ETS domain. The ERG isoforms can also form heterodimers with other member of 
the ETS  family, such as  FLI1, via the N-terminal pointed domain (Carrere et al., 
1998).  There  are  now  some  studies  suggesting  a role  for ERG  in  leukaemia and 
solid  tumours.  Baldus  et  al  showed  over-expression  of ERG  in  AML  patient 
samples.  Since this was not always accompanied by genomic amplification, extra 
copies of the ERG gene are unlikely to explain the level of ERG expression in these 
samples  (Baldus  et  al.,  2004).  The  over-expression  of ERG  in  AML  has  been
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Figure  1.5.  Schematic  representation  of different  ERG  isoforms.  The  five  ERG 
isoforms  are  generated  by  differential  mRNA  splicing  and  alternative  use  of 
polyadenylation  sites  and  translational  codons.  The  functional  domains  include  the 
pointed  domain  (PNT),  located  at  the  amino  terminal  region  which  is  required  for 
protein-protein  interactions. The DNA binding,  ETS domain and the activation domain 
(AD) are situated at the carboxyl terminal region.  There are two exons, A81  (81  bp) or 
the  ERG  specific  domain  (ERS)  and  A72  (72  bp),  which  are  not conserved  in  all  the 
isoforms.  A81  is present in ERG-1, 2, 3 and ERGp38, whereas A72 (72 bp) exon which 
is  only  present  in  the  ERG-3  isoform.  These  exons  are  rich  in  PEST  sequences  (P, 
proline; E, glutamic acid;  S, serine; T, threonine).  There is an inframe deletion of A72 
and  A81  in  the  ERGP49 with  the  5'  region  being  identical  to  the  ERG-3  isoform.  All 
isoforms also differ in their 5' region.  The alternative parts in this region are represented 
by the yellow, grey and black boxes. Diagram adapted from Duterque-Coquillaud et al., 
1993.
6 8reported  by  other  groups  where  the  levels  of  the  protein  have  been  closely 
correlated with the clinical outcome of AML with normal karyotype (Marcucci et 
al., 2005). ERG is also involved in chromosomal rearrangements linked with Ewing 
Sarcoma and prostate cancer. In Ewing sarcoma the t(21;22) translocation results in 
the fusion of the ERG with the EWS gene, producing an ERG-EWS fusion transcript 
(Sorensen et al.,  1994).  In prostate cancer, ERG is fused with TMPRSS2 (Tomlins 
et al., 2005). Different ERG-TMPRSS2 fusion RNAs have been identified and it has 
been  proposed  that  their  expression  level  may  correlate  with  prostate  cancer 
progression (Wang et al., 2006).
1.8 Model of leukaemogenesis in DS
The current model of leukaemogenesis in DS involves multiple steps with the first 
event being acquisition of trisomy 21.  All the cells in an individual affected with 
DS contain trisomy 21,  which occurs at the zygotic stage during development. A 
small  percentage  of patients  develop  TMD,  which  due  to  unknown  mechanisms 
undergoes  spontaneous  remission.  Somatic  mutations  in  the  GATA1  gene  are 
detected  in  TMD  cases,  which  disappear  upon  remission.  The  result  of these 
mutations  is  reduced  megakaryocyte  maturation  and  aberrant  proliferation  and 
accumulation of megakaryoblasts which are the hallmarks of AMKL in DS patients 
(Figure  1.6).  These  mutations  are  believed  to  occur  at  very  early  stages  of 
development, since they are detected in almost all DS individuals that present with 
either TMD or AMKL.
It is becoming clear that GATA1  mutations alone are not sufficient for leukaemic
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Figure 1.6.  Model of leukaemogenesis in DS.  It is generally believed that the development 
of leukaemia in DS is a multi-step process. The first event is the acquisition of an extra copy 
of chromosome 21, which is a distinguishing characteristic in DS.  The origin of trisomy 21 
is believed to be as a result of homologous chromosome non-disjunction  at meiosis stage  I 
and rarely at meiosis stage II, which occurs during embryonic development.  The second step 
is  believed  to  be  somatic  mutations  in  the  GATA1  gene  which  creates  a  shorter  product, 
GATAls.  This mutation is detected in almost all DS patients at birth and thus is predicted to 
occur at very early stages during development.  Approximately  10% of individuals with DS 
develop transient  myeloproliferative  disorder  (TMD),  most of which  undergo  spontaneous 
remission.  GATA1 mutations are lost in TMD patients in remission.  Around 20% of TMD 
patients will develop acute  megakaryoblastic  leukaemia (AMKL).  DS patients as a whole 
have a 600 fold greater chance of developing AMKL than non-DS patients.  It is predicted 
that the GATAls mutation provides the pro-proliferation signal required for the accumulation 
of megakaryoblasts  detected  in  AMKL.  However,  these  mutations  are  not  sufficient  for 
leukemic  development.  Genes  located  on  chromosome  21  and  other  as  yet  unidentified 
mutations  (diamond)  may  provide  the  necessary  events  for  the  progression  of TMD  to 
AMKL and the development of leukaemia in DS.
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70development or progression of TMD to AMKL in DS individuals.  Hollanda et al 
discovered  GATA1  mutations  in  a  family  that  were  not  diagnosed  with  DS.  The 
affected  male  individuals  suffered  from  anaemia  and  myelodysplasia  affecting 
myeloid,  erythroid  and  megakaryocytic  cells  without  progression  to  AMKL 
(Hollanda  et  al.,  2006).  This  study  suggests  that  the  activity  of  GATAls  in 
leukaemic development  may  depend  on a background of trisomy 21.  It has been 
proposed  by  several  groups  that  cooperation  between  GATAls  and  the  genes 
located on chromosome 21 may be required to promote AMKL development.
It  is  important  to  note  that  the  presence  of GATAls  alone  in  cells  trisomic  for 
chromosome  21  is  not  sufficient  for  the  development  of  AMKL,  since  TMD 
disappears in the majority of cases. It has recently been demonstrated that GATAls 
affects  progenitor cells  at a specific  developmental  stage  (Li  et al.,  2005).  It has 
been proposed that, in the setting of trisomy 21, additional mutations are necessary 
at this particular point in development for leukaemic progression of TMD clones. 
In this context, Ahmed et al detected GATA1 mutations in DS individuals that did 
not  present  with  AMKL,  further  suggesting  that  additional  factors  other  than 
GATA1  mutations  and  genes  located  on  trisomy  21  are  required  for  leukaemic 
transformation in DS patients (Ahmed et al., 2004).
In summary,  GATAls  and genes  located on chromosome 21  are required but not 
sufficient  for  AMKL  development  in  DS.  It  is  proposed  that  overexpression  of 
genes on chromosome 21  may promote megakaryopoiesis and increase the pool of 
early  megakaryocytic  progenitors,  while  the  acquired  GATA1  mutation  increases 
proliferation of these megakaryoblasts at the expense of differentiation.
711.9 Myelodysplastic syndrome (MDS)
In  addition  to  TMD,  some  DS  patients  are  predisposed  to  childhood 
myelodysplastic  syndrome  (MDS)  prior  to  AMKL  development.  MDS  precedes 
AML in approximately half of cases in DS (Zipursky et al.,  1992; Creutzig et al., 
1996; Lange et al.,  1998).  DS patients can take several months and up to few years 
to progress from MDS to AML (Creutzig et al.,  1996). Myelodysplatic syndromes 
are  a  group  of  clonal  haematopoietic  disorders,  characterised  by  aberrant 
proliferation and differentiation of the myeloid lineage. The bone marrow is normo 
or hypercellular and ineffective haematopoiesis causes severe peripheral cytopenia 
and  trilineage  dysplasia  (abnormal  cellular  morphology)  involving  myeloid, 
erythroid  and  megakaryocyte  cells.  The  dysplastic  characteristics  include 
micromegakaryocytes,  hypersegmented  neutrophils  and  ringed  sideroblasts.  DS 
patients with MDS have ineffective thrombopoiesis and exhibit dysplastic changes 
in both erythroid and megakaryocytic progenitors. The ineffective haematopoiesis 
has been suggested to be a result of high levels of apoptosis and proliferation in the 
bone marrow. Thus, Albitar and et al have detected increased levels of apoptosis in 
MDS patients, as measured by Annexin V staining and levels of caspase-3 activity 
(Albitar et al.,  2002).  As  the  disease  progresses,  the  bone  marrow cells  become 
more  abnormal  and  in  30-40%  of  MDS  cases,  patients  develop  acute  myeloid 
leukaemia  (AML)  (Matsushima  et  al.,  2003).  Evolution  to  AML,  infection  and 
bleeding are the main cause of death in MDS patients.
MDS  is  primarily  a  disease  of elderly  people  with  the  median  age  at  diagnosis 
being between 65 and 75 years. In addition, mylodysplastic syndromes account for
72about 2% of haematological  malignancies  in children.  There are  five  subtypes of 
MDS  as  classified  by  the  French-American-British  (FAB)  study  group.  The 
different subtypes are based on the percentage of blasts in the bone marrow (T ab le 
3) and all  indicators of good prognosis are associated with particular sub-types of 
MDS.  Although widely used,  this type of classification does not take cytogenetic 
abnormalities and genetic changes that occur in MDS into consideration.
Table 3: Subtypes of MDS as classified by FAB study group.
FAB subtype  % of blasts
Refractory anemia (RA)  < 5 %
Refractory anemia with ringed sideroblasts (RARS)  <5%
Refractory anemia with excess blasts (RAEB)  6-20%
Refractory anemia with excess blasts in transformation (RAEB-T)  20-30%
Chronic myelomonocytic leukaemia (CMML)  As any of above with or
without  increase  of 
monocytes
Several  features  distinguish  MDS  from  de  novo  AML.  There  are  distinct 
differences in the haematopoeitic cells detected in MDS patients, as compared with 
AML.  In  MDS,  there  is  lack  of  terminally  differentiated  cells  or  cells  have 
dysplastic  morphology.  In  contrast,  differentiation  is  blocked  in  AML  and  cells 
have  a blastic  morphology.  In addition,  there  is  an increased risk of apoptosis at 
early  stages  of MDS  and  the  disease  is  highly  associated  with  abnormalities  of 
chromosme  7  and  5.  However,  the  most  common  chromosomal  translocations
73associated with AML are inv (16) a t(16;16), t( 15; 17) and t(8;21). Furthermore, in 
contrast  to  AML,  MDS  patients  respond  poorly  to  treatment  with  cytosine 
arabinoside.
1.9.1  Murine models of MDS
There  are  currently  several  murine  models  of  MDS  that  suggest  the  potential 
importance  of different  genes  in  the  pathogenesis  of MDS  and  AML  evolution. 
EVI1 is involved in chromosomal translocation (t(3;3)(q21;26) and inv(3)(q21q26)) 
associated with MDS.  Mice injected with BM-derived progenitor cells transduced 
with EVI1  expressing retrovirus  display  some phenotypic  characteristics  of MDS 
(Buonamici et al.,  2003).  Megakaryocytic and erythroid hyperplasia was detected 
in the BM and these cells had reduced expression levels of EPO and TPO receptors, 
which are required for effective differentiation.
Transgenic mice expressing the NUP98-HOXD13 fusion gene are also defective in 
myeloid differentiation and develop MDS and eventually AML (Lin et al., 2005). 
Anaemia  and  increased  apoptosis,  features  exhibited  in  MDS  patients,  were 
detected in these mice. In a recent study, retroviral insertional mutagenesis revealed 
the collaborative role of Erg, Meisl, Mnl and miRNA genes with NUP98-HOXD13 
in inducing  leukaemic transformation (Slape et al.,  2007).  This mouse model did 
not completely recapitulate the features observed in patients with MDS, since some 
of the mice developed ALL, a leukaemia which is rarely detected in these patients 
(Disperati  et al.,  2006).  Another murine  model  of MDS  with an AML  evolution 
was demonstrated by generation of a transgenic mouse expressing BCL2 and a RAS
74mutation  (NRASD12),  where  BCL2  is  expressed  in  a  conditional  tetracycline- 
inducible  manner  (Omidvar  et  al.,  2007).  This  mouse  line  was  generated  by 
crossing  the  conditional  BCL2  line  with  the  constitutive  NRAS  mutation. 
Conditional expression of BCL2 was shown to co-operate with constitutive NRAS 
expression  to  induce  high  risk  MDS  with  increased  apoptosis  of haematopoietic 
cells. BCL2 was shown to be an initiating factor in inducing MDS and it was also 
required for the maintenance of the disease. In contrast, the constitutive expression 
of both  BCL2  and  NRASD12  (expression  driven  by  myeloid  MRP8  promoter) 
resulted in AML with no apoptotic cells.  This  study shows that two cooperating 
events,  lead  to  MDS  development  and  progression  to  AML  in  mice.  It  was 
proposed that the differences between the two models may be the type of leukaemic 
cell targeted by BCL2. In the MDS model, the tTABCL2 is under the control of the 
MMTV promoter, which drives the inducible expression of BCL2 in different cell 
types as compared to the AML model, where the constitutive expression of BC12 is 
targeted to myeloid progenitors by the MRP8 promoter.
A  recent  report  has  highlighted  the  possible  contribution  of  RUNX1  to  MDS 
pathogenesis. RUNX1  mutations are correlated with MDS patients that progress to 
AML. Recipient mice transplanted with BM cells transduced with RUNX1 mutants 
(mutations  in  the  RUNT  domain)  succumbed  to  an  MDS  like  disorder  as 
characterised by peripheral cytopenia and erythroid dysplasia (Watanabe-Okochi et 
al., 2008).
Finally,  mice  heterozygous  for  NPM,  exhibit  most  features  detected  in  human 
MDS, including erythroid dysplasia, defective megakaryopoiesis and bone marrow
75hyperplasia (Grisendi  et al.,  2005).  The  percentage  of Terll9  positive  cells  was 
markedly  increased  in the  bone  marrow of NPM+/' as compared  with NPM  wild 
type  mice.  The  effect  of NPM heterozygosity  on  the  accumulation  of immature 
erythroblasts  was  shown  by  the  increase  in  Terl 19hlCD71hl  expressing  cells. 
Although  these  mice  displayed  dysplastic  features  in  the  megakaryocyte- 
erythrocyte  lineage,  there  were  no  observed abnormalities  in the  macrophages  or 
granulocytes. In addition, NPM heterozygotes were shown to have increased risk of 
developing  haematological  malignancies  compared  with  NPM  wild  type  mice 
(Sportoletti et al., 2008).
1.9.2  Chromosomal abnormalities associated with MDS
There are several different chromosomal abnormalities associated with MDS. These
include monosomy and deletions of chromosome 5 and 7, trisomy 8, 20q deletion,
loss of chromosome Y and inv(3) (inversion of chromosome 3). Trisomy 8 is the
most common cytogenetic abnormality correlated with MDS and it is accompanied
with  poor  prognosis  and  short  survival  (Pedersen,  1997).  Various  chromosomal
translocations have also been linked to MDS.  Some of the genes involved include
EVll,  TEL (ETV6), MLL. and Nucleoporin (Mitani et al.,  1994;  Wlodarska et a l,
1995; Taki et al.,  1997; Ahuja et al.,  1999; Grisendi et al., 2005). In addition, the
t(3;5)(q25.1;q34)  rearrangement  results  in  a  fusion  transcript  comprised  of the
nucleophosmin  {NPM)  gene  and  the  myeloid  leukaemia  factor  1   (MLF1)  gene
(Yoneda-Kato  et  al.,  1996).  Existence  of  more  than  one  type  of  abnormal
karyotype is more common in therapy related MDS (t-MDS) than in de novo MDS.
No  clear  correlation  has  been  found  between  any  chromosomal  aberrations  or
specific gene with the onset or progression of MDS.
761.9.3 Nucleophosmin (NPM)
NPM  (also  known  as  B23,  numartin  or  N038)  is  a  ubiquitously  expressed 
phosphoprotein that has a major role in ribosomal assembly and biogenesis. NPM is 
predominantly localised in nucleoli, although it can shuttle between the cytoplasm 
and  nucleus.  The  functional  motifs  of NPM  are  well  characterised.  At  the  N- 
terminus, the protein has a non-polar domain and two highly acidic segments. Both 
regions  are  required  for the  chaperone  function  of NPM  as  revealed  by  deletion 
and functional (Szebeni and Olson,  1999) studies. NPM contains a bipartite nuclear 
localisation  signal  (NLS)  that  has  been  shown to  associate  with  several  proteins 
such as the HIV (Human Immunodeficiency Virus) rev protein (Fankhauser et al., 
1991).  The  C-terminal  section  of  the  protein  is  basic,  apart  from  the  last  35 
residues,  which  forms  an  aromatic  rich  region.  These  domains  are  involved  in 
nucleic  acid  binding.  The  C-terminal  portion  of NPM  in  combination  with  the 
acidic region is also required for the ribonuclease activity of the protein (Hingorani 
et al., 2000) (Figure 1.7A).
There are several reports suggesting an important role for NPM in cell proliferation. 
NPM  has  been  shown  to  inhibit  the  transcriptional  activity  of  several  tumour 
suppressor  proteins  including  IRF1  (interferon  regulatory  factor  1)  and  PKR 
(interferon  (IFN)-inducible,  double-stranded  RNA-dependent  protein  kinase). 
NPM induces IRF1  inactivation by interacting with the protein and interfering with 
its DNA binding (Kondo et al.,  1997). Indeed, IRF1  inactivation as a result of exon 
skipping, which causes removal of the DNA binding domain, is detected in 30% of 
MDS  patients  (Harada  et  al.,  1994).  In  addition,  NPM  induction  of  cellular
77proliferation is partly mediated by  interaction with and inhibition of the catalytic 
activity  of PKR  (Pang  et  al.,  2001).  PKR  induces  apoptosis  and  prevents  cell 
growth  by  inhibiting  mRNA  translation  and  its  activation  is  associated  with  the 
pathogenesis of several diseases such as Fanconi anaemia (FA) (Pang et al., 2001). 
Overexpression  of NPM  was  shown  to  inhibit  PKR-mediated  apoptosis  in  FA 
derived  cell  line  (Pang  et  al.,  2003).  The  high  expression  level  of  NPM  in 
leukaemia and leukaemic cell lines further supports a role for NPM in cell growth 
and survival (Kondo et al.,  1997). The activity of NPM in these processes is likely 
to be complex.  Thus, mouse fibroblasts overexpressing NPM become resistant to 
apoptosis induced by UV damage (Wu and Yung, 2002). In contrast, NPM has been 
shown  to  enhance  and  activate  the  transcriptional  activity  and  function  of the 
tumour  suppressor  protein  p53  (Colombo  et  al.,  2002;  Kurki  et  al.,  2004; 
Korgaonkar et al., 2005).
NPM  also  has  a role  in  maintaining  genomic  stability,  by regulating  centrosome 
duplication during cell cycle (Okuda et al., 2000). To ensure the correct number of 
chromosomes are acquired by daughter cells,  centrosome duplication occurs only 
once per cell cycle. This process is tightly regulated by proteins such PML (Xu et 
al.,  2005),  CDK2/cyclinE  kinase  and  NPM.  At early  G1  phase  of the cell  cycle, 
NPM is bound to the centrosomes.  The dissociation of centrosomes from NPM is 
required  for  centrosome  duplication  and  this  process  is  triggered  upon 
phosphorylation  of  NPM  by  CDK2/CyclinE  complex.  After  this,  NPM  re­
associates  with  centrosomes  during  mitosis.  Aberrant  regulation  of centrosome 
duplication  has  been  correlated  with  abnormal  chromosome  segregation  and 
aneuploidy in AML patients (Neben et al., 2004). NPM mutations, which are highly
78associated with AML may account for this deregulation of centrosome duplication.
Recent  evidence  has  highlighted  the  importance  of NPM  in  tumourgenesis.  The 
NPM  locus  is  involved  in  chromosomal  translocations  associated  with  several 
human malignancies (Morris et al.,  1994; Redner et al.,  1996). In addition, NPM is 
commonly mutated in blasts of AML patients with normal karyotype (Falini et al., 
2005; Nakagawa et al., 2005).  The mutations occur in exon  12 of the NPM gene. 
These frameshift mutations truncate the C-terminal region, causing loss of at least 
one of W288 and W290 tryptophan residues necessary for nuclear localisation.  In 
addition they cause a gain of an NES at the C-terminus, which results in aberrant 
localisation of NPM  in the  cytoplasm  (NPMc+)  (Bolli  et al.,  2007;  Falini  et al., 
2007) (Figure 1.7B). AML patients with NPMc+have a much better responsiveness 
to  chemotherapy  when  compared  with  patients  lacking  this  mutation.  NPMc+ is 
frequently  correlated  with  CEBPA  and  NRAS  mutations  and  internal  tandem 
duplications  of FLT3  (FLT3/ITD)  (Falini  et al.,  2006).  These  patients  appear to 
have  a  worse  prognosis  compared  with  patients  harbouring  NPMc+  alone 
(Christensen and Weissman, 2001).
1.9.4  Myeloid Leukaemia Factor 1 (MLF1)
MLF1  was  first  identified  as  a  gene  fused  with  NPM in  the  t(3;5)  translocation 
associated with MDS.  MLF1  does not belong to any previously identified protein 
family  and  it  comprises  of a  14-3-3  interaction  motif at  its  N-terminus  and  an 
adaptor molecule  (Madm,  MLF1  adaptor molecule) binding domain (Williams et 
al., 1999).  MLF1 contains both a classic RSXSXP 14-3-3 binding motif and a non­
consensus RXSXSX motif.
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Figure 1.7. Schematic representation of NPM, cytoplasmic NPM and MLF1. A.
NPM  is a 249 amino acid protein comprising two nuclear export signal (NES) motif 
at  its  N-terminus,  a  metal  binding  domain  (MB),  two  acidic  amino  acid  clusters 
(AC)  and  two  nuclear  localisation  signals  (NLS).  There  is  a  basic  region  and  an 
aromatic  region at the C-terminus. NPM  contains two tryptophan residues 288 and 
290  at the  C-terminus  required  for  nuclear  localisation.  The  N-terminus  region  is 
required  for  oligomerisation  and  chaperone  activity  of  NPM,  whereas  the  C- 
terminus  is  involved  in  DNA  or  RNA  binding.  An  internal  segment  of  NPM 
protein  is  involved  in histone binding.  B.  Frameshift mutations lead to  loss of the 
tryptophan  residues  (most  commonly  W290)  required  for  nuclear  localisation  and 
result  in  a gain  of NES  at the  C-terminus.  Both of these are required  for aberrant 
localisation  of  NPM  in  the  cytoplasm  (NPMc+).  C.  MLF1  is  a  268  amino  acid 
protein containing two  motifs  required  for interaction with  Madm  protein and two 
putative  RSXSXP  motifs  required  for  14-3-3  binding.  MLF1  contains  NES  and 
two NLS domains.
80Recently,  an  NES  and  two  NLS  motifs  have  been  identified  in  MLF1 
(Winteringham et al., 2006; Yoneda-Kato and Kato, 2008) (Figure 1.7C). MLF1  is 
expressed  in  a  tissue  specific  manner  and  its  localisation  in  the  cytoplasm  is 
dependent on  its interaction with  14-3-3  family member,  14-3-3-^ protein.  MLF1 
interaction with MADM  results  in the recruitment of a serine kinase that leads to 
the  phosphorylation  of MLF1  (Lim  et  al.,  2002).  The  14-3-3-^  protein  interacts 
with  the  phosphorylated  MLF1  keeping  the  protein  within  the  cytoplasmic 
compartment of a cell (Winteringham et al., 2006).
The  murine  homolog  of  MLF1,  Hls-7  (haematopoietic  lineage  switch  7),  is 
involved in erythroid/myeloid lineage switching (Williams et al.,  1999). HLS-7 has 
79%  amino  acid  identity  and  a  90%  homology  (includes  amino  acids  that  are 
different but do not affect the  structure of the protein) with human MLF1.  HLS7 
prevents  erythropoietin  (EPO)  dependent  differentiation  of J2E  erythroleukemic 
cells,  which  are  immortalised  at  the  proerythroblast  stage.  In  contrast,  ectopic 
expression  of  the  protein  promotes  myeloid  differentiation  of  Ml  monoblasts. 
HLS7 mediates a block of erythroid differentiation by suppressing the upregulation 
of the CDK2 inhibitor, p27, and preventing cell cycle arrest (Winteringham et al., 
2004).
In common with hMLFl, Drosophila MLF1  (dMlfl) contains a  14-3-3  interaction 
motif and  it is  localised  in the cytoplasm.  It has  been suggested that dMLFl  can 
translocate into the nucleus and associate with the transcription factor, DREF (DNA 
replication related element-binding factor), which regulates several genes required 
for proliferation in Drosophila (Ohno et al., 2000).
811.9.5 NPM-MLF1
In  the t(3;5)  (q25;q34) translocation,  the NPM gene  located on chromosome  5  is 
fused  with  MLF1  gene  on  chromosome  3,  creating  a  NPM-MLF1  fusion  gene 
(Figure  1.8). The C-terminal region of NPM, containing one NLS and part of the 
acidic  region,  is truncated as  a result of the translocation and NPM is  fused with 
MLF1, lacking first  15 residues at the N-terminal end.  The NPM-MLF1  protein is 
predominantly localised to the nucleus.  Despite the fact that the MLF1  portion of 
the  NPM-MLF1  protein  is  phosphorylated  in  the  cytoplasm  of cells,  it  does  not 
interact with the 14-3-3-^ protein.  However, due to the presence of the NLS within 
the NPM moiety of NPM-MLF1, the fusion protein can translocate into the nucleus 
(Lim et al., 2002).
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Figure  1.8.  Schematic  representation  of NPM-MLF1.  The  arrow  indicates  the 
point at which the NPM and  MLF1  proteins are fused. The acidic domain and one 
NLS are truncated due to the translocation resulting in the fusion of the N-terminus 
portion with  almost the entire  MLF1,  lacking the  first  15  residues.  This creates a 
fusion protein of 428 amino acids.
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The main aim of this study was to analyse the molecular basis for haematological 
abnormalities  leading  to  MDS  and  AMKL.  This  was  investigated  using  two 
models.  In  a  DS  associated  AMKL  model,  the  potential  synergy  between  the 
GATA1  mutation  and  a  chromosome  21  gene,  ERG-3,  in  the  development  of 
AMKL  was  investigated.  The  second  model  is  t(3:5)  associated  with  MDS,  and 
since  t(3;5)  is  the  most  common  translocation,  the  potential  role  of the  resultant 
NPM-MLF1 fusion protein in the development of MDS was investigated.
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Materials and Methods
852.0  Generation of retroviral constructs
Retroviral  vectors used  in this  study include the pMSCV-neo and pMSCV-IRES- 
hCD2 vector.  Both vectors contain the  5'  LTR (long term repeat) and 3' LTR, *F+  
(viral  packaging  signal)  and  Ampr  (ampicillin resistance  gene).  The pMSCV-neo 
comprises the murine PGK (phosphoglycerate kinase) promoter which controls the 
expression of Neor (neomycin resistance gene). The pMSCV-IRES-hCD2 contains 
IRES (Intemal-ribosomal-entry-site) and hCD2 (human CD2 tailless gene).
2.1 pMSCV-£tf G-5-IRES-CD2
The  pMSCV-IRES-CD2  retroviral  vector  was  digested  with  the  EcoRI enzyme. 
The ERGS cDNA is flanked by Mfel sites. The ERGS cDNA was cloned into the 
EcoRI sites  in  the  pMSCV  vector  upstream  of the  IRES  and  the  gene  encoding 
hCD2. The fragment was confirmed by digestion of the vector with BamHl, which 
releases the ERGS insert fragment of 1887 bp.
2.1.1  pMSCV-neo-FLAG-Gata/
A CMV expression vector containing Gatal  cDNA (1241  bp) cloned as a BamHI 
and Xhol insert was obtained from Dr Izraeli (Sheba Medical Center, Israel). There 
is a sequence for the FLAG epitope tag at the N-terminus of Gatal  sequence. The 
FLAG-Gatal  fragment was digested with SacI and overhangs were filled in with 
Klenow to create a blunt 5' end. The fragment was released by cutting with Xhol. 
The  pMSCV-neo  plasmid  was  digested  with  blunt  enzyme  Hpal and Xhol.  The 
SacI-FLAG-Gatal-XhoI fragment was  ligated into the Hpal and Xhol sites in the
87pMSCV vector.
2.1.2 pMSCV-neo-FLAG-Gata/s
The  CMV  expression  vector  containing  the  Gatals  cDNA  (1021  bp)  cloned  in 
EcoRI sites  was  obtained  from  Dr  Izraeli.  The  pMSCV-neo  vector  was  digested 
with EcoRI and Phophatase treated to prevent re-ligation of the vector. The FLAG- 
Gatals cDNA was  released  from the  CMV vector by digesting with EcoRI.  This 
fragment was subsequently cloned into the EcoRI sites of the pMSCV-neo vector 
upstream of PGK-Neor. The orientation of the insert was determined by restriction 
digest and sequencing.
2.1.3 pMSCV-neo-FLAG-ATOf-MLF/
The  pCDNA3  expression  vector  containing  the  NPM-MLF1  cDNA  (1026  bp), 
cloned as a Hindlll and Xhol insert,  was obtained from Stephen Morris (St. Jude 
Children’s  Research  Hospital).  The  pCDNA3-NPM-MLF1  cDNA  was  used  as  a 
template  in  a  PCR  reaction.  Primers  were  designed  to  amplify  the  NPM-MLFI 
cDNA by integrating EcoRI sites at either end of the NPM-MLFI cDNA, as well as 
adding  an  5'  Flag  epitope  sequence.  The  pMSCV-neo  vector  was  digested  with 
EcoRI and phosphatase treated to prevent re-ligation of the vector.  The amplified 
NPM-MLFI cDNA was digested with EcoRI, purified and cloned into the pMSCV- 
Neo vector, upstream of PGK-Neor. The orientation of the insert was determined by 
restriction digest and sequencing.
882.1.4 pMSCV-neo-FLAG-ATW
The  CMV  expression  vector  containing  the  NPM cDNA  (984  bp)  was  obtained 
from  Dr Colombo (Colombo et al., 2002).  PCR primers were designed to amplify 
the cDNA by integrating EcoRI sites at either end of the ATWcDNA, and adding a 
FLAG epitope sequence at the  5'  end.  The pMSCV-neo vector was digested with 
EcoRI and phosphatase treated to prevent re-ligation of the vector.  The amplified 
NPM  cDNA  was  digested  with  EcoRI,  purified  and  subsequently  cloned  into 
MSCV-Neo  vector  upstream  of  PGK-Neor.  The  orientation  of  the  insert  was 
determined by restriction digest and sequencing.
2.1.5 pMSCV-neo-fA/LF/
The MLF1  moiety of NPM-MLFI  was  generated using the NPM-MLFI  pMSCV- 
neo  construct  as  a  template.  The  following  primers  were  used  for  PCR 
amplification:
Forward primer: 5'-AAAGAATTCACCATGGACTACAAGGACGACGACAA 
G  AGTCC ATTCTTGC AC ACCG  A-3'
Reverse primer {MLF1 Reverse: M-R): 5'-AAACTCGAGTTATTTTTTGTTGC 
TTTTCACAGATGA-3'
The  pMSCV-neo  vector  was  digested  with  EcoRI and Xhol restriction  enzymes. 
The XMLF1  (truncated MLF1) PCR product (768 bp) was digested with EcoRI and 
Xhol, purified and cloned into the pMSCV-Neo vector upstream of PGK-Neor.
2.1.6 pMSCV-neo-AfLF7-myc
Full  length  MLF1  was  generated  using  the  pMSCV-neo-tMZF7  construct  as  a
89template.  The following primers were used for PCR amplification:
Forward primer: 5'-AAAGAATTCACCATGTTCAGGATGCTGAACAGCAGT 
TTTGAGGATGACCCCTTCTTCTCTCATTCTTGCACACCGA-3'
Reverse primer:  5 A  A  AC T  C G  AGTT  AC AG  AT  C TTC TT  C AG  A  A  AT  AAGTTTTT 
GTT C TTTTTT  GTT  GC TTTT  C AC AG  AT  G  A-3'
The  pMSCV-neo  vector  was  digested  with  EcoRI and Xhol restriction  enzymes. 
The MLF1  PCR product (806 bp) was digested with with EcoRI and Xhol, purified 
and cloned into pMSCV-Neo vector upstream of PGK-Neor.
2.1.7 pMSCV-neo-FLAG- A/ZF7-NLS
The  MLF1  moiety  of NPM-MLFI  containing  NPM derived  nuclear  localization 
signal  at  the  N-terminus  was  generated  using  the  pMSCN-neo-NPM-MLFl 
construct  as  a  template.  The  following  Forward  primer  was  used  for  PCR 
amplification and M-R (shown above) was used as a reverse primer.
Forward primer: 5'-AAAGAATTCACCATGGACTACAAGGACGACGACAA 
AAG  AG  ACTTCCTCC ACTG-3'
The  pMSCV-neo  vector  was  digested  with  EcoRI and Xhol restriction  enzymes. 
The  PCR  product  was  digested  with  EcoRI  and  Xhol,  purified  and  cloned  into 
pMSCV-Neo vector upstream of PGK-Neor.
2.1.8 pMSCV-neo-FLAG-fATW
The NPM moiety of NPM-MLFI  was generated by using the pMSCV-neo-FLAG- 
NPM-MLF1  construct  as  a  template.  The  following  primers  were  used  for  PCR 
amplification (NPM primer  sequence  obtained  from Bertwistle et a l 2003).  The
90Forward primer contains N-terminal FLAG tag coding sequences.
Forward primer {NPMForward: N-F): 5'-AAAGAATTCACCATGGACTACAAG 
G  ACG ACG  AC A  AG  AT  GAT  GAT  GAT  G  ATTTT  GAT  GAT-3'
Reverse Primer: 5'-AAACTCGAGTTAAAGAGACTTCCTCCACTGCCA-3'
The  pMSCV-neo  vector  was  digested  with  EcoRI and Xhol restriction  enzymes. 
The  PCR  product  was  digested  with  EcoRI and  Xhol,  purified  and  cloned  into 
pMSCV-Neo vector upstream of PGK-Neor.
2.1.9  pMSCV-neo-FLAG-ATWANLS
The NPM retroviral construct lacking the nuclear localization signal was generated 
using the pMSCV-neo-APA/ construct as a template.  The following primers were 
used for PCR amplification {NPM primer sequence obtained from Bertwistle et al., 
2003).  The  forward  primer  N-F  was  used  for  amplification  of tNPM  was  used 
(shown above).
Reverse primer: 5'-AAACTCGAGTTACACAGCTACTAAGTGCTG-3'
The  pMSCV-neo  vector  was  digested  with  EcoRI and Xhol restriction  enzymes. 
The  PCR  product  was  digested  with  EcoRI and Xhol,  purified  and  cloned  into 
MSCV-Neo vector upstream of PGK-Neor.
2.2  Sequencing primers for pMSCV retroviral vectors
The  primers  used  for  sequencing  of  the  pMSCV-neo  vector  include  5'- 
CCCTTGAACCTCCTCGTTCGACC, and 3'-GAGACGTGCTACTTCCATTTGT
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Figure 2.1. A diagram of the retroviral constructs used in this study.  LTR:  long term repeat,  IRES- 
(intem al ribosom e entry site), N eor:  neom ycin resistance gene,  PPGK: phosphoglycerate kinase promoter, 
MSC:  m ultiple  cloning  site,  hCD2t:  human  C D 2  tail-less  gene,  ip+:  viral  packaging  signal,  SV40: 
Simian  Virus 40 early prom oter, CM V:  human cytom egalovirus promoter.
92C, and a 3'- CACATTGCCAAAAGACGG primer was used for the pMSCV-hCD2 
vector.
2.3 Cell lines
The human megakaryoblastic cell  line, Meg-01  (ATCC), was maintained in RPMI 
(Roswell Park Memorial  Institute) containing  10% FCS, 2 mM  L-Glutamine,  100 
U/mL Penicillin,  100 pg/mL Streptomycin (Gibco),  10 mM Hepes,  1   mM sodium 
pyruvate,  4.5  g/L  glucose  and  1.5  g/L  sodium  bicarbonate.  The  human  pro- 
erythroblastic cell line, K562  (ATCC), were maintained in RPMI containing  10% 
FCS, 2 mM L-Glutamine and  100  pg/mL streptomycin and  100 units/mL (U/mL) 
penicillin (Gibco). Mouse NIH3T3 fibroblasts and LinXE ecotropic packaging cells 
were  cultured  in  complete  DMEM  (Dulbeccos  Modified  Eagle  Media)  (Gibco) 
medium containing  10% FCS, 2  mM  L-Glutamine,  100  pg/mL  Streptomycin and 
100  U/mL  Penicillin  (Gibco).  The  LinXE  cells  (Genetica)  (Hannon  et al.,  1999) 
were  maintained  in  75  pg/mL  hygromycin  B  (Calbiochem)  to  select  for  the 
presence  of env  (envelope),  gag  (group  antigen)  and  pol  (reverse  transcriptase) 
genes.
2.4 Transfection of LinXE cells
LinXE cells were transfected with  8  pg DNA.  Lipofectamine reagent (Invitrogen) 
was used at a 5:1  ratio  of LipofectamineiDNA.  The Lipofectamine-DNA mixture 
was added to a final volume of 1.6 mL of Optimem medium (GIBCO). The mixture 
was  incubated at room temperature  (RT)  for 30 min.  Adherent LinXE cells were 
washed with optimem and 6.4 mL of optimum was added to the cells. After 30 min
93the Lipofectamine-DNA mixture was added to the cells and incubated at 37°C for 5 
hrs after which 8 mL of DMEM media containing 20% FCS was added to the cells. 
The following day, media was replaced with fresh DMEM media containing  10% 
FCS.  The  viral  supernatant  was  collected  48  hrs  after  transfection  and  used  to 
transduce haematopoietic progenitor cells (HPCs).
2.5 Isolation of haematopoietic progenitor cells (HPCs)
Foetal  liver  cells  were  harvested  from  day  12  embryos.  Single  cell  suspensions 
were  prepared.  Monoclonal  antibodies  specific  to  c-Kit  (2B8)  (Pharmingen)  and 
Terl 19 (BD Biosciences) was used to purify progenitor cells. The purification was 
carried  out  using  a  magnetic  activated  cell  sorter  (MACS)  (Miltenyi  Biotech) 
according to the manufacturer’s instructions. For adult progenitor cell purification, 
bone  marrow  was  extracted  from  5-Fluorouracil  (5-FU)  treated  mice.  Red  cells 
were lysed by resuspending cells in  1   M Tris (pH 7.2) and 0.144 M NH4CI for 10 
min  at  room  temperature.  Isolated  HPCs  were  cultured  overnight  in  DMEM 
containing  10% FCS,  100 ng/mL SCF,  10 ng/mL IL-3,  10 ng/mL IL-6 (Peprotech- 
EC, London, United Kingdom) and 50 pM 2-mercaptoethanol.
2.6 Transduction of HPCs
Retroviral supernatant was produced by transfecting the LinXE ecotropic retrovirus 
packaging cell line with retroviral vectors. Supernatant was harvested after 48 hours 
and cleared of cell debris by centrifugation at 580g for 5 mins. Virus was aliquotted 
into  1.5  mL  eppendorf  tubes  and  concentrated  for  1   hour  at  16,000g.  The 
supernatant  was  discarded  and  the  virus  was  concentrated  8  fold.  The  viral
94supernatant  was  used  to  transduce  the  purified  c-Kit+Terl 19'  HPCs  by 
spinoculation  (centrifugation  at  700g,  25°C,  45  minutes)  in  the  presence  of  100 
ng/mL  SCF,  10  ng/mL  IL-3,  10  ng/mL  IL-6  and  5  pg/mL  polybrene  (Sigma- 
Aldrich, Poole, United Kingdom).  Transduced HPCs were cultured with the same 
cytokine conditions for 24 hours and subsequently used for colony forming assays.
2.7  Colony forming assays
2.7.1 Myeloid conditions
Transduced  progenitor cells  were  cultured  at  104/mL  in methylcellulose  medium 
3434  (Stem  Cell  Technologies),  supplemented  with  10  ng/mL  GM-CSF  and  1  
mg/mL  of G418  (Gibco)  in the  first  round  of plating.  Cells  were  plated  without 
selection in the subsequent rounds of plating.  Cells were incubated at 37°C  for 7 
days after which colonies were counted and cells were harvested and analysed by 
flow cytometry.
2.7.2 Megakaryocytic conditions
Transduced progenitor cells were cultured at 104/mL in methylcellulose media 3234 
(Stem  Cell  Technologies)  in  the  presence  of 50  ng/mL  TPO  (R&D  systems),  50 
ng/mL  SCF and  1   mg/mL  G418  (Gibco)  in the  first round of plating.  Cells were 
plated without selection in the subsequent round of platings. Cells were incubated 
at 37°C for 5-10 days after which colonies were counted and cells were harvested 
and analysed by flow cytometry.
952.8  Generation and maintenance of immortalised cell lines
Single  cell  suspensions  were  serially  replated  in  methylcellulose  medium 
supplemented  with  the  same  growth  factors  without  G418.  Cell  lines  were 
established  by  picking  single  colonies  following  the  third  round  of plating  and 
propagation  in DMEM  liquid medium containing  10% FCS,  L-glutamine, and 50 
pM 2-mercaptoethanol in the presence of TPO, and SCF or TPO, SCF and, IL-3.
2.9 Cytokine withdrawal assay
Cells were  seeded  at  3xl03  per well  of a 96 well  plate.  Cells were washed and 
cultured in DMEM (10% FCS, 2 mM L-glutamine and 50 pM 2-ME) supplemented 
with various  combinations  of cytokines  (50  ng/mL  TPO,  lOOng/mL  SCF  and  10 
ng/mL IL-3). Cells were assayed for viability using the CellTiter 96® AQue0us One 
Solution (Promega) reagent, added into each well and resuspended thoroughly. The 
cells were incubated in the dark at 37°C and absorbance was measured at 495 nm 
using Microplate reader 680 (Biorad).
2.10 Cytospins
To analyse cellular morphology, cells were removed from methylcellulose cultures 
and washed twice in 10 mL PBS and 0.1% BSA buffer. Cells were resuspended at a 
concentration of 3xl05/mL in the wash buffer. Slides were placed on a metal holder 
and  then  a  cytofunnel  (VWR)  was  placed  on  top.  100  pi  cells  were  carefully 
dropped into the funnel. The cells were centrifuged for 5 min at 500 rpm with low 
deceleration in a Shandon Cytospin 3 (ThermoElectron Corporation).
962.11 Wright-Giemsa staining
The slides were removed and air dried for  10 minutes prior to staining. The slides 
were  stained  using  a  Shandon  varistain  24-4  automated  staining  machine  in  the 
Haematology department at Institute of Child Health (ICH).
2.12 INT staining
Colonies  were  stained  with  1   mg/mL p-iodonitrotetrazolium  (INT)  (Sigma)  in 
phosphate-buffered  saline  (PBS).  The  colonies  were  scanned  on  a  GS-800 
calibrated densitometer (Biorad) 48 hrs following staining.
2.13 Histopathology
Murine  tissues  were  fixed  in  10%  neutral  buffered  formalin  and  were  parafin 
embedded.  Hematoxylin  and  Eosin  (H&E)  staining  was  carried  out  on  4-pM 
sections. This was carried out by Dr Sebire in the Department of Pathology at the 
Institute of Child Health (ICH).
2.14 Determination of viral titre
NIH3T3 cells were seeded the day before at a density of 2.0x105  cells per well of a 
6  well  plate.  Viral  supernatant  was  harvested  from  LinXE  cells  48  hrs  after 
transduction  and  diluted  1:20,  1:200  and  1:2000  in  complete  DMEM  medium. 
NIH3T3 cells were transduced with 2 mL of each virus dilution in the presence of 5 
pg/mL  polybrene.  Infection  efficiency  was  measured  48  hrs  after  infection  by
97measuring  hCD2  expression  levels.  The  viral  titre  was  calculated  using  the 
following formula:
Viral titre (infectious particles / mL):
% of CD2 positive cells x dilution factor  x (4xl05)
2
2.15 NOD/SCID and C57BL/6 Mice
All  mice  were  maintained  in  the  animal  facilities  of the  National  Institute  for 
Medical Research, and the Institute of Child Health. Experiments were performed 
according to Home Office regulations and National Institute for Medical Research 
(NIMR) and Institute of Child Health (ICH) institutional guidelines.
2.16 In vivo transplantation
Retrovirally transduced cells were intravenously injected into sub-lethally irradiated 
(6  Gy)  recipient  C57BL/6-CD45.1  mice  48  hours  after  infection.  Reconstitution 
was  determined  4  weeks  later  by  flow  cytometric  analysis  of peripheral  blood. 
Donor C57BL/6 cells were distinguished from recipient C57BL/6-CD45.1 cells by 
the presence of CD45.2 and CD45.1 markers, respectively.
For secondary transplants, cells (106) isolated directly from primary leukaemic mice 
were  intravenously  injected  into  sub-lethally  irradiated  (6Gy)  recipient  C57BL/6 
mice.
982.17  5-Fluorouracil (5-FU) Treatment
C57BL/6  mice  were  intravenously  injected  with  150 mg/kg of 5-Fluorouracil  (5- 
FU)  (Faulding  Pharmaceuticals).  Treated  mice  were  sacrificed  4  days  post­
treatment and BM cells were isolated.
2.18  Flow Cytometry
Cells  were  stained  with  fluorochrome  conjugated  monoclonal  antibodies  and 
isotype control antibodies.  For the analysis of leukaemic cells, red cells were lysed 
in ammonium chloride solution at RT for 10 min prior to primary antibody staining. 
The cells were washed in staining buffer (PBS with 0.05% sodium azide and  1% 
bovine  serum  albumin  [BSA])  and  pre-incubated  with  unlabeled  anti-Fcy  II/III 
receptor  mAb2 402  for  15  minutes  on  ice.  Cells  were  stained  with  monoclonal 
antibodies  conjugated  with  fluorecein  isothiocyanate  (FITC),  phycoerthyrin  (PE), 
allophycocyanin  (APC)  or  biotin.  Biotin  conjugated  monoclonal  antibodies  were 
detected using Peridinin Chlorophyll Protein (PerCP) or PE conjugated strepavidin. 
Cells were washed twice in the staining buffer and flow cytometry of the cells was 
carried  out  on  either  a  Cyan  ADP  analyser  and  Summit  4.1  software 
(Dakocytomation) or a Beckman Coulter Epics XL analyser and EXP03  software 
(Beckman Coulter).
For  staining  of peripheral  blood  (PB),  recipient  mice were  bled  four  weeks  after 
transplantation.  Blood was washed with 3  mL of FACS  staining buffer.  100 pi of 
primary antibody and anti-Fcy II/III receptor block was added and incubated for 30 
min  on  ice  in  dark.  Samples  were  washed  in  300  pi  of wash  buffer.  100  pi  of
99secondary antibody and anti-Fcy II/III receptor block was added and incubated on 
ice for 30 min in dark. To lyse the red blood cells, 2 mL of lysis buffer was added to 
the samples and incubated at RT for  10 min.  The samples were washed with PBS 
and centrifuged at 370g for 5 min at 4°C. The cells were resuspended in 300 pi of 
PBS+azide and analysed by Flow cytometry.
Table 5: Flow Cytometry antibodies and working dilutions
Antibody Clone Isotype Supplier Dilution
Auti-CD45.1 PE A20 IgG2a k eBiosciences 1:100
Anti-CD2  PE LF-A2 IgG l  K eB iosciences 1:100
Anti-cKit PE 2B8 IgG2aK BD Pharmingen 1:100
A nti-B220  PE R A 3-6B 2 IgG2a k BD  Pharmingen 1:100
Anti-IgGl PE A85-1 IgGlK BD Pharmingen 1:100
Anti-IgG2A PE G 155-178 IgG 2a k B D  Pharmingen 1:100
Anti-IgG2B PE MPC-11 IgG2aK BD Pharmingen 1:100
Anti-C D45.2  FITC 104 IgG 2a k eB iosciences 1:100
Anti-Mac I FITC Ml/70 IgG2b k BD Pharmingen 1:100
Anti-CD41  FITC M W /R eg30 IgG l  K abeam 1:100
Anti-cKit APC 2BB IgG2b k eBiosciences 1:250
Anti-B220 APC R A 3-6B 2 IgG2a k eB iosciences 1:250
Anti-Gr-1 APC RB6 8CS IgG2b k eBiosciences 1:500
A nti-C D45.2  Biotin 104 IgG 2a k eB iosciences 1:100
Anti-CD2 Biotin LFA2 IgG2bg BD Pharmingen 1:100
Strepavidin  PE N /A N /A BD  Pharmingen 1:250
Strepavidin Prep N/A N/A BD Pharmingen 1:350
1002.19 Southern Blotting
Cells were centrifuged and pellets lysed at 5-10xl06 and lysed in 400 pi TNES (TE, 
0.1  M NaCl, 0.1% SDS) containing 0.5 mg/mL proteinase K (Roche) and incubated 
O/N at 37°C. For DNA extraction, 0.5 mL of phenol-chloroform-isoamylacohol (25 
parts  phenol,  24  parts  chloroform,  1   part  Isoamylalcohol)  was  added  and  shaken 
vigorously  for  1   min.  The  top  phase  was  removed  and  transferred  into  a  tube 
containing 1  mL ethanol: 3M NaOAC (25:1) volume ratio and mixed by vortexing. 
DNA was precipitated by incubating on dry ice for 2 hours. The precipitated DNA 
was centrifuged at 13000 rpm for 10 min. The supernatant was removed and added 
to  1   mL of 70% ethanol and centrifuged again for 2 min. The DNA was dissolved 
in  100 pi TE (pH 8.0).  10 pg of the purified DNA was digested O/N at 37°C with 
specific restriction enzymes in the presence of 10 mg/mL of BSA and 10 mg/mL of 
RNase.
The digested DNA was loaded on a 0.8% agarose gel and electrophrosed overnight 
at  35V.  The  DNA  on  the  gel  was  denatured  by  soaking  the  gel  in  a  tray  of 
denaturing solution (1.5  M NaCl,  0.5  M NaOH) for 45  min and the solution was 
changed  every  15  min.  The  gel  was  washed  in  H2O  and  then  soaked  in 
neutralisation  solution  (1  M  Tris  (pH  7.4),  1.5  M  NaCl)  for  30  min  with  gentle 
agitation. The gel was further washed with 10x SSC (National Diagnostics) and the 
DNA  was transferred on to  a nylon membrane  (Amersham)  O/N.  The  DNA was 
fixed  onto  the  membrane  by  incubation  at  80°C  for 2  hrs.  To  prevent  any  non­
specific binding, the membrane was placed in a pre-hybridisation solution (5x SSC, 
0.5%  SDS,  0.1  g/mL  dextran  sulphate  (Sigma-Aldrich),  5x  Denhardts  (Sigma-
101Aldrich)  and  0.5  mg/mL  salmon  sperm  (Sigma-Aldrich)  for  2  hrs  at  65°C  with 
gentle rotation.
DNA  probe  labelling  and  purification  was  carried  out  using  the  Ready-To-Go™ 
DNA labelling beads and Probe Quant™ 96 G-50 Micro Columns, according to the 
manufacture’s instructions (GE Healthcare). The blot was hybridised with the probe 
at 65°C  O/N  with gentle  rotation.  The  blot  was  washed twice  with  several  wash 
buffers (wash buffer A: 2x SSC and 0.1% SDS at 55°C for 30 min, wash buffer B: 
0.5x  SSC  and 0.1% SDS at 55°C  for 20 min). The bands were visualised using a 
typhoon phosphorimager (GE Healthcare).
2.20  Immunobloting
The protein lysates were resuspended in 2x  SDS  sample buffer,  boiled for 5  min 
and were separated on a polyacrylamide  gel.  Protein samples were resolved on a 
10% SDS-PAGE (sodium dodecylsulfate-polyacrylamide gel electrophoresis). The 
main lower gel composed of 10% or 15% acrylamide gel (acrylamideibisacylamide 
37.5:1,  1.5 M Tris-HCl  (pH  8.5) and 2% SDS).  The gel was polymerised by the 
addition of 10%  APS  (ammonium per sulphate)  and 0.01% TEMED  (N,N,N',N'- 
Tetramethylethylenediamine).  The  stacking  gel  composed  of 5%  acrylamide  gel 
(acrylamideibisacylamide  37.5:1,  1.0  M  Tris-HCl  (pH6.8)  and  2%  SDS).  The 
samples  were  run  in  lx  running  buffer  (1.92  M  glycine,  250  mM  tris-base,  1% 
SDS) overnight at constant voltage of 50 V.  The proteins were transferred onto a 
PVDF (polyvinylidenfluoride) membrane (Immobilon-P, Millipore) using 9.5 mM 
CAPs (N-Cyclohexyl-3-aminopanesulfonic acid, pH  11.0) for 5 hrs at  100 V.  The
102membrane was blocked in PBS with 5% nonfat milk and 0.2% Tween-20 for 1 hr at 
room temperature.  The membrane was  incubated with specific primary antibodies 
overnight at 4°C  with constant shaking, washed  3x  with PBS-Tween  and probed 
with  a  secondary  antibody  for  1   hour  at  room  temperature.  The  membrane  was 
washed  3x  with  PBS-Tween  and  proteins  were  detected  using  ECL  reagent 
(Amersham) according to the manufacturer’s instructions.
Table 6: Immunoblotting antibodies
Antibody Clone Supplier Dilution
Rabbit anti-ERG-3 1/2/3 C-17 Santa-Cruz 1:2000
M ouse anti-FLAG M2 Sigm a-Aldrich 1:2000
Mouse anti-Myc 9B11 Cell signalling technologies 1:1000
Goat anti-actin 1-19 Santa-Cruz 1:1000
Mouse anti-NPM Fc-61991 Zymed 1:2000
Rat anti-Tubulin YL1/2 Serotec 1:1000
Mouse anti-GAL4 GAL4-8 Zymed 1:1000
anti-m ouse HRP N /A Santa-Cruz 1:2000
anti-rat HRP N/A Santa-Cruz 1:2000
anti-goat HRP N /A Santa-Cruz 1:2000
anti-rabbit HRP N/A Santa-Cruz 1:2000
2.21  Immunoprecipitation
Mouse NIH3T3  fibroblasts  were  lysed  in RIPA  (radioimmunoprecipitation assay) 
lysis buffer (50 mM Tris HCL, pH 7.5,  150 mM NaCL,  1   mM EDTA,  1% NP40,
1030.5%  sodium  deoxycholate  and  0.1%  SDS)  containing  lx  complete  protease 
inhibitor  tablets  (Roche  Applied  Science).  Cell  lysates  were  pre-cleared  using 
protein  A  coupled  agarose  beads  (Roche)  for  lhr  at  4°C.  The  pre-cleared 
supernatant was removed and  10 pg/mL mouse NPM antibody (FC-61991-Zymed) 
or 3  pg/mL  mouse  FLAG  antibody  (M2-Sigma-Aldrich)  were  used to  precipitate 
complexes.  The  antibody-protein  complex  was  incubated  overnight  at  4°C  with 
constant rotation. Appropriate beads were added to the protein samples for 1  hr at 4° 
C. The immunoprecipitates bound to the beads were collected by centrifugation and 
washed several times with  1   mL of cold lysis buffer.  The beads were boiled for 5 
min  in  2x  SDS  sample  buffer  (125  mM  Tris-HCL  pH  6.8,  4%  SDS,  5%  2- 
mercaptoethanol,  20%  glycerol  and  0.1%  bromophenol  blue).  The  precipitated 
proteins were separated on SDS-PAGE under reducing conditions. The mouse anti- 
FLAG antibody and mouse NPM antibody (Zymed) were used for immunoblotting. 
Mouse  anti-GAL4  antibody  (Zymed)  was  used  as  an  IgG-K  isotype  control  in 
immunoprecipitations.
2.22  Luciferase reporter assay
Mouse NIH3T3  fibroblasts  were  transiently  transfected  with  0.4  pg  of pCDNA3 
expression  vector,  0.4  pg  pCDNA3-NPM-MLFl  or  with  0.4  pg  pCDNA3-A//W. 
Cells were cotransfected with 50 ng p53  luciferase construct (el-Deiry et al,  1992) 
containing 13 repeats of p53 consensus sequence (G/A G/A G/A C A/T T/A G C/T 
C/T  C/T).  Cells  were  also  transfected  with  or  without  a  FLAG  tagged-p53 
expression vector (0.2 pg) obtained from Dr El-Deiry (el-Deiry et al., 1992). Mutant 
p53 luciferase construct containing 15 repeats of p53 consensus sequence mutated at
104four “hot spots” (el-Deiry et al.,  1992) was also used as a negative control. Renilla 
luciferase reporter construct (50 ng) was used as an internal control to normalise for 
transfection efficiency. Luciferase activity was measured in triplicate samples 24 hr 
after transfection with a dual-luciferase reporter system (Promega) according to the 
manufacturer’s instructions. A luminometer LB 9507 machine was used for reporter 
assay measurement.
2.23  Immunofluorescence
Mouse  NIH3T3  cells  grown  on  coverslips  were  fixed  in  4%  paraformaldehyde. 
Cover slips were washed 3x in PBS and permeabilised in 0.5% Triton X-100 for 5 
min at room temperature. Cells were washed in PBS and blocked for 30 min with 
50% horse serum in PBS. Immunolabelling of the cells was carried out for 1   hour 
with the anti-FLAG M2 monoclonal antibody (Sigma). Cells were washed in PBS 
and were subsequently incubated for  1   hour with Rhodamine conjugated anti-IgG 
antibody  (Immunoresearch  Laboratories).  After  several  rounds  of  washing  the 
nuclei was stained with  10 pg/mL Hoechst dye for 5-10 min at room temperature. 
Following two rounds of washing, coverslips were mounted using Citifluor and nail 
varnish.  Slides were examined using a Nodel Axiplan 2 Fluorescence microscope 
(CarlZeiss Microimaging).
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Figure 2.2.  Experimental strategy.  Embryonic day  12.5  (El2.5)  liver was extracted 
from  C57BL6/CD45.2+   mice.  Haematopoietic  progenitor  cells  (HPCs)  were  isolated 
from foetal  liver and cultured in myeloid conditions (SCF, IL-3  and IL-6). HPCs were 
transduced  with  retroviral  vectors  expressing  the  gene  of interest.  The  effect  of the 
genes on HPC development was addressed in vitro by performing colony forming assays 
and by transplantation assays in vivo.  For in vitro studies, transduced cells were cultured 
in  methylcellulose  media  in  pro-myeloid  (GM-CSF)  or pro-megakaryocytic  (TPO and 
SCF) conditions.  Cells were cultured at 37°C  for 5-10 days,  after which the colonies 
formed were counted and single cells were analysed by flow cytometry.  Serial re-plating 
of the transduced ceils was carried out following initial selection of neomycin resistant 
cells in the first round of plating.  The immortalisation capacity of the specific genes was 
investigated by growth of cells from the 3rd round of plating in liquid culture.  For in vivo 
studies,  transduced  cells  expressing  genes  of interest  were  injected  into  sub-lethally 
irradiated  mice  to  determine  the  potential  contribution  of these  genes  to  leukaemic 
development.
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Chapter 3: ERG-3 promotes megakaryopoiesis
DS  children  have  a  20-fold  increased  risk  of  childhood  acute  lymphoblastic 
leukaemia  (ALL)  and  a  600-fold  increased  risk  for  acute  megakaryoblastic 
leukaemia  (AMKL).  Around  10%  of  DS  newborns  have  a  transient 
myeloproliferative  disorder (TMD) that resolves  spontaneously but approximately 
20% of TMD patients  will  progress to develop AMKL during early childhood.  It 
has been proposed that overexpression of one or more genes on chromosome 21 are 
crucial in the leukaemogenic transformation of megakaryoblasts.  Several candidate 
genes  have  been  identified  such  as  RUNX1,  BACH1,  ETS2  and  ERG.  ERG  is  a 
potentially good candidate as the ERG-3 haematopoietic isoform has been shown to 
be  expressed  in  DS  and  non-DS  AMKL  patient  samples  and  to  be  involved  in 
megakaryocytic differentiation (Rainis et al., 2005). This study also identified ERG- 
3 as the main haematopoietic ERG isoform.  Truncated forms of ERG are involved 
in  several  oncogenic  fusion  translocations  in  leukaemia,  Ewing  sarcoma  and 
prostate cancer. Overexpression of ERG has been recently reported to characterize 
myeloid leukaemias with a particularly poor outcome, however it is unclear if this 
overexpression  is  simply  correlative  or  has  a  direct  oncogenic  role  in  these 
leukaemias.  We  set  out  to  investigate  the  role  of  ERG-3  in  murine 
megakaryopoiesis.
1083.1  TPO and SCF cytokines give optimal conditions for MK development
Our  experimental  strategy  was  to  transduce  foetal  HPCs  with  the  appropriate 
retrovirus  and  carry  out  colony  forming  assay  under  cytokine  conditions  that 
support  limited  megakaryopoiesis.  Different  cocktails  of cytokines  were  used  to 
determine  the  cytokine  combination  that  is  required  for  megakaryocyte 
differentiation and HPC  survival and growth.  HPCs isolated from E l2.5  FL were 
cultured  in  methylcellulose  in  the  presence  of TPO  (thrombopoietin)  alone,  TPO 
and  SCF  (stem cell  factor),  TPO  and  IL-3  (Interleukin-3)  or TPO,  IL-3  and  IL-6 
(Interleukin-6).  Cells were harvested at 5  days  and  10 days  following culture and 
analysed  for the  expression  of CD41,  a marker of megakaryocyte  differentiation, 
and c-Kit, a marker expressed on HPCs.  At days  5  and  10 the percentage of cells 
expressing CD41  was higher in the presence of TPO than in the presence of other 
cytokine  combinations  (Figure  3.1A).  In  this  context,  there  was  megakaryocytic 
differentiation in the presence of TPO alone but very few colony formation (Figure 
3.2), further demonstrating that in addition to TPO, there is a requirement for other 
growth factors that promotes HPC survival and colony formation. The percentage of 
CD41  expression was reduced in the presence of SCF but was not greatly altered in 
the presence of IL-3 or IL-6. However, the number of colonies was increased 2-fold 
with IL-3  and  3-fold  with  IL-3  and  IL-6.  Interestingly,  IL-3  has  been reported to 
promote  megakaryocyte  colony  formation.  We  chose  the  TPO  and  SCF  cytokine 
combination to carry out in vitro megakaryocyte colony forming assays. Since IL-3 
also drives megakaryocytic proliferation, this cytokine was omitted from cultures in 
order to avoid masking of potential proliferative activity of ERG-3.
1093.3  Generation of ERGS, Gatal and Gatals retroviral constructs
The  Gatal  and  Gatals  cDNAs  were  cloned  into  the  murine  stem  cell  (MSCV)- 
based retroviral vector, pMSCV, containing a neomycin resistance (neor) gene. The 
ERGS  cDNA  was  cloned  into  the  pMSCV-IRES-hCD2  retroviral  vector,  which 
expresses the human CD2 (hCD2) gene lacking the cytoplasmic signalling domain 
(tailles).  The  internal  ribosome  entry  site  (IRES)  allows  the  translation  of two 
proteins  from  a  bicistronic  mRNA  (Figure  3.3A).  The  expression  of  GATA1, 
GATAls  and  ERG-3  proteins  was  confirmed  by  Western blot  analysis  of LinXE 
cells  transfected  with  pMSCV-Gatal,  pMSCV-Gatals  and  pMSCW-ERGS 
retroviral constructs (Figure 3.3B). An anti-Flag antibody revealed the presence of 
the  50  kDa GATA1  protein  and the  40  kDa GATAls  protein,  whereas  the  anti- 
ERG-3 antibody revealed the presence of a 53 kDa ERG-3 protein.
3.4  ERG-3 promotes megakaryopoiesis
A  function  for  ERG-3  in  megakaryopoiesis  was  demonstrated  by  the  ectopic 
expression  of the  protein  in  HPCs  isolated  from  El2.5  Foetal  liver.  HPCs  were 
cultured in methyl cellulose in the presence of TPO and SCF. Colonies were counted 
after 7-10 days and single cells were analysed by flow cytometry. Cells transduced 
with vector alone generated few colonies in the first round of plating and these cells 
could not be replated into the subsequent round. Cells expressing ERG-3 produced 
around 50 colonies, however the number of colonies formed was markedly reduced 
in the second round (Figure 3.4A) and these cultures failed to re-plate subsequently 
(data  not  shown).  Analysis  of colony  morphology  revealed  that  cells  transduced 
with vector formed  very  small  compact  colonies  and the  ERG-3  expressing  cells
110formed  large  sparse  colonies  in  the  presence  of TPO  and  SCF  (Figure  3.4B). 
Wright-Giemsa  staining  of  ERG-3  cultures  revealed  presence  of  mature 
megakaryocytes (Figure 3.4C). Analysis of ERG-3 expressing cells harvested from 
the  first round  of plating  revealed 45% percent of CD41  expression as compared 
with  21%  CD41  expression  in  cells  transduced  with  vector  alone  (Figure  3.5). 
These data demonstrate that ERG-3 is involved in megakaryocytic development.
3.5  ERG-3 immortalises progenitor cells in the presence of IL-3
Since ERG-3 did not immortalise progenitors in the presence of TPO and SCF, we 
attempted  to  identify  a  cytokine  combination  capable  of supporting  the  potential 
immortalisation capacity of ERG-3 expressing cells in colony forming assays. Cells 
transduced with ERG-3 were cultured in the presence of TPO, SCF, IL-6 and IL-11. 
Both IL-6 and IL-11  are added to the cultures as they are associated with enhanced 
megakaryocyte  proliferation  and  cell  expansion  (Lazzari  et al.,  2000).  IL-11   can 
stimulate the proliferation of the human megakaryocytic cell line, CMK (Kobayashi 
et al.,  1993) and it increases the percentage of high ploidy megakaryocytes derived 
from both murine  and  human bone marrow cells,  suggesting its role  in triggering 
terminal  maturation  (Burstein  et  al.,  1992).  Furthermore,  both  IL-6  and  IL-11  
synergise with TPO and SCF to enhance ex vivo expansion of megakaryoblasts from 
human  CD34+   bone  marrow  cells  (Williams  et  al.,  1998).  IL-11   and  IL-6  also 
synergise  with  IL-3  to  increase  proliferation  of progenitors  by  shortening the  Go 
phase of the cell cycle in stem cells (Musashi et al.,  1991). In the presence of IL-6 
and IL-11, cells transduced with vector alone formed the same number of colonies 
as  cells expressing  ERG-3  and control  cells failed to  form colonies  following the 
first round (Figure 3.6A). Cells transduced with ERG-3 ceased to re-plate on to the
111fourth round (data not shown). At the third round of plating, there was low number 
of colonies present in the ERG-3 cultures. The colonies detected were not spread out 
and some were fused. In contrast, when ERG-3 expressing cells were plated in TPO, 
SCF  and  IL-3  alone,  they  could  be  serially  replated  up  to  the  seventh  round  of 
plating.  IL-3 has megakaryocytic colony stimulating activity and it synergises with 
TPO  to  stimulate  megakaryocyte  production  and  colony-forming  units- 
megakaryocyte (CFU-MK) (Dolzhanskiy et al.,  1997). Cells transduced with vector 
retrovirus  also  formed  colonies  up  to  the  sixth  round  of plating  (Figure  3.7A). 
However,  there  was  a  profound  difference  in  the  morphology  of  the  colonies 
formed.  ERG-3 transduced cells formed large, hyperproliferative colonies whereas 
vector  transduced  cells  formed  small,  intact  colonies  at  each  round  of plating 
(Figure 3.7B).  Furthermore,  cells expressing ERG-3  were mostly c-Kit+CD41+ as 
compared  with  cells  transduced  with  empty  vector  which  expressed  the  early 
progenitor cell marker c-Kit but not CD41 (Figure 3.7C).
3.6  ERG-3  immortalised  cell  lines  have  an  immature  megakaryoblastic 
phenotype
Single colonies were picked from the third round of plating and cultured in liquid in 
DMEM  complete  medium  supplemented  with  TPO,  SCF  and  IL-3.  Four  ERG-3 
immortalised  cell  lines  were  generated  and  these  had  the  same  rate  of growth 
(Figure 3.8A). Cells transduced with vector alone were not viable in liquid culture 
(data not shown). The presence of the 53 kDa ERG-3 protein in these cell lines was 
detected  using  an  anti-ERG-3  antibody  (Figure  3.8B).  The  cell  lines  were  all 
positive for hCD2 and expressed high levels of c-Kit and low CD41  (Figure 3.9A). 
These cells also had an immature megakaryoblastic phenotype, as shown by Wright-
112Giemsa staining (Figure 3.9B).
3.7  ERG-3 immortalised cell lines are dependent on SCF and IL-3 for survival
To  determine  the  cytokine  dependence  of the  immortalised  cells,  an  MTS  cell 
viability  assay  was  carried  out.  Cells  were  grown  in  DMEM  complete  medium 
supplemented  with  various  combinations  of TPO,  SCF  and  IL-3.  Cells  were  also 
cultured in the absence of IL-3, TPO or SCF. Cell viability was measured 48 hrs and 
72 hrs after cytokine withdrawal. At 48 hrs, the absence of TPO did not have any 
effect  on  the  cell  viability  whereas  there  was  a  significant  reduction  in  cellular 
growth in the absence of SCF for all four ERG-3 immortalised cell lines. There was 
an additional reduction in viability in the absence of IL-3 with cell lines E3-1, E3-2 
and  E3-3  but  not  E3-4.  There  was  no  difference  in  cell  viability  between  E3-4 
supplemented with TPO, SCF and IL-3  and cultures lacking IL-3.  In addition, this 
cell  line  appeared  to  be  more  dependent  on  SCF  than  the  other  three  cell  lines 
(Figure 3.10A). At 72 hrs, there was a further decrease in viability in comparison 
with  cultures  containing  SCF  and  IL-3  with  cell  lines  E3-1,  E3-2  and  E3-3.  In 
contrast,  although  there  is  a  reduction  in  viable  cells  in  the  absence  of IL-3  as 
compared with cultures containing TPO, SCF and IL-3 or TPO and IL-3, E3-4 cells 
appeared to be independent of IL-3 (Figure 3.10B).
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Figure 3.1. TPO and SCF are optimal for megakaryocytic differentiation.  Dot
plots  represent  the  expression  of CD41.  The  numbers  show  the  percentage  of 
positive  cells.  HPCs  were  isolated  from  El2.5  Foetal  liver  and  were  plated  in 
methycellulose  medium  3234  in  the  presence  of various  cytokine  combinations: 
TPO (50 ng/mL) alone, TPO and SCF (50 ng/mL each), TPO and IL-3 (10 ng/mL) 
or TPO, IL-3 and of IL-6 (10 ng/mL).  Cells were harvested at days 5 and  10.  The 
data is a representative of two independent experiments.
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Figure 3.2. TPO and SCF are sufficient for megakaryocytic colony formation.
HPCs were  isolated  from  E l2.5  Foetal  liver and were cultured in methylcellulose 
media  3234  supplemented  with  either TPO  (50  ng/mL)  alone,  TPO  and  SCF  (50 
ng/mL),  TPO,  IL-3  (10  ng/mL)  or  TPO,  IL-3  and  IL-6  (10  ng/mL).  Cells  were 
cultured for 10 days.  A. Number of colonies produced in the first round of plating. 
B.  Total number of cells  harvested from the pooled duplicate cultures in the first 
round of plating.
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Figure 3.3. Expression of GATA1, GATAls and ERG-3 in LinXE cells.  A.
Diagram depicting the retroviral constructs used to express ERG-3, Gatal  (FLAG), 
and Gatals (FLAG).  B.  Western blot analysis of protein lysates from LinXE cells 
transfected  with  pMSCV-neo,  pMSCV-G^47>t7,  pMSCV-GATAls  and  pMSCV- 
ERG-3  constructs.  FLAG  tagged  GATA1  and  GATAls  proteins  were  detected 
using an anti-FLAG antibody and ERG-3 protein was detected using an anti-ERG- 
3 antibody.
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Figure  3.4.  ERG-3  promotes  megakaryopoiesis.  A.  Bar  chart  showing  the 
number of colonies (left panel) and number of cells (right panel) at each round of 
plating.  The data represents mean and ±  S.D. of duplicate cultures.  HPCs were 
transduced  with  vector  or  ERG-3  retrovirus  and  cultured  in  methylcellulose 
medium  in  the  presence  of TPO  and  SCF.  Colonies  were  scored and  single  cells 
counted. B.  Typical  morphology of colonies formed at the first and second round 
of plating (original magnification x40). C. Representative Wright-Giemsa staining 
of cells expressing ERG-3 (original magnification, x400).
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Figure 3.5.  Flow cytometry:  ERG-3  promotes  megakaryopoiesis. HPCs 
were  transduced  with  vector  or  ERG-3  retrovirus  and  cultured  in 
methylcellulose in the presence of TPO and SCF.  Flow cytometry carried 
out on single cells isolated from the first round of plating. Dot plots show the 
expression of c-Kit+CD41+ cells  within the CD2 positive population.
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Figure 3.6.  ERG -3  does  not  im m ortalise  H PC s  in  the  presence o f T PO ,  SC F, IL-6 
and  IL-11.  A.  Bar chart showing the number of colonies (left panel) and number of 
cells (right panel) at each round of plating.  The data represents mean and ± S.D. of 
duplicate  cultures.  HPCs  were  transduced  with  vector  or  ERGS  retrovirus  and 
cultured  in  methylcellulose  in  the  presence  of TPO,  SCF,  IL-6  and  IL-11.  Colonies 
were scored and single cells counted.  B.  Typical morphology of colonies formed at 
the  first  and  second  round  of  plating  (original  magnification,  x40).  The  arrows 
indicate the absence of colony formation and cell number.
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Figure 3.7.  ERG-3  immortalises  HPCS in  the  presence of IL-3.  A.  Bar chart 
representing the number of colonies (left panel) and number of cells (right panel) at 
each round of plating.  The data represents the mean and ± S.D. of duplicate cultures. 
HPCs were transduced with vector or with ERGS retrovirus .  Colony forming assays 
were performed by culturing cells in the presence of TPO (50ng/ml), SCF (lOOng/ml) 
and IL-3 (lOng/ml) for 6-10 days. Colonies were scored and the total cell number was 
counted  from  third  round  of  plating.  B.  Representative  morphology  of colonies 
formed by transduced cells (original magnification, xlOO).  C.  Dot plots represent c- 
kirCD4T expression in cells transduced with Vector or ERG-3.
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Figure 3.8. Generation of ERG-3  immortalised cell lines.  Single colonies were 
picked and cultured in the presence of TPO, SCF and IL-3.  Cells transduced with 
vector did not survive  in  liquid culture.  A.  Fold increase in cell number of four 
ERG-3  immortalised cells lines.  B. Western blot analysis of protein  lysates from 
ERG-3 immortalised cell lines.  The presence of ERG-3 protein was detected using 
an anti-ERG-3 antibody.  Protein lysate from the megakaryoblastic cell line (Meg- 
01)  was  used  as  a  positive  control  for the  expression  of ERG-3.  An  anti-actin 
antibody was used as loading control.
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Figure  3.9.  Immortalised  cell  lines  have  immature  megakaryoblastic 
phenotype..  A.  Phenotype  of  a  representative  ERG-3  immortalised  cell  line. 
Histogram depicting the expression of hCD2, c-Kit and CD41.  B.  Representative 
morphology of  ERG-3  immortalised cell line as demonstrated by Wright-Giemsa 
staining, (Original magnification x 200).
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Figure 3.10.  ERG-3  immortalised  cell  lines are dependent on IL-3 and SCF.
The cytokine requirement of each ERG-3 immortalised cell line was assessed using 
an MTS assay.  Each cell line was grown  in the presence of TPO, SCF and IL-3, 
TPO and SCF, SCF and IL-3 or TPO and IL-3.  MTS assay was carried out 48 hrs
(A)  or 72 hrs (B) following cytokine withdrawal.  Absorbance was measured at 490 
nm.  The data represents mean and ± S.D. of duplicate cultures.
1233.8 Discussion
The molecular mechanism for leukaemogenesis in DS is as yet unclear.  Particular 
genes on chromosome 21  have been implicated in the pathogenesis of DS but not 
much  is  known  about  what  causes  abnormal  megakaryopoiesis  in these  patients. 
There are  a number of genes  located on  chromosome 21  that are  involved in the 
regulation of different aspects of haematopoiesis. These genes, in combination with 
GATA1  mutation  may  be  contributing  factors  in  leukaemic  evolution  in  DS. 
RUNX1,  BACH1  and  ETS related  genes  (ETS1,  ETS2  and  ERG)  are  few  of the 
candidate genes,  located in the Down syndrome critical region (DSCR), that have 
been  shown  to  have  a  role  in  megakaryocytic  development.  RUNX1  is  a 
transcription factor which plays a vital role in gene regulation in the haematopoietic 
system.  The importance of RUNX1  as the positive regulator of megakaryopoiesis 
was revealed in a conditional knock out mouse in which Runxl was deleted in most 
of haematopoietic progenitor cells. Megakaryocytic maturation is defective in these 
mice as measured by the presence of abnormally small immature megakaryocytes, 
low levels of platelets and aberrant polyploidisation in comparison with wild type 
mice (Ichikawa et al.,  2004).  In contrast to RUNX1, BACH1  negatively regulates 
genes required for megakaryocyte maturation, as shown by the reduction of platelets 
in the Bachl transgenic mice (Toki et a l 2005).
ERG-3  is  another  gene  located  on  the  DSCR  on  chromosome  21  and  data  from 
Rainis  et  al  show  ERGS  mRNA  expression  in  cell  lines  established  from  DS 
patients. In addition, the possible role of ERG-3 in megakaryopoiesis was suggested 
using  in  vitro  studies  where  ectopic  expression of ERG-3  in  K562  cells  induced
124megakaryocyte maturation at the expense of erythropoietic differentiation (Rainis et 
al.,  2005).  The  aim  of our  study  was  to  establish  if there  is  any  co-operativity 
between the expression of the GATA1 mutation, detected in DS patients, and ERG- 
3.  To  examine  this,  we  first  wanted  to  determine  if  ERG-3  had  any  role  in 
megakaryopoiesis.  We  generated  MSCV-based  retroviral  vectors  to  express 
GATA1, GATAls or ERG-3 and confirmed their ability to produce each protein by 
immunoblotting.  We  used  progenitor  cells  isolated  from  El2.5  FL,  as  data  from 
Gatals knockin mice have shown that El2.5  FL contains a significant fraction of 
hyperproliferative megakaryocytic precursors which diminishes very rapidly at later 
days in embryonic development.
Colony  forming  assays  were  carried  out  using  isolated  HPCs  in  the  presence  of 
various cytokine  combinations to  determine the  optimal  combination required for 
megakaryopoiesis. Several cytokine conditions have been used by various groups in 
colony forming assays. The main haematopoietic cytokine required for commitment 
of HPCs along the  megakaryocytic  lineage  is  TPO.  Recombinant TPO  stimulates 
the growth and differentiation of murine megakaryocytes in vitro (Wendling et al., 
1994).  We  have  shown  that  although  TPO  alone  induced  a  marked  increase  in 
megakaryocytic  maturation,  it  did  not  support  the  growth  of  megakaryocytic 
colonies.  Indeed,  in a study by Guerriero et al, megakaryocytes were generated in 
the presence of TPO  alone,  but their proliferation was  significantly compromised 
(Guerriero et al.,  1995).  In addition, TPO has been shown to  synergise with SCF, 
erythropoietin  (EPO),  IL-3,  IL-6  and  IL-11  to  promote  megakaryocytic 
proliferation,  differentiation  and  platelet  production  both  in  human  and  murine 
HPCs.  In  our  study,  TPO  in  combination  with  SCF,  IL-3  and  IL-6  promoted
125megakaryopoiesis.  Expansion of early progenitors was observed with the addition 
of just IL-3  and IL-6. This observation is supported by studies that show that IL-3 
promotes the early stages of megakaryocytic development, while inhibiting terminal 
differentiation (Dolzhanskiy et al., 1998; Murphy and Leavitt, 1999).
ERG-3 was shown to promote megakaryopoiesis in the presence of TPO and SCF. 
The  cells  generally  exhibited  a  megakaryoblastic  phenotype,  as  shown  by  their 
expression  of CD41.  However,  HPCs  expressing  ERG-3  were  not  able  to  from 
colonies  past  the  second  round  or  past  the  third  round  in  some  experiments.  To 
determine  whether  ERG-3  could  induce  immortalisation  of  megakaryocytic 
progenitor cells, the cytokines used in these cultures was altered. It was shown that 
cells  expressing  ERG-3  were  immortalised  in  the  presence  of  IL-3  but  not  in 
cultures with IL-6 and IL-11. Indeed, IL-6 and IL-11   cooperate with TPO to induce 
late maturation of megakaryocytes (Koike et al., 1990; Burstein et al., 1992) and the 
clonogenic potential of progenitor cells in the presence of IL-6 and IL-11   is lower 
than  in  cultures  with  IL-3  alone  (Lazzari  et  al.,  2000).  Although  IL-3  has  been 
shown  to  inhibit  megakaryocytic  differentiation  (Dolzhanskiy  et  al.,  1997),  the 
presence  of  ERG-3  promotes  commitment  and  maturation  of  cells  along  this 
lineage.  However,  control  cells  that  were  transduced  with  vector  alone  did  not 
express  the  megakaryocytic  marker  CD41.  Furthermore,  all  the  cells  in  these 
cultures were c-Kit positive in the presence of IL-3, which is in contrast to the very 
low c-Kit expression levels detected in cultures with TPO and SCF alone. This data 
is  in  line  with  current  evidence  that  IL-3  is  required  for  maintenance  of early 
megakaryocytic progenitors (Broudy et al.,  1995; Williams et al.,  1998). Our study 
shows that ERG-3 commits progenitor cells to the megakaryocytic lineage and TPO
126and SCF synergise with IL-3 to provide an optimal conditions to trigger expansion 
of HPCs expressing ERG-3.
The  mechanism  for  ERG-3  mediated  immortalisation  is  unknown.  For  future 
studies, ERGS deletion constructs can be generated to determine which domains of 
this  transcription  factor  are  essential  for  megakaryocytic  commitment  and 
progenitor immortalisation. The generation of miRNA/siRNA against ERGS would 
determine  whether  the  immortalised  cells  were  dependent  upon  the  presence  of 
ERG-3. It may be that ERG-3 is essential for the initiation of immortalisation but its 
presence is not required for survival of immortalised cells. Finally, the generation of 
cell  lines  with  inducible/conditional  expression  of  ERG-3  would  allow  the 
identification of primary ERG-3 target genes, which could ultimately lead to a better 
understanding of the function of ERG-3 and its potential role in development of DS 
associated AMKL.
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128Chapter 4: ERG-3 collaborates with GATAls
GATAl  normally  suppresses  the  proliferation  of megakaryocytic  and  erythroid 
precursors while promoting their differentiation. Somatic mutations acquired during 
foetal  haematopoiesis  in  the  GATAl  transcription  factor,  are  detected  in 
megakaryoblasts  from  all  DS  patients  with  either  TMD  or  AMKL.  Normal 
haematopoetic  cells  express  both  full  length  GATAl  and  GATAls  proteins.  The 
GATAl mutations introduce a premature stop codon or interfere with the alternative 
splicing of exon 2.  This leads to initiation of translation from exon 3, replacing full 
length  GATAl  protein  with  a  shorter  isoform,  GATAl s.  However,  GATAl 
mutations alone are insufficient for leukaemogenesis, since replacement of GATAl 
with  GATAls  causes  transient  proliferation  of  immature  foetal  megakaryocytic 
progenitors but no postnatal haematopoietic abnormalities.  In addition, individuals 
with  germline  GATAls  show  no  reported  malignancies,  strongly  suggesting  that 
trisomy 21  is essential for leukaemic development.
4.1  ERG-3 cooperates with GATAls to initiate immortalisation of HPCs
Serial methylcellulose replating assays were carried out to investigate the possible 
cooperative  effects  between  ERG-3  and  GATAls  in  transforming  murine  HPCs. 
HPCs isolated from E l2.5  foetal  liver were transduced with retroviruses encoding 
ERG-3,  Gatal,  Gatals  alone  or  ERGS  with  Gatal  or  Gatals  and  cultured  in 
megakaryocyte conditions (SCF  and TPO).  Cells expressing ERG-3  +  GATA1  or 
with ERG-3  + GATAls,  formed more colonies than cells transformed with vector 
alone or ERG-3, GATA1  and GATAls alone (Figure 4.1). This suggests a potential 
cooperation  of  ERG-3  with  either  GATA1  or  GATAls.  However,  significant
129differences were observed between the transduced cells at the third round of plating. 
Progenitors  expressing  ERG-3,  GATA1  or  GATAls  alone  exhausted  their  self­
renewal potential and cells expressing ERG-3 + GATA1  failed to re-plate after the 
third round, indicating that these cells were not transformed. In contrast progenitors 
expressing ERG-3 and GATAls continued to re-plate up to fifth round, and in some 
experiments up to the seventh round of plating (Figure 4.1). The increased number 
of colonies formed by  cells transduced with ERG-3  and GATAls was evident by 
the staining of cultures with /7-iodonitrotetrazolium (INT) at each round of plating 
(Figure 4.2A).  The colonies  formed had a hyperproliferative morphology (Figure 
4.2B).  Cell  lines  co-expressing  ERG-3  and  GATAls  were  generated  from  these 
cultures. These cells were maintained in liquid culture for up to 8 weeks (Figure 4.3 
and 4.4A). The cytokine dependence of two cell lines was examined using the MTS 
assay  and  it  was  demonstrated  that  both  cell  lines  were  TPO  dependent  (Figure 
4.4B). The cell lines generated expressed high levels of c-Kit and CD41 cell surface 
markers,  characteristic  of  megakaryocyte  progenitors  (Figure  4.4C).  Our  data 
shows  that  ERG-3  co-operates  with  the  GATAls  mutation  to  immortalize  foetal 
megakaryocytic  progenitors.  These  immortalised  cells  have  the  phenotypic 
characteristics of the megakaryoblasts found in AMKL patients.
4.2  ERG-3 + GATAls cell lines do not induce leukaemia in NOD/SCID mice
The  leukaemogenic  potential  of  the  immortalised  cell  lines  were  examined  by
transplanting cells into NOD/SCID mice. The immortalised cell lines expressed the
CD45.2 cell surface marker whereas the recipient cells in the NOD/SCID mice were
CD45.1  positive.  This  allowed  us  to  distinguish  donor  from  recipient  cells.  The
analysis of bone marrow,  spleen and thymus of injected mice showed that all the
130cells  were  CD45.2  negative  and  most  were  CD45.1  positive  (Figure  4.5A) 
suggesting that the immortalised cells did not transplant / survive in the NOD/SCID 
mice after seven months. The CD45.1  negative cells in the thymus and spleen were 
also  negative  for CD45.2  and  CD2  (data not  shown).  The  analysis  of B  cell  and 
myeloid cell populations in bone marrow and spleen showed a normal distribution 
pattern of B220 positive and Macl  positive cells in these lymphoid organs (Figure 
4.5B).  In contrast, the CD4 positive and CD8 positive T cell population appeared 
abnormal  in these mice (Figure 4.5B).  The total cell number in the bone marrow 
and spleen of 8 mice injected with ERG-3 + GATAls immortalised cells lines were 
within the normal  range  (Figure 4.5C).  These data show that ERG-3  + GATAls 
cell lines were not leukaemogenic in the NOD/SCID transplantation model.
4.3  Induction  of  leukaemia  in  mice  transplanted  with  ERG-3  or  ERG-3  + 
GATAls transduced cells.
To  test  the  leukaemogenic  potential  of ERG-3  and  GATAls  in  vivo,  HPCs  co­
transduced with  ERG-3  and  GATAls  were  directly transplanted  into  sub-lethally 
irradiated  C57BL/6  mice  24  hours  after  infection.  For  controls,  cells  transduced 
with  vector,  Gatals  and  ERG-3  retrovirus  alone  were  also  transplanted  into 
recipient mice. The infection efficiency was measured by analysing the expression 
of human CD2 (hCD2). More than 90% of haematopoietic cells were infected with 
the  hCD2  expressing  retrovirus  (Figure  4.6A).  Consistent  with  the  published 
oncogenic  function  of  ERG-3,  all  recipient  mice  transplanted  with  ERG-3 
transduced  cells  succumbed  to  leukaemia  within  100  days.  In  addition,  cells 
transduced  with  ERG-3  and  GATAls  induced  leukaemia  with  similar  latency 
(Figure  4.7).  These  mice  had  splenomagly  (Figure  4.8A)  and  there  was  a
131significant increase in cell number in the spleen and reduction in cell number in the 
bone marrow of the leukaemic mice as compared with control (Figure 4.8B). This 
reduced cell number was  due to the presence of leukaemic blasts within the bone 
marrow.  Wright-Giemsa staining of the cells isolated from the spleen and the bone 
marrow  revealed  the  presence  of  blasts  (Figure  4.9).  Haematoxylin  and  Eosin 
(H&E) staining of tissues revealed a significant infiltration of leukaemic cells into 
the liver but not kidney of mice that underwent transplantation with cells expressing 
ERG-3  and  cells  expressing  both  ERG-3  and  GATAls  (Figure  4.10).  The  B 
lymphocyte  follicles  and  red  pulp,  containing  predominantly  erythrocytes,  were 
apparent in the spleens of control mouse.  The architectural  structure of the spleen 
was completely masked by the high presence of blasts in the spleen of leukaemic 
mice and the bone marrow was  also  filled with leukaemic  cells.  The presence  of 
ERG-3  and  GATAls  protein  in the  splenocytes  of these  mice  was  confirmed by 
Western blot analysis (Figure 4.11). Integration of the ERGS and Gatals provirus 
in the  leukaemic cells was confirmed by  Southern blot analysis.  The  leukaemias 
were oligoclonal as shown by multiple proviral integrations (Figure 4.12). There is 
a unique, neo integration in mouse #2, as shown by the presence of a single band 
and  two  bands  detected  with  the  hCD2  probe,  shows  several  ERG  provirus 
integrations  in  the  same  mouse.  The  third  band,  which has  a  lower  intensity  is 
probably due to a partial digest of genomic DNA.
4.4  ERG-3 + GATAls transduced cells induce a heterogeneous leukaemia
To characterise the phenotype of the leukaemic cells, flow cytometry analysis was
carried out on splenocytes of the leukaemic mice.  A cohort of 8 ERG-3 + GATAls
and 15 ERG-3 leukaemic mice were examined.  As the ERGS cDNA was cloned in
132the  pMSCV-IRES-hCD2  vector,  the  expression  of hCD2  in  the  splenocytes  was 
indicative of ERG-3 expression. The leukaemia detected with ERG-3 alone or with 
ERG-3 + GATAls consisted of heterogeneous populations of cells with some mice 
exhibiting cells that are predominantly c-Kit positive whereas others have cells that 
are mostly CD41  positive  (Figure 4.13).  There was a significant reduction in the 
percentage  of CD41  positive  cells  detected  in  mice  with  ERG-3  +  GATAls  as 
compared  with  mice  with  ERG-3  transduced  cells  but  there  was  no  significant 
difference  in  the  percentage  of  c-Kit  positive  cells  (Figure  4.14).  Whilst  the 
leukaemic cells expressed high levels of CD2, they lacked CD45.2 expression. This 
is consistent with the report suggesting that mature cells of the MegE lineage lack 
CD45  expression  (Forsberg  et  al.,  2006).  These  data  show  that  ERG-3  alone  is 
oncogenic and it collaborates with GATAls in vivo to alter the proliferation and/or 
maturation of leukaemic cells.
The transplantability of leukaemias induced by ERG-3 and ERG-3 + GATAls was 
examined by tail vein injection of leukaemic splenocytes and bone marrow cells into 
secondary  sub-lethally  irradiated  recipient  mice.  The  mice  injected  with  the 
leukaemic cells did not develop leukaemia and remained healthy (data not shown).
4.5  Leukaemic cell lines could not be grown in vitro
In order to generate leukaemic cell  lines  in vitro, ERG-3  expressing cells isolated
from  bone  marrow  were  cultured  in  methylcellulose  under  either  myeloid  or
megakaryocytic conditions. In myeloid cultures, leukaemic cells expressing ERG-3
could not be re-plated past the third round of plating. Whilst there was an increase in
colony number at the second round, the total cell number was not increased as the
133colonies  formed  were  very  small  (Figure  4.15).  In  megakaryocytic  conditions, 
ERG-3  leukaemic  cells  failed  to  form  any  colonies  in the  second  round  (Figure 
4.16). Leukaemic cells expressing both ERG-3 + GATAls had limited self renewal 
potential  in  myeloid  (Figure  4.17A)  and  megakaryocytic  conditions  (Figure 
4.18A).  In the first round of plating, colonies formed under the myeloid conditions 
were  small  and  very  dense,  resembling  the  morphology  of typical  immortalised 
colony. However, the colonies became sparse in the second round after which cells 
failed to replate (Figure 4.18B).  In megakaryocytic conditions, the colonies formed 
were very sparse (Figure 4.18B). These data indicate that the conditions used here 
were  not  optimal  for  culturing  leukaemic  cells  expressing  ERG-3  or  ERG-3  + 
GATAls in vitro.
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Figure  4.1.  ERG-3  collaborates  with  GATAls  to  immortalise  HPCs  in  the 
presence of TPO and SCF.  Bar chart representing the number of colonies (A) and 
number of cells (B) at each round of re-plating.  The data represents mean and ± S.D. 
of  duplicate  cultures.  HPCs  isolated  from  foetal  liver  of  El2.5  embryos  were 
transduced with either vector, ERG-3, GATA1, GATAls, ERG-3 + GATA1 or ERG- 
3 + GATAls.  Transduced cells were cultured in methylcellulose supplemented with 
TPO and SCF.  Selection (G418) was applied in the first round of plating only.A
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Figure  4.2.  ERG-3  +  GATAIs  immortalise  HPCs.  A.  P-
iodonitrotetrazolium  (INT)  stained  methylcellulose  cultures  at 
each  round  of  plating.  B.  Typical  morphology  of  colonies 
formed  by  cells expressing both  ERG-3  and GATAIs (original 
magnification, x40).
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Figure  4.3.  Generation  of ERG-3  +  GATAIs  immortalised  cell  lines.  Fold 
increase  in cell  number of 8  ERG-3  + GATAIs (E3+ls)  immortalised cell  lines. 
Single  colonies  were  picked  at  the  third  round  of methylcellulose  plating  and 
cultured in complete DMEM medium supplemented with TPO and SCF.
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Figure 4.4. Characterisation of ERG-3 + GATAIs immortalised cell lines.  A.
Fold  increase  in  cell  number  of  immortalised  cells  expressing  both  ERG-3  and 
GATAIs.  Single colonies were picked from the third round of plating (independent 
experiment to Figure 4.3) and cultured in complete DMEM medium  supplemented 
with  TPO  and  SCF.  B.  Bar  chart  showing the  absorbance  measured  at 490  nm  of 
two  ERG-3  +  GATAIs  (E3+ls)  immortalised  cell  lines  grown  in  the  presence  of 
TPO,  SCF,  TPO  alone  or  SCF  alone.  The  data  represent  mean  and  ±  S.D.  of 
triplicate  cultures.  MTS  assay  was  carried  out  48  hrs  after  cytokine  addition.  C. 
Representative histograms of CD41  and c-Kit expression in immortalised cell  lines 
expressing  both  ERG-3  and  GATAIs.  Empty  plot  represents  isotype  control  and 
filled plot represent cells positive for the indicated cell surface marker.
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Figure 4.5. ERG-3 + GATAIs immortalised cell lines are not leukaemogenic 
in NOD/SCID mice.  A.  Histogram showing CD45.1  cells in the bone marrow, 
spleen  and  thymus.  Empty  plot  represents  isotype  control  and  filled  plot 
represents cells positive for CD45.1.  B. Dot plots show B220 and Macl  positive 
cells in the bone marrow and spleen and CD4, CD8 positive cells in the thymus. 
C.  Bar  chart  representing  number  of  bone  marrow  (grey  bar)  cells  and 
splenocytes (black bar) from 8 mice analysed.
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Figure 4.6. Efficiency of progenitor cell transduction  prior to injection into sub- 
lethally  irradiated  recipient  mice.  Histogram  depicting  the  expression  level  of 
hCD2 (shaded grey) against an isotype control (black line). ERG-3 cDNA cloned into 
pMSCV-lRES-hCD2  vector,  whereas,  Gatals  cDNA  is  cloned  into  pMSCV-Neo 
vector.  Purified  c-Kit+Terl 19'HPCs  were  isolated  from  E12.5  foetal  liver.  Cells 
were  co-transduced  with  vector  (pMSCV-Neo  and  pMSCV-IRES-hCD2),  ERG-3 
(pMSCV-£7?G-3-IRES-CD2 retrovirus and pMSCV-Neo), Gatals (pMSCV-Gatals- 
neo  retrovirus  and  MSCV-IRES-hCD2)  and  ERGS  +  Gatals  (pMSC V-i^G-i- 
IRES-CD2 retrovirus and pMSCV-Gata7s-neo retrovirus).  Infection efficiency was 
determined  48  hrs  following  infection  by  analysing  the  expression  of hCD2.  No 
selection was applied.
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Figure 4.7.  Progenitor cells transduced with ERG-3  and ERG-3 + GATAIs 
induce leukaemia with short latency.  Survival curve shown for cohorts of mice 
injected with cells transduced with indicated viruses (n=10 for vector control and 
n=5 for GATAIs, n=17 for ERG-3  and n=14 for ERG-3 + GATAIs). Mice were 
sub-lethally irradiated (6Gy) 24 hr prior to injection of transduced HPCs.  Mice 
injected with cells expressing GATAIs did not succumb to leukaemia.  All mice 
injected with ERG-3 and ERG-3 + GATAIs succumb to leukaemia but there is no 
significant difference in the latency (p=0.47).
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Figure 4.8.  Splenomegaly in mice injected with ERG-3 and ERG-3 + GATAIs.
A.  Comparative  spleen  size  in  mice  injected  with  ERG-3  and  ERG-3  +  GATAIs 
versus wild type B6 mice. B.  Bar chart showing bone marrow cell number (left panel) 
and  spleen  cell  number  (right  panel).  Bone  marrow  cells  were  reduced  in  the 
leukaemic  mice  (B6  vs  ERG-3  p=0.0034,  B6  vs  ERG-3  +  GATAIs  p=<0.0001  and 
ERG-3  vs  ERG-3  +  GATAIs  p=0.031).  Splenocytes were  significantly  increased as 
compared with wild type mice (B6 vs ERG-3 p=0.0003 and B6 vs ERG-3 + GATAIs 
p=0.0007).  There  was  no  significant  difference  between  splenocytes  in  mice  with 
ERG-3 as compared with mice transduced with ERG-3 + GATAIs ( p=0.81).
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Figure  4.9.  Morphology  of leukaemic  cells.  Single  cells  were  isolated  from 
spleen (top panel) and  BM  (bottom  panel) of wild type  mice,  mice  injected with 
ERG-3  and  ERG-3  +  GATAIs  and  stained  with  Wright-Giemsa  (original 
magnification, x400). Wild type splenocytes contain mainly lymphocytes whereas 
megakaryoblasts  are  observed  in  the  spleen  of mice  with  ERG-3  and  ERG-3  + 
GATAIs.  Although  neutrophils  are  detected  in  the  wild  type  bone  marrow  (as 
shown by an arrow), they are replaced with myeloblasts in the leukaemic mice.
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Figure  4.10.  Histological  analysis  of  wild  type  and  leukaemic  mice.
Leukaemic  cell  infiltration  into  different  organs  was  determined  by 
haematoxylin and eosin (H&E) staining.  Liver, spleen, bone marrow (BM) and 
kidney  were  isolated  from  a  control  mouse  and  leukaemic  mice.  The  organs 
were fixed  in formalin and H&E  staining was carried out by the department of 
Pathology at the Institute of Child Health (ICH).  No infiltration was detected in 
kidney,  whereas  there  is  a  significant  infiltration  in  the  liver.  There  was  a 
replacement  of other  lineages  by  the  leukaemic  blasts  in  the  spleen  and  bone 
marrow (original magnification, x400).
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Figure  4.11.  Western  blot  analysis  of  splenocytes  from  leukaemic  mice
Expression of ERG-3  and GATAIs  in leukaemic mice was detected using an 
anti-ERG-3 and anti-FLAG antibodies, respectively, and an anti-NPM antibody 
was used as a loading control.  Protein lysates from spleen were made from two 
independent  mice  with  ERG-3  and  two  independent  mice  with  ERG-3  + 
GATAIs.  For a negative control, protein lysates were prepared from B6 wild 
type mice. The protein lysates were resolved on a 10% polyacrylamide gel.
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Figure  4.12.  Southern  blot  analysis  of  genomic  DNA  isolated  form 
leukaemic  splenocytes  of ERG-3  +  GATAIs  mice.  A.  The  indicated  neo 
cDNA fragment  probe  was used to  detect the  Gatals provirus  following Bglll 
digest  of genomic  DNA.  The  indicated  hCD2  fragment  probe  was  used  to 
detect  the  ERG  provirus  following  EcoRI  digest  of  genomic  DNA.  Both 
enzymes  cut  once  within  the  pMSCV  retroviral  vector  which  is  integrated 
within  the  genomic  DNA.  B.  CD2  and  neo  probe  were  used  to  identify  the 
pattern of integration for pMSCV-ERG-3 and pMSCV-Gatals DNA.
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Figure  4.13.  Immunophenotypic  analysis  of  leukaemic  splenocytes.  Flow 
cytometric  analysis  of leukaemic  splenocytes of representative  animals  injected 
with ERG-3  (Top panel) or ERG-3  + GATAIs (Bottom panel).  The histograms 
show the percentage of hCD2 positive cells in the spleen.  Dot plots show c-Kit 
and CD41  expression within the hCD2 positive population.  The numbers in the 
plots represent the percentage of c-Kit positive and CD41 positive cells.2 o
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Figure  4.14.  Leukaemic  cells  expressing  ERG-3  +  GATAls  have  a  less 
mature phenotype.  Plot shows the percentage of CD41  (A) (p=0.03) and c-Kit
(B)  positive  cells  (ns,  not  significant) within the hCD2 positive  splenocytes of 
mice  transplanted  with  cells  expressing  ERG-3  only  or  both  ERG-3  and 
GATAls.
148160
5=  120 & ▼ »
&
k .
3
E 3
> *
C
o
o o
80-
40
i
1  2  3
R ound of Plating
B 8 i
s   •
J§
E 3
© o
2 -
I
1  2  3  4
R ound of Plating
Figure 4.15.  Bone marrow cells isolated from ERG-3 leukaemic mice cannot be 
maintained in vitro under myeloid conditions.  A. Bone marrow was isolated from 
leukaemic  mice  transplanted  with  ERG-3  transduced  HPCS.  Bone  marrow  cells 
were  counted  and  104  cells  were  cultured  in  methylcellulose  under  myeloid 
conditions.  Colonies formed (A) at each round of plating were counted and single 
cells (B) were serially plated into the second round and third round after which cells 
ceased to replate. The arrows indicate absence of colony formation and cell number. 
The data represents mean and ± S.D. of duplicate cultures.
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Figure  4.16.  Bone  marrow  cells  isolated  from  ERG-3  leukaemic  mice 
cannot  be  maintained  in  vitro  under  megakaryocytic  conditions.  Bone 
marrow  was  isolated  from  mice  transplanted  with  ERG-3  transduced  HPCS. 
Bone marrow cells were counted and 104 cells were cultured in methylcellulose 
under megakaryocytic  conditions  in the presence of TPO  and  SCF.  Colonies 
formed (A) and number of cells (B) was counted at the first round of plating. 
ERG-3  transduced cells  could  not be replated following the  first round.  The 
arrows  indicate  absence  of  colony  formation  and  cell  number.  The  data 
represents mean and ± S.D. of duplicate cultures.
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Figure 4.17.  Bone  marrow cells  isolated  from ERG-3 + GATAls leukaemic 
mice cannot be maintained in vitro under myeloid conditions.  A. Bone marrow 
was  isolated  from  mice  transplanted  with  ERG-3  +  GATAls  transduced  HPCS. 
Bone  marrow  cells  were  counted  and  104  cells  were  cultured  in  methylcellulose 
under myeloid conditions.  Colonies formed at each round of plating were counted 
and single cells were serially re-plated.  ERG-3 + GATAls transduced cells could 
not be re-plated  following the second  round.  B.  Typical  morphology of colonies 
formed  at the  first  and  second  round  of re-plating  (original  magnification,  x40). 
The  arrows  indicate  absence  of colony  formation  and  cell  number.  The  data 
represents mean and ± S.D of duplicate cultures.A
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Figure 4.18.  Bone  marrow cells  isolated from  ERG-3 + GATAls leukaemic 
mice  cannot  be  maintained  in  vitro  under megakaryocytic conditions.  Bone 
marrow was  isolated  from  mice  transplanted with  ERG-3  + GATAls transduced 
HPCS.  Bone  marrow  cells  were  counted  and  104  cells  were  cultured  in 
methylcellulose  under  megakaryocytic  conditions  in  the  presence  of  TPO  and 
SCF.  A.  The  number  of colonies  formed  (Left  panel)  and  the  number  of cells 
(Right  panel)  were  counted  after  the  first  round  of plating.  ERG-3  +  GATAls 
transduced  cells  could  not  be  replated  following  the  first  round.  B.  Typical 
morphology  of  colonies  formed  at  the  first  round  of  re-plating  (original 
magnification, x40).  The arrows indicate the absence of colony formation and cell 
number.  The data represents mean and S.D. of duplicate cultures.
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Figure 4.19.  Model of leukaemogenesis in DS.  Acquisition of chromosome 21 
during early embryonic development is believed to be an early initiating event in 
the pathogenesis of DS.  We propose that increased dosage of ERG-3 acts on early 
progenitor  cells  to  promote  megakaryopoiesis  and  increases  the  pool  of early 
megakaryocytic  cells.  Cells trisomic  for chromosome  21  also  harbour  GATAls 
mutations thus promoting hyperproliferation of megakaryoblasts at the expense of 
differentiation.  Not  all  DS  patients  with  GATAls  mutation  develop  AMKL, 
suggesting that  ERG-3  and  GATAls  are  not  sufficient  for  leukaemogenesis  and 
other as yet unidentified mutations are required for AMKL development in these 
individuals.
1534.5 Discussion
4.5.1  ERG-3 collaborates with GATAls in vitro
To determine a potential link between overexpression of chromosome 21 genes with 
GATA1 mutations in the DS children, we initially assessed the synergistic effect of 
ERG-3 with GATAls in vitro. The murine equivalent of the target cell responsible 
for TMD and acute megakaryocytic leukaemia in children with Down syndrome is 
present in El2.5  foetal  liver  (Li  et  al.,  2005).  Therefore,  primary E l2.5  FL cells 
were  enriched  for  haematopoietic  progenitors  by  depletion  of Terll9  expressing 
cells and selection for c-Kit+ progenitor cells.
Colony forming assays using transduced HPCs were carried out in the presence of 
TPO and SCF. GATAls alone enhances the proliferation of megakaryoblasts.  Since 
IL-3  also  drives  megakaryocytic  proliferation,  this  cytokine  was  omitted  from 
cultures in order to avoid masking of GATAls activity. HPCs co-expressing ERG-3 
and  GATAls  could  be  serially  re-plated  suggesting  that  these  cells  were 
immortalised. This phenotype was further confirmed by transferring single colonies 
from methylcellulose into liquid culture containing TPO and SCF, upon which the 
cells  expanded  and  divided  continuously  over  an  extended  time  course. 
Immunophenotypic analysis revealed that the ERG-3 + GATAls immortalized cells 
had a characteristic immature megakaryoblastic phenotype expressing high levels of 
c-Kit  and  CD41  cell  surface  markers.  HPCs  expressing  GATAls  could  not  be 
serially re-plated.  Indeed, TMD clones harbouring GATAls disappear in most DS 
individuals, strongly suggesting that GATAls alone is not sufficient to immortalise 
TMD blasts.  The inability of ERG-3  alone to immortalize progenitor cells in this
154experiment  demonstrates  the  requirement  of ERG-3  expressing  cells  for  IL-3  in 
addition to  TPO  and  SCF.  Furthermore,  the  data suggest a classic oncogenic  co- 
operativity  between  GATAls  and  ERG-3  that  immortalise  megakaryoblasts 
analogous to the megakaryoblastic leukaemia cells found in DS-AMKL.
Cell lines immortalised with ERG-3 + GATAls were transplanted into NOD/SCID 
mice to assess their leukaemogenic potential in vivo. Following the analysis of the 
injected mice, the CD45.2 positive immortalised cell lines could not be detected in 
the  bone  marrow,  spleen  or  thymus.  Factors  such  as  cytokines,  chemokines  and 
adhesion molecules are essential for the homing of cells from peripheral injection 
site to the bone marrow in NOD/SCID mice (Peled et al., 2000). It is possible that 
the homing capability and responsiveness to  specific cytokines of these cell lines 
have been lost / reduced due to in vitro culture of the cells prior to transplantation. 
Furthermore,  the  differentiation  status  of the  cells  following  in  vitro  culture may 
prevent engraftment in the recipient mice. Our result shows that ERG-3 + GATAls 
immortalised cell  lines  are  not leukaemogenic  in NOD/SCID mice.  To  overcome 
this  problem,  HPCs  freshly  co-transduced  with ERG-3  +  GATAls  were  injected 
directly into sub-lethally irradiated mice.
4.5.2  ERG-3 acts as an oncogene in vivo
To determine the leukaemogenic potential of ERG-3 in vivo, we transplanted HPCs 
transduced with ERGS  retrovirus  into  sub-lethally irradiated syngeneic  C57BL/6. 
Our  data  show  that  haematopoietic  progenitors  transduced  with  ERG-3  rapidly 
develop leukemia in vivo.
155The location of the ERG-3 gene has suggested that its amplification associated with 
DS-AMKL  may  be  a  contributing  factor  in  leukaemogenesis  in  these  children 
(Bourquin  et al.,  2006).  This  study provides  evidence that overexpression  of the 
ERGS  gene  is  necessary  to  exhibit  transforming  activity.  It  will  be  useful  to 
determine what domains of ERG-3 are required for tumourgenesis. ERG-3 may act 
through  gene  dosage  effect  on  processes  such  as  megakaryocytic  commitment, 
proliferation and differentiation and may be an important factor for the initiation of 
leukaemia in DS  children.  Indeed,  over-expression of other candidate  genes have 
exhibited biological characteristics detected in DS.  Gene dosage effects have been 
suggested to be important in non-haematological DS abnormalities.  Increased copy 
number  of the  ETS2  is  one  example  of  gene  dosage  effect  related  to  the  DS 
phenotype.  ETS2  is  overexpressed  in brain  and  fibroblasts  from DS  patients  and 
increased apoptosis has been detected when Ets2 gene was overexpressed in murine 
neuronal  cultures  (Tymms  and  Kola,  1994;  Wolvetang  et al.,  2003).  In addition, 
ETS2  overexpression  in  transgenic  mice  suggests  a  potential  role  for  this 
transcription factor in the skeletal abnormalities associated with DS (Sumarsono et 
al.,  1996).  Another promising candidate gene is DYRK1A, which encodes a dual­
specificity  tyrosine  phosphorylation-regulated  kinase  (Guimera  et  a l,  1996). 
DYRK1A protein is increased in the brains of DS patients as well as in the trisomic 
T65Dn murine model of DS  (Dowjat et al., 2007).  It has been proposed that the 
overexpression  of  DYRK1A  may  be  a  contributing  factor  to  the  cognitive 
difficulties in DS subjects.
ERG involvement in cancer has been highlighted by the involvement of ERG gene 
in  chromosomal  translocations,  which  results  in the  truncation  of the  ERG-3  N-
156terminus.  This  observation  suggests  that  the  N-terminus  of ERG  may  confer  a 
tumour suppressive function.  Although increased expression of full length ERG has 
been associated with poor prognosis of AML, it is unclear if this simply represents 
the  early  differentiation  stage  of the  leukaemic  blasts  or  if  ERG  has  a  direct 
leukaemogenic  activity.  Our  data  demonstrate  for  the  first  time  that  increased 
expression of the full  length ERG protein causes aggressive leukaemia in mice. It 
would  be  interesting  to  determine  the  target  cell  for  ERG-3-mediated 
leukaemogenesis. In vivo transplantation assays using ERG-3 expressing HSC, MEP 
or  CMP  could  determine  if ERG-3  is  capable  of transforming  HSCs  or  a more 
committed progenitor cell.
4.5.4  ERG-3  collaborates  with  GATAls  to  induce  a  megakaryoblastic 
leukaemia in vivo
To  determine  the  leukaemogenic  potential  of ERG-3  and  GATAls  in  vivo,  we 
transplanted HPCs co-transduced with ERGS and GATAls expressing retroviruses 
into  sub-lethally  irradiated  syngeneic  C57BL/6.  Haematopoietic  progenitors 
transduced  with  ERG-3  or  ERG-3  +  GATAls  rapidly  develop  leukemia  in  vivo 
when transplanted.
The  GATAls  mutation  results  in  the  truncation  of  the  GATA1  N-terminal 
transactivation  domain,  making  the  protein  transcriptionally  less  active  than 
GATA1.  HPCs  expressing  GATAls  have  ineffective control  of proliferation but 
the  differentiation capacity  is  retained  albeit to  a reduced  level.  This  suggests  a 
possible explanation for the phenotype observed in that the balance between ERG-3 
and GATAls determines the level of differentiation.  Hence leukaemias expressing
157ERG-3  alone  have  higher  levels  of CD41  expressing megakaryoblasts than those 
expressing  both  ERG-3  +  GATAls.  This  is  in  agreement  with  the  current  data, 
emphasizing the effect of GATAls in proliferation. GATAls is associated with the 
loss of repression of several GATA1  target genes that have proliferative functions. 
These  genes  include,  KIT and MYC,  which are downregulated in the presence of 
GATA1  and are upregulated in DS-AMKL cells harbouring GATAls and lacking 
GATA1  (Li et al., 2005; Bourquin et al., 2006). Furthermore, the failure to rescue 
the  hyperproliferative  phenotype  of  GATA1  deficient  by  GATAls  expression, 
further supports the role for GATAls in cell proliferation and also highlighted the 
importance  of  the  activation  domain  in  the  regulation  of  genes  required  for 
megakaryocyte  proliferation  (Muntean  and  Crispino,  2005)).  This  study  also 
showed that GATAls affects the proliferation and not the differentiation process in 
megakaryocytes as GATAls was able to restore differentiation of GATA1 deficient 
cells. In our system, ectopic expression of GATAls with ERG-3 results in enhanced 
proliferation  of  early  progenitor  cells  in  the  presence  of  endogenous  levels  of 
GATA1 and the percentage of CD41 positive cells is reduced when both ERG-3 and 
GATAls are present.  It may be that the expression of proliferative genes, such as 
Kit and Myc are  higher  in ERG-3  +  GATAls  leukaemic cells,  as  compared with 
ERG-3 leukaemic cells.
Therefore,  if  fetal  HPCs  from  DS  children  trisomic  for  ERG  are  predisposed 
towards  megakaryopoiesis,  those  megakaryoblasts  which additionally harbour the 
GATAls mutation will exhibit increased proliferation in the absence of full length 
GATA1. In addition, GATAls may affect the function of GATA2, which has been 
shown to compensate for GATA1 in early megakaryopoiesis (Chang et al., 2002). In
158this regard, GATA2 expression was shown to be upregulated in DS-AMKL cells as 
compared with non DS-AMKL (Bourquin et al., 2006).
The  high  expression  levels  of  ERG  in  patients  with  AMKL,  highlights  its 
importance  in  leukaemic  development.  It  is  therefore  possible  that  the 
overexpression of ERG-3 could contribute to leukaemic transformation by inducing 
a growth advantage to  HPCs,  a phenotype that may be further exacerbated in the 
context of GATAls. Although most DS patients with trisomy 21  and the GATA1 
mutation  develop  TMD  in  the  first  year  of  life,  most  undergo  spontaneous 
remission. Therefore, it is likely that the acquisition of additional genetic events is 
required for leukaemic development.  We propose that the increased expression of 
ERG  in  fetal  haematopoietic  progenitors  trisomic  for  chromosome  21  promotes 
megakaryopoiesis.  This  event  co-operates  with  the  enhanced  proliferation 
associated  with  the  GATAls  mutation  (Figure  4.19)  giving  rise  to  a  clone  that 
serves as a target for additional mutations of leukaemic transformation.
Somatic  mutations  in  the JAK2  (Janus  Kinase)  and JAK3  genes  are  proposed to 
account  for the  additional  mutations  required  for  the  transformation  of TMD  to 
AMKL in DS patients.  Indeed, mutations in the JAK2 and JAK3 tyrosine kinase 
have  been  detected  in  AMKL  cell  lines  and  in  some  DS-AMKL  patients, 
respectively  (Mercher et a l,  2006;  Walters  et a l,  2006).  These mutations  cause 
constitutive  activation  of  STAT-5  (Signal  transduction  and  activator  of 
transcription) (Spiekermann et al, 2003), and in common with activating mutations 
in tyrosine kinases,  such  as  in KIT and in internal tandem duplication (ITD)  and 
activation loop mutations in FLT3, cause constitutive activation of STAT-5 (Signal
159transduction  and  activator  of  transcription)  (Spiekermann  et  al.,  2003).  The 
activation  of the  JAK-STAT  signaling  pathway  is  important  in  early  stages  of 
megakaryocytic  differentiation  and  decreased  activation  is  required  for  terminal 
maturation.  Therefore, JAK mutation  associated  with  DS-AMKL  may result in a 
block  in  terminal  differentiation,  causing  abnormal  accumulation  of 
megakaryoblasts.  ERG-3 and GATAls may work in concert with JAK mutations to 
induce AMKL in DS individuals.  Furthermore, mutations in FLT3, KIT and RAS, 
confer a selective advantage to HSCs,  and may work in conjunction with ERG-3 
and  GATAls  to  induce  AMKL.  Other  contributing  factors  may  be  activation  of 
pathways  such  as  Notch,  Sonic  hedgehog  (shh)  and  Wnt  signaling.  The 
identification of secondary genetic events necessary for the progression into AMKL 
would allow the application of therapeutic strategies at the TMD stage of disease to 
prevent leukaemic transformation. For example, the use of tyrosine kinase inhibitors 
may be good therapeutic agents, if indeed activating tyrosine kinases provided the 
additional genetic factor.
Although  in  humans,  trisomy  21  and  GATAls  are  not  sufficient  for  leukaemic 
transformation, over-expression of ERG-3 in the presence of GATAls was enough 
to  induce  leukaemia  in  our  murine  model.  It  is  likely  that  this  is  due  to  the 
difference in the expression levels of ERG-3. The level of ERG expression achieved 
in our retroviral transplantation studies may well  be higher than the expected  1.5 
increase in ERG expression  in foetal  liver HPCs  of DS  embryos.  Therefore,  it is 
quite  likely  that  other  chromosome  21  genes  cooperate  with  ERG  in  the 
pathogenesis  of DS  AMKL.  These  include  BACH1  and  SON genes,  which were 
shown  to  be  overexpressed  in  DS-AMKL  as  compared  with  non  DS-AMKL
160patients. The negative regulation of megakaryocytic differentiation by BACH1  and 
increased proliferation by SON may be additional events that cooperate with ERG 
and GATAls to induce transformation. Our model does not rule out a role for other 
chromosome 21 genes in DS AMKL. Recent work has argued against a requirement 
for RUNX1  (Kirsammer et al., 2008) but has emphasized the possible involvement 
of ETS2  in  DS-AMKL  (Stankiewicz  and  Crispino,  2007;  Ge  et al.,  2008).  High 
expression levels of ETS2 in megakaryoblastic leukaemias, has suggested its role in 
DS-AMKL development. Furthermore, in common with ERG-3, ectopic expression 
of ETS2 in K562 cells induced a lineage switch, from erythroid to megakaryocytic 
development  (Ge  et  al.,  2008).  In  accordance  with  our  data,  Stankiewicz  and 
Crispino  have  shown that  ERG  induces  megakaryopoiesis  and  it  synergises  with 
GATAls to enhance colony formation (Stankiewicz and Crispino, 2007).
4.5.5  Primary leukaemic cells were not transplantable
Several factors could account for the failed transplantation of cells into secondary
recipients.  Acute  leukaemias  can  be  defined  by  any  combination  of either  the
accumulation of at least 20% blasts in spleen or bone marrow, lethality to primary
animal with latency of 4 weeks or less and transplantable to normal, or sub-lethally
irradiated  secondary  mice  (Kogan  et  al,  2002).  The  leukaemias  detected  in  our
system fit the first two  criteria for defining myeloid leukaemias and are therefore
classed as acute leukaemias even though they lack transplantable activity. There are
currently no reports of AMKL cells from DS patients being xeno-transplanted into
immunodeficient mice.  The  low availability of patient samples may be a limiting
factor in performing these experiments. Alternatively, it is possible that AMKL cells
derived from DS patients are not transplantable. The frequency of LSC could also
161contribute to the  effectiveness  of transplantation.  In our study,  only  106 unsorted 
primary leukaemic cells were transplanted into secondary recipients. As the rarity 
and the nature (HSC or committed progenitor) of the putative LSC is not known in 
our system, the total cell number should be increased for secondary transplantation 
in the  future  studies.  To  investigate  whether  leukaemia originates  from the  HSC 
pool  or from  the  committed  progenitor pool,  cells  can be  purified  based  on cell 
surface markers that enrich for normal stem cells or progenitors. These cell fractions 
can  be  subsequently  transplanted  into  recipient  mice,  which  would  allow  us  to 
identify the cell population responsible for leukaemia.
In our system, the acquisition of mutations in genes such as Jak3 or other tyrosine 
kinases (Flt3/Kit) may be essential for the maintenance of leukaemic stem cells or 
progenitor  cells,  which  is  required  for  serially  transplantable  leukaemia.  JAK3 
mutation, associated with AML and AMKL is one example of a genetic mutation, 
which was shown to give rise to AMKL phenotype in a murine model (Walters et 
al., 2006).  However, the disease was not transplantable and it was proposed that 
cooperating mutations with the GATAls mutation in the background of trisomy 21 
is required for full AMKL transformation.
Another  contributing  factor  may  be  the  differentiation  status  of the  ERG-3  and 
ERG-3  +  GATAls  transformed  cell.  Different  cellular  populations  have  varied 
homing  capacities.  For  example,  xeno-transplantations  experiments  show  that 
primitive  CD34+CD38‘  progenitors,  which  have  long  term repopulating  capacity, 
homed to the BM and spleen whereas more mature progenitors CD34+CD38+ were 
not able to home (Kerre et al., 2001). In addition, Bonnet and Dick have shown that
1 6 2only leukaemic blasts with phenotypic characteristic similar to normal HSCs were 
transplantable  in  NOD/SCID  mice  (Bonnet  and  Dick,  1997).  However,  other 
published  data  show  that  more  mature  cells  can  be  a  target  of  leukaemic 
transformation (Cozzio et al., 2003; Huntly et al., 2004). Based on these data, it is 
possible that the target cell for ERG-3 and GATAls is a more committed progenitor 
cell such as an MEP. Our data suggests that the accumulated leukaemic cells have 
an early megakaryoblastic phenotype as shown by the expression of CD41  as well 
as cellular morphology.
Whilst overexpression of ERG-3 and GATAls are sufficient to transform progenitor 
cells, other activating mutations that confer a self renewal advantage are required 
for  transplanting  the  leukaemic  cells.  Targeting  of the  leukaemic  stem  cells  by 
chemotherapeutic  drugs  is  currently  a major  obstacle in treatment  of leukaemias. 
Current therapies for leukaemia typically target proliferating cells; however LSCs 
are quiescent which makes them less responsive to such agents. If the target cell in 
DS-AMKL  is  a  more  differentiated  progenitor  cell,  it  may  explain  why  these 
patients have a very good responsiveness to chemotherapy as compared with non 
DS-AMKL  individuals.  This  may  be  also  due  to  increased  expression  of  the 
chromosome 21  gene SOD (superoxide dismutase), which promotes apoptosis. The 
increased  expression  of  another  chromosome  21  gene,  CBS  (cystathionine  P- 
synthetase),  which catalyses  the  condensation of serine  and homocystein to  from 
cystathionine, has been correlated with increased sensitivity to cytosine arabinoside 
(ara-C)(Taub et al., 1999; Ge et al., 2003).
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164Chapter 5: Role of NPM-MLF1 associated with MDS
MDS  is  characterised  by  abnormal  differentiation  and  development  of myeloid 
cells,  erythrocytes  and  megakaryocytes.  There  are  a  number  of  chromosomal 
translocations  and  genetic  mutations  associated  with  MDS,  one  of which  is  the 
chromosomal translocation that generates the NPM-MLF1  fusion gene. In order to 
investigate the potential  role  of NPM-MLF1  in  inducing MDS  we  carried out in 
vitro colony forming assays.
5.1 Generation of retroviral constructs
Human NPM-MLF1, NPM and MLF1  cDNAs were cloned into the pMSCV based 
retroviral vector, containing a neomycin resistance gene (Figure 5.1A). The NPM- 
MLF1 and NPM constructs contain a FLAG epitope at the N-terminus, whereas the 
MLF1 contains a Myc epitope at the C-terminus. Human LinXE packaging cell lines 
were tranfected with retroviral constructs and total lysates were prepared 48 hours 
after transfection. Immunoblotting with an anti-Flag antibody revealed the presence 
of 48 kDa NPM-MLF1  protein and a 37 kDa NPM protein. An anti-Myc antibody 
was used to detect the expression of an approximately 31  kDa MLF1  protein.  An 
antibody against a-tubulin was used as a loading control (Figure 5.1B).
6.2 NPM-MLF1 affects myeloid differentiation
We have used mouse BM-derived progenitor cells isolated from 5-FU treated mice 
to  examine the  role  of NPM-MLF1  in the  pathogenesis  of MDS.  BM cells were 
transduced  with  vector  or  NPM-MLF1  retrovirus  and  cells  were  cultured  in
165methylcellulose  media  supplemented  with  GM-CSF  to  promote  proliferation  and 
differentiation  of HPCs  along  the  myeloid  lineage.  Due  to  the  presence  of the 
neomycin resistance gene in the retroviral vectors we were able to select for infected 
cells in G418 in the initial round of plating. After 7 days of culture at 37°C, colonies 
were  counted  and  cells  were  harvested  for  flow cytometry.  The  ability  of NPM- 
MLF1  expressing  cells  to  self-renew  and  form  colonies  in  culture  was  also 
examined. Vector transduced cells formed approximately equal numbers of colonies 
in the first two rounds, whereas there was a significant increase in the number of 
colonies  formed by NPM-MLF1  transduced  cells  at the  second round  of plating. 
Cells transduced  with vector  alone  failed to  replate  following  the  third round of 
plating.  There  was  a  marked  reduction  in  colony  formation  by  NPM-MLF1 
expressing  cells  in the  third  and  fourth  round  after which cells  ceased to  replate 
further (Figure 5.2A).  There  was  also  a distinct difference  in the morphology of 
colonies formed by NPM-MLF1  and vector.  Colonies formed by cells transduced 
with  vector  alone  were  typically  large  and  sparse  in  contrast  to  small,  compact 
colonies formed by NPM-MLF1 expressing cells (Figure 5.2B).
The  harvested  cells  were  analysed  for  cell  surface  expression  of  myeloid 
differentiation markers Macl  and Grl  and the early progenitor cell marker c-Kit. In 
the  first  round  of plating,  the  percentage  of cells  expressing  Macl  and  Grl  was 
reduced  in  NPM-MLF1  expressing  cultures.  Furthermore,  there  was  a  two-fold 
increase in the number of c-Kit+ progenitor cells (Figure 5.3A). In the subsequent 
rounds,  90%  of cells  from  both  cultures  expressed  c-Kit  (Figure  5.3B).  These 
results show that NPM-MLF1  causes expansion of early progenitor cell and blocks 
myeloid differentiation when expressed in BM progenitors.
166Although,  MDS  is  primarily  a  disease  of elderly  individuals,  many  DS-AMKL 
children  are  predisposed  to  MDS  development  prior  to  leukaemic  progression 
within the first 3 years of life. It is believed that the initiating events that contribute 
to  TMD  and  AMKL  occur  during  embryogenesis.  It  is  therefore  possible  that 
genetic changes required for MDS  development occur at very early stages during 
development.  We therefore targeted NPM-MLF1  to progenitor cells isolated from 
foetal liver to compare the effect of the fusion protein and its potential function in 
progenitor  cells  isolated  from  adult  bone  marrow.  NPM-MLF1  expression  was 
targeted  to  FL-derived  HPCs  by  retroviral  infection.  FL  cells  were  enriched  for 
haematopoietic progenitors by depletion of Ter 119 expressing cells and selecting for 
c-Kit+ progenitor cells.  Cells were transduced with NPM-MLF1  retrovirus and the 
full  length  NPM and  MLF1  retroviral  constructs.  There  was  an  increase  in  the 
number  of  colonies  formed  at  the  third  round  of  plating  with  NPM-MLF1 
transduced cells and this was further increased at the fourth round of plating, after 
which a reduction in colony formation was observed. The vector, NPM and MLF1 
transduced cells  formed  similar number of colonies,  however,  these cells  did not 
replate past the sixth round, whereas NPM-MLF1  expressing cells formed colonies 
in the seventh round (Figure 5.4A). There was no significant difference in the total 
number of cells between each culture even though the number of colonies formed 
by NPM-MLF1  cells  was  much higher (Figure  5.4B).  This  is due to the type of 
colonies  detected  in  each culture,  with the NPM-MLF1  colonies being  small and 
compact.  Analysis of cells harvested from the first round of plating revealed an 8- 
fold  reduction  in  the  percentage  of Macl  positive  cells,  expressing  NPM-MLF1 
compared with vector alone (Figure 5.5).  The fold reduction in Macl  expression 
detected in NPM-MLF1  transduced cells as compared to empty control cells were
167demonstrated  in  four independent infection experiments  (Figure 5.6).  These data 
demonstrate that NPM-MLF1 may cause ineffective differentiation of myeloid cells.
Cells from third round of plating were put in liquid culture in the presence of SCF, 
IL-3  and IL-6 to establish if NPM-MLF1  can immortalise progenitor cells. NPM- 
MLF1 expressing cells grew at a much higher rate than cells transduced with vector, 
NPM or MLF1 retrovirus (Figure 5.7). However, NPM-MLF1  expressing cells did 
not immortalise progenitor cells as the cells failed to grow past 47 days.
6.3  NPM-MLF1 does not affect megakaryocytic development
In order to examine the role of NPM-MLF1 in megakaryopoiesis, El2.5 FL-derived 
HPCs were transduced with NPM-MLF1 retrovirus and cultured in methylcellulose 
medium in the presence of TPO and SCF in order to promote megakaryopoiesis. As 
a control,  progenitor  cells  were  also  transduced  with  full  length  NPM or  MLF1 
retrovirus.  Transduced  cells  were  selected  for  using  G418  in the  first  round  of 
plating.  Following  10  days  in  culture,  colonies  were  harvested  and  cells  were 
analysed by flow cytometry. The number of colonies generated by cells expressing 
the different retroviruses was similar in the first and second round of plating. At the 
third round of plating, however, the number of colonies formed by NPM expressing 
cells was  increased  3-fold,  whereas the  colony number of NPM-MLF1  decreased 
(Figure 5.8A and B).
In  the  first  round  of plating,  the  percentage  of CD41  positive  progenitor  cells
transduced with NPM-MLF1  was similar to the cells transduced with vector alone
or MLF1 retroviral vector. In contrast, there was an approximately 30% increase in
168the number of immature megakaryocytes as measured by CD41 cell surface marker 
(Figure 5.9A). Although the CD41  positive cells decrease in the subsequent round 
of plating,  the  CD41  expression  on  cells  overexpressing NPM  remained  high  in 
comparison with the other viruses (Figure 5.9B). Almost all of the cells in the first 
round of plating were c-Kit positive progenitor cells (Figure 5.9C). Two additional 
infection  experiments  further  suggested  that  full  length  NPM  promoted 
megakaryocyte development. An increase in the CD41  positive cells were detected 
with progenitor cells transduced with NPM  (Figure  10).  These data suggest that 
NPM but not NPM-MLF1 affects the maturation of megkaryocytes.
5.4  In vivo transplantation
There are currently several murine models for MDS. By performing reconstitution 
experiment using cells transduced with NPM-MLF1, we may be able to gain better 
understanding  of  the  exact  role  of  the  chimeric  protein  in  MDS.  To  further 
investigate  the  potential  role  of NPM-MLF1  in  MDS,  El2.5  FL-derived  HPCs 
transduced  with  NPM-MLF1  were  transplanted  into  sub-lethally  irradiated  mice. 
The  NPM-MLF1  and  NPM  cDNA  were  cloned  into  the  pMSCV-IRES-CD2 
retroviral vector. The infection efficiency was measured by the expression level of 
hCD2  gene  (Figure  5.11 A).  Infection  efficiencies  were  typically  70%,  55%  and 
40%  for  cells  expressing  vector,  NPM  and  NPM-MLF1,  respectively  (Figure 
5.11B).
Donor and the recipient cells can be identified due to the differential expression of
allotypic  cell  surface  markers.  The  transduced  progenitor  cells  express  CD45.2
whereas the recipient cells express the CD45.1  antigen. As the infection efficiency
169was typically low for NPM-MLF1, the viral titre for the retroviruses was measured 
by infecting mouse 3T3 fibroblasts with the serial dilutions of retroviral supernatant. 
The infection efficiency was measured 48 hrs after transduction by measuring the 
level  of hCD2  expression  (Figure  5.12A).  The  results  indicate  that NPM-MLF1 
retrovirus produces lower viral titre than M W  retrovirus (Figure 5.12B).
The transduced cells were injected into sub-lethally irradiated mice and peripheral 
blood was analysed for reconstitution,  6 weeks  after injection.  The percentage of 
donor  CD45.2+CD2+  cells  expressing  NPM-MLF1  was  extremely  low  (2.0%) 
compared with cells expressing NPM (21%) or vector (23%) (Figure 5.13A). The 
small  population  of cells  that  were  CD2  positive  and  CD45.2  negative  may  be 
erythrocytes or megakaryocytes as these cells are thought to lack CD45 expression 
(Forsberg et al., 2006). Poor contribution to reconstituted cells was detected in all 4 
mice  that  were  injected  with  NPM-MLF1  expressing  progenitor  cells  (Figure 
5.13B).  Long-term  reconstitution  was  examined  by  analysing  BM  cells  and 
splenocytes a year and two months after injection. The percentage of CD45.2+CD2+ 
cells  was  reduced  in  comparison to  the  analysis  at  6  weeks  post transplantation 
(Figure 5.14).
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Figure  5.1.  Retroviral  constructs  used  to  transduce  primary  HPCs.  A.
Human  NPM-MLF1,  NPM and  MLF1  were  cloned  into  the  pMSCV  retroviral 
based  vectors.  MCS  (multiple  cloning  site).  B.  Immunoblotting  to  detect  the 
expression  of FLAG-tagged NPM-MLF1,  FLAG-tagged NPM and  MFC-tagged 
MLF1  proteins.  Non-specific  bands  are  indicated  by  an  asterisk.  LinXE  cells 
were  transfected  with  indicated  retroviral  constructs  and  total  lysates  were 
prepared 48 hours after transfection.
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Figure 5.2. BM derived HPCs from  5-FU  treated  mice:  NPM-MLF1  enhances 
self renewal potential of HPCs under myeloid conditions. A.  Bar chart  showing 
number  of colonies  formed  (left  panel)  and  number  of cells  (right  panel)  at  each 
round  of plating.  C57BL/ 6  mice  were  injected  with  5-FU  and  bone  marrow  cells 
were extracted 5 days after treatment.  Cells were transduced with empty vector and 
NPM-MLF1 retrovirus and cultured in 3434 methylcellulose media in the presence of 
GM-CSF.  Transduced  cells  were  incubated  at  37°C  for  7  days  after  which  the 
number of colonies formed and the total cell number were counted. B.  Morphology 
of colonies from the second and third round of plating (original magnification x 100). 
Colonies were counted as clusters of more than 50 cells.
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Figure 5.3. BM derived HPCs from 5-FU treated mice: NPM-MLF1  impairs 
myeloid  differentiation.  A.  Histogram depicting the percentage  of c-Kit,  Macl 
and Grl  positive cells.  Single cells from the first round of  plating were analysed 
by  flow  cytometry  for  cell  surface  expression  of c-Kit,  Macl  and  Grl.  The 
number  in  the  plots  represent  the  percentage  of positive  cells.  B.  Bar  chart 
representing the percentage of c-Kit, Macl  and Grl  positive cells from the first, 
second, third and fourth round of plating.
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Figure 5.4. HPCs derived from E12.5 FL: NPM-MLF1 enhances self renewal 
potential of HPCs under myeloid conditions. A.  Bar chart showing number of 
colonies formed at each round of plating.  B.  Bar chart showing number of cells 
at each  round of plating.  HPCs  isolated  from  El2.5  FL were transduced with 
vector, NPM-MLF1, NPM or MLF1  retrovirus.  Transduced cells were cultured in 
3434 methylcellulose media in the presence of GM-CSF and incubated for 7 days 
at 37°C.
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Figure 5.5. HPCs derived from E12.5 FL: NPM-MLF1 inhibits myeloid differentiation.
Representative flow cytometry data from the first round of an infection experiment.  Dot plot 
shows  the  percentage  of  Macl  positive  cells  on  HPCs  transduced  with  the  indicated 
retrovirus. The numbers in the plot represent the percentage of positive cells.
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Figure  5.6:  Macl  expression  level  is  reduced  on  NPM-MLF1  transduced 
cells. Bar chart showing the fold reduction in the percentage of Macl  positive 
cells  as  compared  to  vector.  HPCs  isolated  from  El2.5  FL  were  cultured  in 
methylcellulose  in  the  presence  of  GM-CSF,  SCF,  IL-3  and  L-6  and  the 
transduced  cells  were  selected  in  G418.  Cells  were  analysed  from  the  first 
round of plating of four separate infection experiments.
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Figure  5.7.  Cells  transduced  with  NPM-MLF1  can  not  be  maintained  in 
liquid  culture.  Fold  increase  in  cell  number  of cells  transduced  with  vector, 
NPM-MLF1, NPM or MLF retrovirus. Total cells from the third round of plating 
were grown in liquid culture supplemented with SCF, IL-3, IL-6 and GM-CSF.
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Figure  5.8.  NPM  enhances  colony  formation  of HPCs  under  megakaryocytic 
condition.  A.  Total  number  of  cells  (Left  panel)  and  total  number  of  colonies 
formed was counted and  scored  at each round  of plating.  The  data  represents  mean 
and  ±  S.D  of one  experiment  performed  in  duplicate.  B.  Typical  morphology  of 
colonies  formed  by  the  indicated  retrovirus  at  the  third  round  of plating  (original 
magnification  xlOO).  Progenitor cells  were  isolated  from  E12.5  FL  and  cells  were 
transduced  with  empty  vector,  NPM-MLF1,  NPM   or  MLF1  retrovirus.  The 
transduced cells were subsequently cultured in methylcellulose 3234 in the presence 
of TPO and SCF.  Cells were grown in culture for 10 days at each round.
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Figure 5.9. CD41 expression level is increased on NPM transduced cells.  A. Dot
plots represent the percentage of CD41 and c-Kit positive cells from the first round of 
plating.  The  number  in  the  plots  represent  the  percentage  of positive  cells.  Flow 
cytometry  performed  on  cells  harvested  from  first round  of plating.  B.  Bar chart 
showing the  percentage  of CD41  positive cells from the first and second round of 
plating. C. Bar chart representing the percentage of c-Kit positive cells from the first 
round  of plating.  HPCs  were  isolated  from  El2.5  FL  and  were  transduced  with 
indicated  retroviruses.  Cells  were  plated  on  methylcellulose  media,  3234 
supplemented with TPO and SCF.
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Figure 5.10.  NPM  promotes  megakaryocytic  differentiation.  Summary 
of the percentage CD41   positive cells at the first round of plating from three 
independent  infection  experiments.  There  is  an  increase  in  CD41  positive 
cells with cells transduced with NPM as compared with vector, NPM-MLF1 
and MLF1 expressing cells.
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Figure 5.11.  Infection  efficiency of transduced  cells  prior to  injection  into sub- 
lethally irradiated  mice.  A.  Schematic diagram of pMSCV-IRES-CD2 constructs. 
NPM and NPM-MLF1  cDNA  were cloned  into  pMSCV  retroviral vector.  B.  HPCs 
were  isolated  from  E l2.5  FL and were transduced  with  either vector alone, NPM or 
NPM-MLF1 retrovirus. Cells were cultured in myeloid conditions (SCF, IL-3  and IL- 
6).  Infection efficiencies were measured 24 hrs following transduction by measuring 
the  expression  of hCD2.  Cells  were  subsequently  intravenously  injected  into  sub- 
lethally y-irradiated mice. The numbers represent the percentage of positive cells.
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Figure  5.12.  NPM-MLF1-IRES-CD2  has  a  low  viral  titre.  Determination  of 
viral  titre  for  pMSCV-IRES-CD2  retroviruses.  Retroviral  supernatant  was 
harvested  from  LinXE  cells  and  diluted  at  1:20,  1:200  and  1:2000  with  DMEM 
complete  medium.  Mouse  3T3  fibroblasts  were  transduced  with  either  empty 
vector,  NPM or  NPM-MLF1  retroviral  supernatant  at  the  different  dilution.  A. 
Histogram  showing  the  expression  of  hCD2  expression  48  hrs  after  infection 
(Retroviral  supernatant  at  1:200  dilution).  B.  The  calculated  viral  titre  for  the 
indicated viruses.
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Figure  5.13.  HPCs  expressing  NPM-MLF1  are  incapable  of  short  term 
reconstitution.  Analysis of peripheral blood 6 weeks following injection.  A. 
Representative dot plots showing the percentage of CD45.2 and CD2 positive 
cells from mice  injected with  HPCs expressing vector, NPM or NPM-MLF1. 
Number  represent  the  percentage  of positive  cells.  B.  The  percentage  of 
CD45.2 and CD2 positive cells injected mice.
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Figure 5.14. HPCs expressing NPM and NPM-MLF1 fail to reconstitute the 
recipient mice:  Analysis  of bone  marrow and spleen  1  year after injection.
Bone  marrow  and  splenocytes  were  analysed  by  flow cytometry  1   year  and  2 
months after injection.  Representative histogram showing the percentage of CD2 
positive cells from bone marrow (Top panel) and spleen (Bottom panel).
1845.5 Discussion
5.5.1 NPM-MLF1 impairs myeloid differentiation
It has been postulated that myelodysplasia detected in MDS  occurs as  a result of 
ineffective  haematopoiesis  and  differentiation.  The  disease  is  characterised  by 
abnormal proliferation of cells in the bone marrow and high levels of apoptosis in 
the  blood.  In  MDS,  the  balanced  t(3;5)  translocation  rearranges  MLF1  on 
chromosome 3 and NPM located on chromosome 5. This translocation leads to the 
expression of NPM-MLF1  fusion transcript. The contribution of this fusion protein 
to the pathogenesis of MDS is unknown. Lymphoid cells are not involved in most 
MDS patients and unlike the mature myeloid cells, are not derived from the MDS 
clone.  It is therefore predicted that the initial transformation event may occur in a 
myeloid  restricted  progenitor  cell.  However,  it  is  highly  likely  that  the  primary 
genetic  changes  in  MDS  occur  at  the  HSC  level,  and  the  effect  of  these 
transformation  events  is  myeloid  restricted,  leaving  the  commitment  and 
differentiation  of lymphoid  progenitor  unaffected.  It  is  likely  that  the  B  and  T 
lymphocytes in MDS patients are derived from the residual normal HSCs.  The cells 
that define the disease are clonally derived and since trilineage dysplasia in MDS 
affects cells of the myeloid and megakaryocytic  lineage, we set out to investigate 
the growth and differentiation effects of NPM-MLF1 in these lineages.
Based on colony growth assays, we have shown that NPM-MLF1  impairs myeloid 
differentiation,  as  characterised  by  the  reduction  in  the  levels  of Macl  and  Grl 
expression.  This  is  coupled  to  an  increase  in  the  proportion  of immature  c-Kit 
positive  progenitor  cells,  which  are  the  only  cells  detected  in  the  NPM-MLF1
185cultures  in  the  first  round  of plating.  The  absence  of differentiated  cells  in  the 
subsequent  rounds  further  suggests  that  NPM-MLF1  blocks  differentiation.  The 
effect  of NPM-MLF1  can  be  seen  in  both  foetal  and  adult  progenitor  cells.  One 
explanation for these results is that NPM-MLF1  negatively regulates genes required 
for  differentiation  of  progenitor  cells.  Alternatively,  the  accumulation  of  c-Kit 
positive progenitor suggests that NPM-MLF1 may increase self renewal potential or 
enhance proliferation of these cells.
Cells transduced with NPM-MLF1  also have a transient increase in their capacity to 
form myeloid colonies. Colonies formed by the NPM-MLF1  expressing cells were 
of a  smaller  and  more  compact  size  and  probably  represent  a  less  differentiated 
progenitor population,  as  compared  to  control  cells.  However,  the  fusion protein 
does not immortalise the transduced progenitor cells in colony growth assays or in 
liquid culture. A secondary event may be required for the immortalisation of these 
cells. Inhibition of apoptosis is a central component to the progression and evolution 
of MDS to AML. This is supported by the studies showing increased expression of 
the pro-apoptotic (BAX/BAD) versus anti-apoptotic (BCL2/BCLXL) proteins in the 
CD34 compartment of patients with MDS (Parker et al.,  1998).  A decrease in this 
ratio is associated with evolution to leukaemia (Parker et al.,  1998; Boudard et al., 
2002).  Similar  alterations  in  this  ratio  have  been  associated  with  expression  of 
fusion  proteins.  For  example,  BCR/ABL  expression  in  myeloid progenitor cells 
was  shown to promote myeloproliferative disorder whereas its co-expression with 
BCL2 lead to AML development in mice (Jaiswal et al, 2003).  In vitro studies in 
NIH3T3  cells  have  shown  that  NPM-MLF1  induced  apoptosis  upon  serum 
starvation.  Control NIH3T3  cells and cells transfected with BCL2 alone failed to
186proliferate  under  these  conditions  (Yoneda-Kato  et  a l,  1999).  Interestingly 
however,  BCL2  rescued  NPM-MLF1  mediated  apoptosis  and  more  than  90%  of 
cells incorporated BrdU under these conditions, thus suggesting that expression of 
both  BCL2  and  NPM-MLF1  confer  a  growth  advantage  to  cells.  It  is  therefore 
possible  that  NPM-MLF1  may  collaborate  with  BCL2  or BCLXL to  immortalise 
HPCs in a sub-optimal environment.
The mechanism underlying the multi-step pathogenesis of MDS  is as yet unclear. 
The peripheral cytopenia occurs as a result of apoptosis that is detected in the early 
stages of the disease. The apoptosis can be partially explained by the deregulation of 
BCL2  proteins  and  other  apoptotic  pathways.  A  general  increase  in  apoptosis  in 
haematopoietic  cells  would be predicted to result in hypocellular BM.  It may be 
possible that in MDS patients, NPM-MLF1  increases the accumulation of immature 
progenitor cells and blocks their differentiation (Figure 5.15). The accumulation of 
cells results in a hypercellular BM which is a characteristic phenotype of MDS.  The 
increased apoptosis may be due to ineffective or aberrant differentiation and maybe 
a mechanism to prevent acquisition of further mutations culminating in leukaemic 
transformation.  Expression  of  the  fusion  protein  is  probably  not  sufficient  to 
transform  a  cell  but  it  may  instigate  a  so  called  “pre-leukaemic”  state.  As  the 
disease  progresses,  clonal  progenitor  cells  expressing  NPM-MLF1  accumulate 
genetic  events  that  would  allow  the  cell  to  overcome  the  pro-apoptotic  signals. 
Acquisition of additional mutations that would cooperate with the fusion protein to 
enhance the  survival  or proliferative advantage of a cell could ultimately result in 
the progression of MDS to AML.
187The impaired differentiation and the transient increase in colony formation detected 
by NPM-MLF1  expressing cells recapitulate some of the clinical features that are 
detected  in  MDS  patients.  Our model  can  thus  be very  useful  in  vitro  to  further 
analyse the mechanism in which NPM-MLF1 contributes to MDS pathogenesis.
5.5.2  NPM-MLF1 does not affect megakaryopoiesis
The  ineffective  megakaryopoiesis  detected  in  MDS  patients  is  reflected  in  the 
peripheral  thrombocytopenia  and  dysplasia  in  megakaryocytes.  Dysplasia  is 
characterised  by  abnormalities  in  cell  size,  failure  of  nuclear  segmentation  in 
megakaryoblasts  and nuclear hypersegmentation  in mature megakaryocytes.  MDS 
patients with the NPM-MLF1  fusion have megakaryodysplasia but there is no direct 
evidence  implicating  the  involvement  of  the  fusion  protein  in  the  aberrant 
maturation  of these  cells.  Therefore,  we  set  out  to  investigate  the  role  of NPM- 
MLF1 in megakaryocytic development.
Foetal  liver  progenitor  cells  were  transduced  with  NPM-MLF1  retrovirus.  By
performing colony-forming assays under conditions that promote megakaryopoiesis,
we were able to examine the effect of NPM-MLF1  protein on the development of
these  cells.  Our  data  suggests  that  NPM-MLF1  does  not  have  any  effect  on
megakaryopoiesis. There was no difference in the percentage of CD41 positive cells
or in number of colonies formed by the NPM-MLF expressing cells as compared to
vector  control  cells.  This  implies  that  the  megakaryodysplasia  detected  in  MDS
patients  is  not directly  related to the NPM-MLF 1   chimeric protein.  Although no
other chromosomal abnormalities were detected in these patients, it is conceivable
that  other  genetic  alterations  exist  in  genes  that  are  essential  for  regulating
188megakaryocytic  development.  The  responsiveness  of  progenitor  cells  to  TPO, 
abnormal expression of TPO receptor or defect in signal transduction pathways can 
also  explain  the  ineffective  maturation  of  megakaryocytes  detected  in  MDS. 
Alternatively,  the  effect  of  NPM-MLF 1   may  only  be  evident  in  BM-derived 
progenitor  cells.  For  future  studies,  colony  forming  assays  should  be  carried  out 
using  lineage  negative  BM  cells  transduced  with NPM-MLF 1.  In  addition,  there 
may be a difference between the activities of NPM-MLF 1   in murine versus human 
progenitors.
However, our preliminary data suggest that regulation of NPM may be essential in 
megakaryocytic  development.  In  vitro  colony  assays  show  that  progenitor  cells 
transduced with NPM have an increased megakaryocytic differentiation potential as 
measured by the expression of CD41  There was also an increase in the clonogenic 
potential of NPM expressing cells. In common with our results, ectopic expression 
of NPM in LSK (Lin', Scal+, c-Kit+) cells results in increased proliferation of these 
cells (Li et al., 2006). It is possible that in MDS, NPM-MLF1 may have a dominant 
negative  effect  on  endogenous  NPM  and  as  a  result  suppress  megakaryocytic 
differentiation. Alternatively, NPM gene dosage may be an important factor in the 
regulation of megakaryopoiesis. Therefore, the loss of one wild type NPM allele as 
a result of chromosomal  translocation  in  MDS  may have  an  inhibitory  effect on 
megakaryocytic  development.  In  accordance  with this,  loss  of an NPM allele  in 
NPM" ' mice resulted in many features observed in human MDS, such as dysplastic 
megakaryocytes,  (Grisendi  et  al.,  2005).  Furthermore,  these  mice  had  a  higher 
propensity  for  developing  haematological  malignancies  as  compared  with  NPM 
wild type mice (Sportoletti et al., 2008), suggesting that quantative abnormality of
189NPM  may  be  a  crucial  contributing  factor  in  the  pathogenesis  of  MDS  and 
progression to AML.
5.5.2  Transplantation of NPM-MLF1 expressing cells
The  capacity  of  NPM-MLF 1   to  affect  myeloid  differentiation  and  transiently 
enhance  cell  survival  indicates  that  our  model  system  recapitulates  some  of the 
biological properties of human MDS  in vitro.  This led us to examine the effect of 
fusion expression in vivo. Cells transduced with NPM-MLF 1, NPM or vector, were 
injected into sub-lethally irradiated mice. This system allowed us to investigate how 
efficiently  NPM-MLF 1   expressing  cells  repopulate  the  mouse  haematopoietic 
system and what effect the fusion had on the development of the myeloid lineage.
Transduction efficiency, as measured by hCD2 expression was approximately 70%
and 60% for cells expressing vector and NPM, respectively. In contrast, the hCD2
expression of NPM-MLF 1   expressing cells was as low as  30%.  The difference in
the levels of hCD2 expression was shown to be due to the production of low viral
titre from the NPM-MLF 1   retroviral construct. To determine the level of short term
reconstitution in these mice, the peripheral blood of recipient mice was analysed 6
weeks post injection.  The inability to detect donor cells expressing NPM-MLF 1   is
probably  due  to  the  low  infection  efficiency  of  transplanted  cells.  Since  the
retroviral  supernatant used to  infect progenitor cells was already concentrated, we
could not further increase the viral titre produced by this construct. The presence of
an  IRES  can  interfere  with the  expression  levels  of CD2  detected in  cells.  IRES
mediated translation is dependent on the interaction of cellular proteins with RNA
in the translation initiation complex, a process that can be regulated by cell type or
190cell  status  (Borman et a l,  1995;  Stoneley et a l,  2000).  Indeed, the level of CD2 
expression is much higher in 3T3 cells or LinXE cells than when murine progenitor 
cells  are  transduced  with  NPM-MLF1  retrovirus.  For  future  studies,  NPM-MLF1 
should  be  cloned  into  a  retroviral  expression vector  lacking  IRES.  Alternatively, 
since  hCD2  expression  was  not  affected  with  the  empty  vector,  the  NPM-MLF 1  
cDNA  may  interfere  with  the  function  of an  IRES  and  hence  the  expression  of 
hCD2, which could result in miss-representation of transduced cells.
In contrast to the data presented by Pang’s group, cells overexpressing NPM did not 
affect  the  myeloid  lineage  in  our  system.  Li  et  al  showed  that NPM  expressing 
progenitors from bone marrow of 5-FU treated mice had increased reconstitution in 
syngeneic  mice.  NPM  expressing  cells  had  reduced  propensity  to  commit to  the 
myeloid lineage and in contrast to our study, NPM inhibited myeloid differentiation. 
Secondary  transplantation  also  revealed  the  long  term  repopulating  capability  of 
HSCs expressing NPM (Li et al., 2006). Differences in the progenitor cell targeted 
by NPM could account for the lack of reconstitution observed in our system. The 
current data on the role of NPM in haematopoiesis is based on colony forming assay 
using transduced bone marrow derived progenitor cells or the injection of these cells 
into recipient mice. It is possible that NPM has distinct functions in foetal and adult 
haematopoiesis. This can be addressed by transducing BM derived progenitor cells 
and their subsequent injection into irradiated recipient mice to determine the effect 
of  NPM-MLF 1   in  haematopoiesis  and  transformation.  Another  source  of  BM 
derived progenitor cells could be obtained from the NPM  mice, which have been 
obtained from Grisendi et al (Grisendi et al., 2005). The progenitor cells from these 
mice  would  be  ideal  in  analysing  the  functional  contribution  of NPM-MLF 1   to
191MDS  as  the  NPM  haploinsufficiency  resembles  to  the  progenitor  cells  in  MDS 
patients.
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Figure 5.15. Possible roles of NPM-MLF1 in myelopoiesis.  There are number of 
factors  that  can  regulate  different  stages  of  HPC  development.  HPCs  can 
proliferate and commit to differentiate along a specific lineage.  NPM-MLF 1   fusion 
protein  may  act  at  distinct  stages  of myeloid  development.  A.  In  MDS,  NPM- 
MLF 1  may fail to differentiate  effectively.  These  cells  can  appropriately proceed 
along  a  specific  pathway  but  are  unable  to  terminally  differentiate,  resulting  in 
production of abnormally differentiated cells.  B.  Alternatively, NPM-MLF 1   may 
block  differentiation,  causing  accumulation  of  immature  progenitor  cells.  C. 
NPM-MLF 1   could increase HPC self-renewal at the expense of differentiation.
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NPM is involved in a number of translocations that are detected in individuals with 
different  leukaemic  subtypes.  In  the  t(5;17)  translocation NPM is  fused with the 
retinoic  acid receptor-a  (RAR-a)  gene  and the resultant fusion gene is  associated 
with  the  pathogenesis  of  acute  promyelocytic  leukaemia  (APL)  (Redner  et  al., 
1996).  In anaplastic large cell lymphoma (ALCL), NPM is fused to the anaplastic 
lymphoma kinase receptor gene (ALK). The chimeric protein generated results in the 
constitutive activation of ALK tyrosine kinase function (Morris et al.,  1994). NPM- 
ALK has been shown to interact with endogenous NPM (Bischof et al., 1997). This 
association  is  important  for the  localisation  of NPM-ALK to  the  nucleus,  and  is 
essential  for  transformation  of cells  by  the  fusion  protein.  The  identification  of 
proteins  that  interact  with  NPM-MLF 1   will  allow  a  better  understanding  of the 
function of this fusion protein.  As the homodimerization domain is retained in all 
NPM fusion proteins, we set out to investigate if NPM-MLF 1   interacts with NPM 
and to determine if this interaction has any functional significance.
6.1  NPM-MLF1 interacts with NPM
To determine whether NPM-MLF 1   interacts with NPM, immunoprecipitations were
performed using whole cell  lysates  from mouse  3T3  fibroblasts.  These cells were
transduced  with  NPM-MLF1  retrovirus.  The  transduced  cells  were  selected  by
growth in G418. To determine whether NPM interacts with NPM-MLF 1, whole cell
lysates were prepared from the transduced 3T3  cells, using RIPA lysis buffer. The
lysates  were  pre-cleared  with  protein  A  coupled  agarose  beads  for  1  hr  at  4°C.
Initially,  immunoprecipitation  was  carried  out  using  a  mouse  NPM  monoclonal
195antibody.  The  antibody  was  raised  against the  C-terminal portion of NPM that is 
truncated in the fusion protein and is replaced with MLF1. The use of this antibody 
enabled us to differentiate between the endogenous NPM and NPM-MLF 1.
The  precipitated  protein  complexes  were  analysed  on  SDS-PAGE.  The  fusion 
protein was tagged with a FLAG epitope at the N-terminus and a FLAG antibody 
was  used  to  detect  the  presence  of  co-precipitated  NPM-MLF 1   fusion  protein 
(Figure  6.1A).  In  order  to  measure  the  relative  expression  of the  protein that  is 
precipitated,  10% of the whole cell lysate was used to run on the gel. Lysates from 
untransduced 3T3  cells  and cells transduced with the vector alone were used as a 
control  (lanes  1   and  2  respectively).  A  protein  of  approximately  48  kDa  was 
detected in the whole cell lysate (lane 3), corresponding to the FLAG tagged fusion 
protein.  The  FLAG-NPM-MLF1  protein  was  detected  in  the  precipitated  NPM 
complex  (lane  6)  and not  in control  cell  lysates.  This  indicates that in 3T3  cells, 
endogenous NPM interacts with NPM-MLF 1.
In order to further confirm the interaction between NPM and NPM-MLF 1, FLAG 
antibody was used to precipitate NPM-MLF 1  protein and to establish whether the 
endogenous  NPM  protein  is  within  the  precipitated  complex.  The  interaction  of 
FLAG-NPM-MLF1   with the 38 kDa NPM protein was revealed by immunobloting 
with  an  anti-NPM  antibody  (Figure  6.1B).  The  immunoprecipitates  revealed  an 
association  between  the  fusion  protein  and  NPM  (lane  6).  High  levels  of NPM 
protein  were  present  following  immunodepletion  with  the  FLAG  antibody, 
suggesting that only a proportion of endogenous NPM interacts with NPM-MLF 1  
(lanes 10-12). These data show that NPM-MLF 1  interacts with endogenous NPM.
1966.2  NPM-MLF1 is localised to the nucleoli
Subcellular  localisation  of  NPM-MLF 1   in  3T3  cells  was  determined  by 
immunostaining. Cells were grown on coverslips and fixed with paraformaldehyde. 
In order to permeabilise the cells, they were treated with Triton X-100. Cells were 
stained with Hoechst dye which stains chromosomes within the nucleus (Figure 6.2, 
right panel).  FLAG antibody was used to detect cells expressing the NPM-MLF 1  
fusion protein.  One  cell  within the  highlighted  section  is  expressing NPM-MLF 1  
and the merged image shows the localisation of the protein to the nucleoli (Figure 
6.2, merged image).
6.3  Generation of deletion constructs to determine the domain required for the 
interaction between NPM-MLF1 and NPM
Several retroviral deletion constructs were generated to determine which domains of
NPM-MLF 1   contribute to  the  interaction with NPM.  The  first deletion construct,
truncated NPM (tNPM), comprised the N-terminal domains of NPM retained in the
NPM-MLF 1   fusion protein.  tNPM contains two nuclear export signals (NES), the
metal binding domain, the acidic domains and one nuclear localisation signal (NLS)
(Fig 6.3B).  In theory,  tNPM protein could  shuttle between the cytoplasm and the
nucleus due to the presence of NES and NLS. It has been shown that this segment of
NPM is responsible for the localisation in the nucleoli and nucleoplasm (Bertwistle
et a l, 2004). As NPM is mainly localised in the nucleoli, a construct was generated
in which the NLS domain was deleted (NPM-ANLS). This construct would allow us
to establish the importance of NPM cellular localisation for interaction with NPM-
MLF 1, since the absence of the NLS would prevent NPM localisation to the nucleus
197and  hence  prevent  interaction  with  endogenous  NPM,  which  is  predominantly 
present in the nucleoli.  In addition, NPM shuttling activity between the cytoplasm 
and nucleus would be affected. Indeed, Bertwistle et al have shown the localisation 
of NPM-ANLS  protein  to  be  predominantly  in  the  cytoplasm  (Bertwistle  et  al., 
2004).
To  determine  if MLF1  is  required  for  the  interaction  of the  fusion  protein  with 
NPM,  truncated  MLF1  (tMLFl)  was  also  generated.  This  deletion  mutant 
corresponded to the MLF1  moiety present in NPM-MLF1. It has been reported that 
MLF1  is sequestered in the cytoplasm by the  14-3-3 protein.  Since NPM-MLF1  is 
present in the nucleoli, an NPM-MLF1  construct was generated containing only the 
NPM derived NLS joined to the MLF1  moiety (MLF1-NLS). The presence of the 
NPM-NLS should be sufficient to allow the translocation of MLF1 into the nucleus, 
where NPM is located.  Co-immunoprecipitation would reveal if the MLF1  portion 
of the fusion protein is  required  for the  interaction with NPM.  The expression of 
proteins was determined in transduced 3T3 cells. Western blot analysis of total cell 
lysates revealed the expression of Flag tagged proteins of the expected molecular 
weights (Figure 6.4).
6.4  The NPM moiety of NPM-MLF1 is required for interaction with NPM
The  deletion  mutants  were  retrovirally  expressed  in  mouse  3T3  fibroblasts.  The 
cells  were  selected  in  G418  for  10  days  and  total  cell  lysates  were  used  in  co- 
immunoprecipitations. FLAG tagged NPMt was shown to interact with endogenous 
NPM.  It is likely that the oligomerization domain at the N-terminal portion of NPM
198mediates this interaction. The NPM mutant lacking the NLS domain (NPM-ANLS) 
was  also  co-immunoprecipitated  with  NPM  (Figure  6.5).  Although  NPM  is 
primarily found in the nuclei, reports have shown that it can also shuttle between the 
nucleus  and  the  cytoplasm.  It  is  therefore  possible  that  NPM-ANLS,  which  is 
localised  to  the  cytoplasm,  interacts  and  forms  a  complex  with  the  residual 
endogenous NPM in the cytoplasm.  FLAG tagged MLFlt or MLF1-NLS proteins 
did  not  co-immunoprecipitate  with NPM  (Figure  6.5).  These  data  show that  the 
NPM segment of the NPM-MLF1, and not MLF1, is required for interaction with 
NPM.
6.5  NPM activates p53 reporter activity
NPM interacts with many proteins, such as HDM2, ARF and p53  (Colombo et al., 
2002; Kurki et al., 2004; Colombo et al., 2005; Lambert and Buckle, 2006). NPM 
expression  has  been  shown  to  regulate  p53  protein  stability  and  transcriptional 
activity (Colombo et al.,  2002;  Maiguel et al., 2004). The exact effect on the p53 
function  appears  to  be  dependent  on the  level  of NPM present within  a cell.  To 
examine the functional significance of NPM-MLF1  interaction with NPM, the effect 
of NPM-MLF1 expression on the p53 luciferase reporter activity was examined.
Mouse  3T3  cells  were  tranfected  with  vector  alone,  NPM-MLF 1   or  NPM 
expression  vectors.  Cells  were  co-transfected  with  a  p53  luciferase  promoter 
comprising of 13  repeats  of a p53  consensus  sequence (el-Deiry et al.,  1992) and 
with an expression vector encoding the p53 protein. As a control for p53 activation 
of the  p53  promoter,  cells  were  also  transfected  with  a  mutant  p53  promoter
199comprising of 15  repeats of a similar sequence with mutations at critical positions 
(el-Deiry et al.,  1992) (Figure 6.6A).  Cells were also co-transfected with a renilla 
luciferase  reporter  gene  to  normalise  for  transfection  efficiency.  Cells  were 
harvested,  and p53  luciferase  activity was measured, 24 hr after transfection.  The 
data  in  Figure  6.6B  show  the  fold  change  in  the  p53  luciferase  activity.  The 
luciferase  activity  measured  from  cells  transfected  with wild type  or mutant p53 
promoters, in the absence of p53 expression vector, represent the basal level of p53 
activity in this experiment. Co-transfection with the p53 expression vector resulted 
in the activation of the wild type promoter, but not the mutant p53 promoter. NPM- 
MLF 1   does  not  enhance  or  inhibit  p53  activation  of the  luciferase  promoter.  In 
contrast  to  the  fusion  protein,  NPM  was  shown  to  significantly  enhance  p53 
activation of the wild type p53  luciferase reporter (Figure 6.6B). These data show 
that NPM activates p53 promoter activity.
6.6  NPM-MLF1 inhibits NPM mediated activation of p53 promoter
We have  shown that NPM-MLF 1   interacts  with endogenous NPM in mouse  3T3 
fibroblasts.  NPM-MLF 1   may  act  as  a  dominant  negative  protein  inhibiting  the 
function of NPM.  To  address this,  we ectopically overexpressed NPM and NPM- 
MLF 1   and  examined  the  effect  on  the  p53  luciferase  activity.  Co-expression  of 
NPM with NPM-MLF 1   resulted in marked inhibition of p53 promoter activation as 
compared  to  activation  observed  when  cells  were  transfected  with  NPM  alone 
(Figure  6.7).  These  preliminary  results  show  that  NPM-MLF 1   may  have  a 
dominant  negative  effect  by  interacting  with  NPM  and  preventing  its  normal 
function.
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Figure  6.1.  NPM-MLF1  interacts  with  NPM.  Mouse  3T3  fibroblasts  were 
transduced with vector  alone  or NPM-MLF1  retrovirus.  Cell  lysates were prepared 
with RIPA lysis buffer and the immunoprecipitated complexes were resolved on a 10% 
SDS  polyacrylamide  gel.  A.  Whole  cell  lysates  were  immunoprecipitated  with  an 
antibody  against  NPM  or  with  an  IgG-K  antibody  as  an  isotype  control  and 
immunobloted (IB) with FLAG antibody. The 48kDa NPM-MLF 1  protein (Asterisk) is 
detected  within  the  immunoprecipitated  complex.  B.  Whole  cell  lysates  were 
immunoprecipitated with a FLAG antibody and immunobloted with an NPM antibody. 
40kDa NPM protein (Asterisk) is detected within the immunoprecipitated Flag-NPM- 
MLF1 complex.
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Figure 6.2.  NPM-MLF1  is localised  in the nucleoli.  Transduced 3T3  cells 
were grown on coverslips.  Cells were fixed and permeablised at RT for 5 min. 
Following several  rounds of washing,  cell  were  blocked and  labeled with an 
anti-FLAG  antibody.  Cells  were  washed  in  PBS  and  incubated  with  a 
secondary  Rhodamine  antibody.  The  nucleus was  stained  with  Floechst dye 
and the localisation of the fusion protein in the nucleoli is shown in the merged 
image.  Cells transduced with empty vector retrovirus were used as a negative 
control.
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Figure 6.3: NPM and MLF1  deletion constructs. A.  Full length wildtype NPM, 
MLF1  and  NPM-MLF 1   fusion  protein.  B.  Diagram  depicting  the  functional 
domains in the deletion constructs  generated.  cDNAs were cloned into pMSCV- 
neo retroviral vector. Deletion constructs NPMt includes the section of NPM that is 
retained  after  t(3;5)  translocation.  NPM-ANLS  is  truncated  NPM  lacking  the 
nuclear  localisation  signal.  MLF1-NLS  is truncated  MLF1  retained  in the  fusion 
protein containing a segment of NPM which has the NLS signal. tMLFl entails the 
region of MLF1 retained after t(3;5) translocation.
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Figure  6.4.  Expression  of NPM  *«d  MLF1  deletion  mutants.  A.
The  PCR  amplified  NPM  and  MLF1  fragments  were  cloned  into 
pMSCV  retroviral  vector  containing  a neomycin resistance  gene.  B. 
3T3  mouse  fibroblasts  were  transduced  with  the  deletion  mutant 
retrovirus and were grown in G418 for 10 days.  Total cell lysates were 
prepared and resolved on a  10% polyacrylamide gel.  FLAG antibody 
was used to detect the proteins.  An  anti-tubulin antibody was used as 
loading control.
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Figure  6.5.  Endogenous  NPM  interacts  with  NPM  moiety  of NPM-MLF1.  3T3
cells were transduced with tNPM, NPM ANLS, MLF1-NLS and tMLFl retroviruses and 
were grown  in selection  for  10 days. As positive controls, cells were transduced with 
NPM and NPM-MLF  1  constructs.  As  a  negative  control,  cells  were transduced  with 
empty  vector  retrovirus.  10%  of  total  cell  lysates  were  used  as  input. 
Immunoprecipitations were carried out using an NPM antibody and the FLAG antibody 
was  used to  identify  FLAG-tagged protein  in the  immunoprecipitated complex.  The 
proteins were resolved on a 10% polyacrylamide gel.  Non-specific bands are shown by 
an asterisk.
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Figure  6.6.  NPM  activates  p53  luciferase  promoter  activity.  A.  Wild type  and 
mutant  p53  luciferase  promoter  used  in  transient  transfection  experiments.  pG13 
contains 13 copies of the p53-binding consensus sequence and pG15 contains 15 copies 
of a similar sequence mutated at critical positions (El-Deiry et al 1992).  B. Mouse 3T3 
fibroblasts were transiently  transfected with  either pCDNA3  expression vector alone 
(0.4  ug),  NPM-MLF 1  (0.4  ug)  or  with  NPM (0.4  ug).  Cells  were  transfected  with 
constant concentration of wild type p53-luciferase vector (0.05 ug) or with mutant p53- 
luciferase  vector (0.05  ug).  Cells  were  also transfected with (black bar)  or without 
(grey bar) a p53 expression vector (0.2 ug).  The p53-luciferase activity was measured 
24 hr following transfection. The data represents mean and ± S.Ds of one experiment 
in triplicate. The NPM-mediated p53 activation is statistically significant p=0.000176) 
as indicated by asterisk.
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Figure  6.7.  NPM-MLF1  inhibits  NPM  mediated  p53  transcriptional  activation.
Mouse  3T3  fibroblasts  were  transiently  transfected  with  either  pCDNA3  expression 
vector alone (0.4 ug), NPM-MLF  1  (0.4 ug), NPM (0.4 ug), or co-tranfected with NPM 
and NPM-MLF  1.  Cells were transfected with a constant concentration of wild type p53- 
luciferase vector (0.05 ug) or with a mutant p53-luciferase vector (0.05 ug).  The cells 
were also transfected with (black bar) or without (grey bar) a p53 expression vector (0.2 
ug).  The p53-luciferase activity  was measured 24 hr following transfection. The data 
represents  mean  and  ±  standard  S.Ds  of one  experiment  in  triplicate.  The  statistical 
significance  of the  NPM-MLF 1   mediated  repression  is  p=0.00046  (as  indicated  by 
asterisk).
2076.7 Discussion
To  gain  more  insight  into  the  function  of  NPM-MLF 1   and  potentially  the 
pathogenesis  ot  MDS  we  aimed to  examine the potential  interaction between this 
fusion protein and wild type NPM. NPM is localised in the nucleoli and since NPM- 
MLF 1   shares the same  sub-cellular localisation (Yoneda-Kato et al.,  1996) we set 
out to investigate whether these two proteins interact with each other and examined 
the  functional  significance  of  this  interaction  in  the  context  of  p53  activity. 
Immunoprecipitation  revealed  that  NPM-MLF 1   did  interact  with NPM  in  mouse 
fibroblasts.  To  establish  the  region  required  for  this  interaction,  several  deletion 
constructs were generated. The NPM moiety of the fusion protein was found to be 
essential for this interaction, probably mediated by the homodimerization domain at 
the N-terminus of the NPM protein.
A construct containing the MLF1 portion found in NPM-MLF 1, joined to the NPM- 
derived  NLS  motif  was  generated.  This  NLS  was  thought  to  be  sufficient  for 
translocation of MLF1  into the nucleus, where the protein could interact with other 
nuclear proteins.  We demonstrated that this region of the protein does not interact 
with endogenous NPM.  MLF1  was thought to be a cytoplasmic protein which was 
retained in the cytoplasm by interaction with 14-3-3 proteins. Recent published data 
have  identified  two  new  functional  domains  of MLF,  a  nuclear  export  signal  at 
residues  88-100,  and  two  NLS,  located  at  residues  168-174  and  232-236 
(Winteringham  et  al.,  2006;  Yoneda-Kato  and  Kato,  2008).  MLF1  was  shown to 
also be  localised to the  nucleus.  These data indicate that the MLF1  region of the 
fusion protein contains NLS  and NES motifs, which questions the hypothesis that
208NPM-MLF 1   induces leukaemogenesis primarily as result of delocalising MLF1  to 
the nucleus.
We have shown in transient transfection studies, that NPM enhances p53-mediated 
activation  of  a  p53  luciferase  promoter.  NPM  directly  interacts  with  p53  via 
residues  249-262  located  at  the  C-terminus  region  (Lambert  and  Buckle,  2006). 
There are several lines of evidence to suggest that NPM increases the stability and 
hence transcriptional activity of the p53 tumour suppressor protein (Colombo et al., 
2002; Kurki et al., 2004). One mechanism by which NPM increases the activity of 
p53  is by  interacting  with Mdm2  (Hdm2  in humans),  repressing Mdm2-mediated 
p53 degradation through the proteosome (Kurki et al., 2004). In contrast, NPM has 
also been shown to negatively regulate p53 activity (Maiguel et al., 2004). Based on 
the current published data, it appears that the p53 regulation by NPM is dependant 
on  several  important  factors  such  as  the  type  of  cell  line  used  in  the  study, 
irradiation dose and the level of NPM expression in the cell.
The mechanism by which NPM affects p53 function is also dependent on the tight 
regulation of several cellular proteins and the physiological state of the cell. One of 
these important cellular components, involved in the regulation of growth and cell 
death,  is  the  tumour  suppressor  ARF  (Alternative  Reading  Frame-pl9A R F).  This 
protein  interacts  with  and  controls  the  function  of both  NPM  and  p53  (Figure 
6.9A).  NPM  and  ARF  are  involved  in  a  coregulatory  loop,  whereby,  in  a
physiological  state  moderate  levels  of NPM  maintain  ARF  in  the  nucleoli.  This 
prevents ARF transport into the nucleoplasm, where it inhibits Mdm2-mediated p53 
degradation  and  induces  growth  arrest  or  apoptosis  (Bertwistle  et  al.,  2004;
209Korgaonkar et  al.,  2005).  This  interaction  between NPM  and  ARF  also  prevents 
ARF degradation, by retaining the protein in the nucleolus. Upon oncogenic stress, 
however, expression of both ARF and NPM are upregulated. As ARF expression is 
increased,  it  translocates  to  the  nucleoplasm,  where  it  induces  programmed  cell 
death  by  inhibiting  Mdm2  degradation  of  p53.  As  ARF  expression  becomes 
stabilised  in  the  cell,  it  represses  NPM-rRNA  processing,  which  is  required  for 
cellular growth, by promoting ubiquitin dependent degradation of NPM. However, 
upregulation  of  NPM,  and  other  genetic  mutations  can  override  the  negative 
regulation of ARF and result in uncontrolled cellular proliferation.
We have shown that in contrast to NPM, NPM-MLF 1  does not affect p53 activity in 
mouse  fibroblasts.  We  therefore  examined  whether  NPM-MLF 1  can  enhance  or 
have  a  dominant  negative  effect  on  NPM  function.  Co-transfection  experiments 
revealed  that  co-expression  of NPM  with  NPM-MLF 1   resulted  in  a  significant 
repression of p53 promoter activation by NPM. Neither the p53-binding region nor 
the region required for the interaction with ARF, are present in NPM-MLF 1. ARF is 
an important regulatory component of NPM-Mdm2-p53 pathway.  For this reason, 
in  future  experiments,  we  would  like  to  determine  whether ARF  is  in the NPM- 
MLF 1-NPM complex and examine the effect of these interactions on ARF activity.
A recent study has found that NPM causes a reduction in the levels of p53 protein in 
BM-derived  HPCs  (Li  et  al.,  2006).  In  addition,  in  vivo  data  have  revealed  the 
importance of NPM in suppression of p53 function.  NPMf' MEFs were shown to be 
more  susceptible  to  p53-mediated  cell  death  than  NPM^A  cells  (Grisendi  et  al., 
2005).  It is believed that NPM can act as an oncogene or a tumour suppressor
210gene depending  on its  level  of expression.  It would be interesting to determine if 
NPM-MLF 1   can  rescue  the  NPft/T'  cells  from  senescence  or  whether  it  would 
repress the function of NPM and induce premature senescence, comparable to what 
is detected in NPM ' MEFs.
In the  context  of MDS  and  progression to  AML,  cells  harbouring  t(3;5)  may be 
more susceptible to ARF degradation.  These cells have low levels of NPM due to 
one NPM allele being disrupted by a translocation. This may result in reduced NPM 
binding  by  ARF,  and  hence  increased  ARF  degradation  (Figure  6.9B). 
Furthermore, NPM-MLF 1  may compete with ARF for NPM binding in the nucleoli. 
This would also be expected to result in increased ARF degradation. The net effect 
of increased ARF degradation, in cells harbouring NPM-MLF 1, is increased Mdm2 
mediated p53  degradation, causing unregulated proliferation of cells, which in the 
presence of additional genetic mutations could lead to leukaemic progression. It is 
possible  that  NPM-MLF 1  may  also  induce  leukaemogenesis  by  regulating  the 
function of both NPM  and MLF1,  inhibiting the  Mdm2-p53  and CNS3-COP1-53 
tumour  suppressor  pathway,  respectively.  Evidence  showing  that  NPM-MLF 1  
reduces p53  expression upon oncogenic stress provides support for this hypothesis 
(Yoneda-Kato and Kato, 2008).
Furthermore,  in  a  normal  state,  the  shuttling  of MLF1  between the  nucleus  and 
cytoplasm is tightly regulated and in MDS, the shuttling imbalance of MLF1 due to 
t(3;5) can lead to leukaemogenesis. This hypothesis is supported by the observation 
that the MLF1-derived NES motif is required for the function of wild type MLF1 
and NPM-MLF 1.  Expression of  MLF1  harbouring a mutation in the NES domain
211resulted  in  enhanced  p53  activity  in  mouse  fibroblasts,  as  compared  with  cells 
expressing  wild type  MLF1.  This  suggests  that the  shuttling  activity  of MLF1  is 
essential  for  regulation  of p53  function.  Furthermore,  cellular  transformation  of 
MEFs  and  increased  proliferation  of BM-derived  HPCs  induced  by  NPM-MLF 1  
was abrogated by disrupting the NES  sequence in the MLF1  moiety of the fusion 
protein (Yoneda-Kato and  Kato,  2008).  The level of p53  and p21  was reduced in 
NPM-MLF 1  expressing cells than in control cells and treatment with UV irradiation 
failed  to  upregulate  p53  and  p21  upregulation  in  these  cells  but  there  was  an 
accumulation of p53 and p21  in cells expressing NPM-MLF 1   containing a mutation 
in MLF1 derived NES motif. This study suggests that increased shuttling activity of 
NPM-MLF 1   may have an important role in cellular proliferation in MDS patients. 
In accordance with this, mutations in NPM that lead to the acquisition of an NES 
cause  abnormal  localization  of the  protein  in  the  cytoplasm  (NPMc+).  These 
mutations  are  highly  associated  with  AML  patients  and  further  highlight  the 
importance  of  shuttling  imbalances  in  leukaemogenesis.  Our  results  show  that 
NPM-MLF 1   interacts  with  NPM  and  affects  the  NPM-mediated  p53  regulation. 
Understanding  the  mechanism  by  which NPM-MLF 1   influences  the  p53  activity 
would allow a better understanding of the pathogenesis of MDS.
212Figure  6.9.  Regulation  of  the  p53  tumour  suppressor  pathway.  A.  The 
regulation  of ARF-Mdm2-p53  by NPM  and  MLF1.  NPM and ARF exist in a 
negative regulatory loop, whereby NPM forms a complex with ARF preventing it 
from degradation as well  as retaining the protein  in the  nucleoli.  ARF  regulates 
NPM  subcellular shuttling activity through its direct  interaction  with the  protein, 
thus  retaining  it  in  the  nucleoli.  In  addition,  ARF  inhibits  NPM  ribosome 
biogenesis  by  inducing  NPM  polyubiquitination  and  proteosome  degradation. 
Upon  oncogenic  stress,  NPM  expression  is  increased,  which  results  in  the 
stabilisation of ARF.  This leads to ARF translocation into the nucleoplasm where 
it induces growth arrest by inhibiting Mdm2- mediated p53 degradation.  NPM also 
positively  regulates  p53  activation  by  suppressing  Mdm2  activity.  NPM  can 
homodimerise and it can shuttle between the cytoplasm and the nucleoli where it is 
predominantly  localised.  In  contrast  MLF1  is  mainly  present  in  the  cytoplasm 
through interaction with  14-3-3 proteins, but it can shuttle between the cytoplasm 
and  nucleus.  MLF1  also  induces  cell  cycle  arrest  by  inhibiting  CNS3-COP1 
mediated  degradation  of p53.  B.  The  role  of NPM-MF1  in  regulating  the 
tumour suppressor pathway in MDS.  NPM-MLF1, formed as a result of t(3;5), 
is localised in the nucleoli where it can interact with the remaining NPM protein 
pool.  NPM-MF1  may  compete  with  ARF  for  interaction  with  NPM,  which  can 
ultimately result in ARF degradation.  Alternatively, NPM-MLF 1   interaction with 
NPM may suppress NPM mediated activation of p53. There is also increased sub- 
cellular shuttling of NPM-MLF 1   protein due to the acquisition of  NLS  and NES 
motifs derived from the MLF1 moiety of NPM-MLF.  The loss of one MLF1  allele 
due  to  t(3;5)  may  cause  aberrant  regulation  of the  CNS3-COPl-p53  pathway. 
Alternatively, NPM-MLF 1   may inhibit p53 mediated cell cycle arrest by repressing 
the  function  of  wild  type  MLF1.  The  net  affect  of  these  events  would  be 
uncontrolled cellular proliferation.
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2147.0 Conclusions
The main aim of this project was to investigate the molecular basis of AMKL and 
MDS.  DS-AMKL  is  an  ideal  model  for  studying  AMKL  as  the  molecular 
predisposition is known in these individuals, thus allowing us to identify genes and 
pathways that lead to AMKL development.  DS patients are highly predisposed to 
AMKL development as compared to non-DS patients. Furthermore, AMKL patients 
with DS, but not those without DS, have somatic mutations in the X-linked gene, 
GATA1. The extra copy of genes on chromosome 21 is another predisposition factor 
in DS patients that is believed to be important in AMKL development. A number of 
studies  have  attributed  the  increased  sensitivity  of  DS-AMKL  to  therapy,  to 
overexpression of chromosome 21  genes. Defining a part of the molecular pathway 
leading to AMKL would not only lead to more specific therapies for DS-AMKL but 
may also yield important mechanistic insights into AMKL in general.
The  potential  link  between  a  chromosome  21  gene,  ERGS,  and  the  GATAls 
mutation was investigated in murine haematopoiesis. This study indicates that ERG- 
3 has a role in megakaryopoiesis and it collaborates with the GATAls mutation to 
immortalize progenitor cells  in vitro, and induce leukaemia in vivo, with an early 
megakaryoblastic  phenotype.  ERG-3  was  shown  to  be  oncogenic  in  vivo  and  it 
immortalized  foetal  liver  derived  progenitors  only  in  the  presence  of  specific 
cytokines.
To  further understand the development of AMKL,  future  studies  should focus on 
isolating  putative  leukaemic  stem  cells  responsible  for  the  initiation  and
215maintenance of the disease.  In addition, identifying GATA1  target genes that are 
dysregulated by GATAls  and ERG-3  would identify molecular pathways that are 
involved  in  AMKL.  This  study  highlights  the  pro-leukaemic  effect  of  the 
overexpression of a chromosome 21 gene, as seen in DS-AMKL individuals, and its 
collaborative  effect  with  the  GATAls  mutation  in enhancing the  proliferation of 
haematopoietic  progenitor  cells.  We  propose  that  ERG-3  promotes 
megakaryopoesis  and  synergises  with  GATAls  to  increase  the  proliferation  of 
megakaryoblasts.  In addition, the deregulation of genes encoding tryosine kinases 
(KIT/JAK2/FLT3), or genes in the RAS pathway (NRAS/KRAS), may enhance the 
proliferation or survival of stem cells leading to AMKL development in DS patients.
The molecular basis of MDS was also investigated in this study. Peripheral blood 
cytopenia, high levels of apoptosis in the bone marrow, abnormal development and 
differentiation of cells of the myeloid lineage and frequent progression to AML are 
all hallmarks of MDS. Based on the colony forming assays carried out in this study, 
it appears  that the  role  of NPM-MLF 1   in the pathogenesis  of MDS  may  be  cell 
context  dependent.  In  myeloid  cells,  the  fusion  protein  impairs  myeloid 
differentiation whereas it does not affect the development of megakaryocytes. The 
transient expansion of progenitor cells may reflect the clonal expansion detected in 
MDS  patients  and  other  factors  may be  required  for cooperation with the  fusion 
protein  for transformation  of progenitor cells  in  vitro  and progression into AML. 
Megakaryocyte  development was  demonstrated to  be  enhanced by NPM,  but not 
NPM-MLF 1.  It  is  possible  that  the  effect  of  NPM-MLF 1  is  masked  by  the 
endogenous NPM in haematopoietic progenitors. The megakaryodysplasia detected 
in MDS individuals may be as a result of reduced expression levels of NPM, since
216one NPM allele is involved in chromosomal translocation. In addition, NPM-MLF 1  
was shown to interact with its wild type counterpart NPM. This interaction resulted 
in inhibition of NPM-mediated p53  activation in mouse fibroblasts.  Both p53  and 
ARF have been shown to regulate cellular proliferation through induction of growth 
arrest or apoptosis.  Reduced expression levels and a shuttling imbalance of NPM 
and MLF1  can  lead to  reduced  activation of both p53  and ARF,  which result in 
increased cellular proliferation. The increased cellular proliferation by NPM-MLF 1  
may be mediated by the impaired shuttling activity of the protein, which is induced 
by the acquisition of NLS  and NES  sequences,  from its MLF1  and NPM moiety. 
These events,  in combination with acquisition of mutations  in genes required for 
cell  maintenance  and  DNA  repair  as  well  as  increased  expression  levels  of anti- 
apoptotic molecules, could result in MDS progression to AML.
A major goal in developing novel and specific therapies for MDS is the induction of 
apoptosis  and/or  differentiation  of  the  aberrant  haematopoietic  progenitor  cells 
causing  the  disease.  Future  studies  should  focus  on  identifying  the target cell  of 
transformation  in MDS  and  factors  that contribute to the progression of MDS  to 
AML. It is also important to use the fusion gene to develop a mouse model for MDS 
that recapitulates  all  the  features  of human  disease.  Transplantation  assays  using 
bone  marrow  derived  progenitors  expressing  NPM-MLF 1   may  provide  useful 
insight  to  the  role  of the  fusion  protein  in  the  multi-step  pathogenesis  of MDS. 
Furthermore, the use of NPM+/' mice would be an ideal model to dissect the effect 
of NPM-MLF 1   on HSC  and progenitor cell development.  The NPM*7 ' progenitor 
cells resemble progenitor cells  found in MDS  patients  as they were  shown to be 
defective in megakaryocyte and erythrocyte differentiation.
217In  conclusion,  this  study  provides  support  for  the  multi-step  nature  of 
leukaemogenesis.  In  the  DS-AMKL  model,  the  mechanism  of leukaemogenesis 
appears to be based on the underlying GATAls mutation associated with the disease 
in a context of a specific  genetic  background,  which is trisomy 21.  Loss  of full 
GATA1  protein  provides  a  loss  of  differentiation  signal,  while  acquisition  of 
GATAls provides the pro-proliferation signal required for initiation of leukaemic 
transformation.  In the MDS model, acquisition of t(3;5) most likely represents an 
early event in the multi-step development of MDS. The NPM-MLF 1   fusion protein 
inhibits differentiation of myeloid cells and can deregulate the p53 pathway required 
for DNA repair and proliferation either directly, or via interference with the function 
of  its  wild  type  counterparts  NPM  and  /  MLF1.  Analysing  the  potential 
transforming  and  oncogenic  activities  of ERG-3  and  GATAls,  in  AMKL,  and 
NPM-MLF 1 in MDS will yield important mechanistic insights into these diseases.
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